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ABSTRACT 
Hepatitis C virus (HCV) leads to chronic liver disease in up to 80% of those infected. 
While thought to be mainly hepatotrophic, HCV has been considered to be able to 
replicate in cells of the immune system. The extent and implications of viral replication 
in immune cells are unknown, however, this site may represent an important reservoir 
from which the release of infectious virions, leading to viral reactivation may take place. 
We hypothesize that HCV-naive lymphocytes are susceptible to infection with wild-
type HCV and are capable of supporting the full cycle of its replication, including the 
release ofbiologically competent virions. We also postulate that small amounts of virus, 
lingering for years after apparent complete clinical resolution of hepatitis C, retains its 
infectious potential. 
This thesis is comprised of three related, but also stand-alone studies. In the first 
study, we established an in vitro infection system in which wild-type HCV was used as 
inoculum and primary human lymphocytes served as infection targets. Employing this 
system, we demonstrated that HCV can infect T lymphocytes, as it became apparent via 
detection of HCV genome replicative intermediates, non-structural proteins, and the 
appearance of unique variants in infected cells. We further identified and characterized 
the biophysical properties of virion particles by sucrose gradient centrifugation and by 
immune electron microscopy with HCV -specific antibodies directed against virus 
envelope (E2) protein, and by examining the in vitro infectivity of secreted virions by 
their serial passage in virus-naive lymphocytes. 
In the second study, we revealed that in vitro infection ofT cells with HCV can lead to 
an altered T cell subset distribution characterized by an enrichment of CD8+ T cells that 
11 
appears to be a result of an inhibition of CD4+ cell proliferation but not virus-related 
apoptotic death of the cells. 
In the third study, by utilizing the system established in the fust study, we revealed for 
the first time that small amounts of HCV persistently circulating after apparent complete 
clinical resolution of hepatitis C due to antiviral therapy can infect HCV naive human T 
cells. This finding may have significant pathogenic (residual liver disease) and 
epidemiological (infectivity) consequences. 
Overall, our findings provide conclusive evidence that cells of the immune system can 
act as reservoirs of HCV and that virus replication in this compartment leads to the 
production of infectious virions. Furthermore, we described that virus exposure can alter 
the proliferative ability of lymphoid cells, possibly impairing their response to virus and 
slowing viral clearance in vivo. Finally, we documented the infectious potential of 
residual virus that lingers in essentially asymptomatic patients after resolution of chronic 
hepatitis C. While the clinical significance of our findings are currently under 
investigation, the in vitro system established, capable of supporting the entire cycle of 
HCV replication in the natural cell milieu, may serve as a valuable tool to study poorly 
understood aspects of HCV infection, including factors determining cell susceptibility 
and virus-induced cytopathic mechanisms induced by the virus, as well as being 
applicable for evaluations of novel anti-HCV agents. 
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Chapter One: Introduction: 
1.1. VIRAL HEPATITIS 
Hepatitis, from the Greek words hepato, meaning ' liver' and itis, reflecting 
'inflammation', refers to inflammatory disease of the liver that is characterized by the 
presence of hepatocyte injury and lymphomononuclear cell infiltrates. Viral infections 
are one of the major causes of hepatitis, referred to as viral hepatitis. The causative 
agents include hepatitis A through G viruses. Thus, hepatitis A virus (HA V) is an RNA 
virus and a member of the Picornaviridae family that is transmitted by the fecal-oral 
route. HA V infection has an acute course with no tendency to progress to chronic 
hepatitis (Melnick, 1995). A vaccine exists for HA V that provides lifelong protection 
from infection (Wiedermann et al., 1997). Hepatitis B virus (HBV) is a highly infectious, 
deoxyribonucleic acid (DNA) virus and member of the Hepadnaviridae family. HBV is 
transmitted by bodily fluids and induces a persistent infection which may result in both 
acute and chronic hepatitis, as well as asymptomatic occult long-term virus carriage 
(Mulrooney-Cousins and Michalak, 2007; Liang, 2009). Presently, 2 billion people are 
thought to be infected with HBV worldwide with at least 350 million individuals having 
symptomatic chronic hepatitis B (Lavanchy et al. , 1999). Currently, a vaccine that 
confers lasting immunity is widely available, however, new infections in vaccine non-
protected individuals and in children born to infected mothers are still a great global 
health problem (Hoofnagle, 2006). Hepatitis D virus (HDV) is a negative sense, single-
stranded, closed circular ribonucleic acid (RNA) virus of the genus Deltavirus. HDV is a 
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satellite virus for HBV in that it requires coinfection with HBV to infect, assemble and 
release virions (Farci, 2003). Hepatitis E virus (HEV) is a small non-enveloped single-
stranded positive-sense RNA virus. It is the sole member of the genus Hepevirus and is 
mainly transmitted by the fecal-oral route (Mushahwar, 2008). Hepatitis G virus (HGV) 
is an RNA virus of the Flaviviridae family which appears to be closely related to 
hepatitis C virus (HCV), replicates primarily in lymphocytes, and does not appear to 
cause liver disease (Kleinman, 2001 ). HCV and infection caused by this virus are the 
subject of this dissertation and will be discussed in detail in the subsequent Sections. 
1.2. EPIDEMIOLOGY OF HCV INFECTION 
Identified in 1989 as the causative agent of non-A, non-B hepatitis (Kuo et al. , 1989), 
HCV is a small single-stranded RNA virus that belongs to the Flaviviridae family and is 
a member of the hepacivirus genus. HCV is a highly genetically variable virus with 6 
major HCV genotypes, as currently recognized, and over 100 subtypes that are classified 
based on viral nucleotide sequence heterogeneity (Simmonds, 1999; Ramia and Eid-
Fares, 2006). The main target and the site of HCV replication is the hepatocyte, although 
HCV has been shown to replicate in extrahepatic sites, particularly lymphoid cells, 
including BandT lymphocytes and dendritic cells (DC) (Bronowicki et al., 1998; 
Radkowski et al., 2000; Goutagny et al. , 2003 ; Pham et al. , 2004; Pham et al., 2008). In 
the steady state of HCV infection, hepatocytes contribute the majority of HCV virions 
found in circulation (Pawlotsky, 2006), although this may not be the case following liver 
transplantation due to HCV -induced, end-stage liver disease where the majority of the 
virus might be derived from infected lymphoid cells (Pal et al., 2006). 
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The course of disease observed in HCV infection is characterized by an acute phase 
with 15-25% of infections resulting in spontaneous resolution of hepatitis and with the 
remaining 75-85% leading to chronic hepatitis C (CHC) defined as HCV RNA positivity 
for at least 6 months (Hoofnagle, 2002). The course of acute and chronic hepatitis C, as 
well as spontaneous resolution of hepatitis C will be discussed in detail in Sections 1.5.1 
and 1.5.2., respectively. 
HCV is considered to be a non-cytopathic virus. Thus, liver injury occurs as a result 
ofthe virus-specific host immune response to infection ofhepatocytes (Guidotti and 
Chisari, 2006). At the same time, in vitro studies examining the effect of HCV on 
primary human hepatocytes showed that HCV may also have a direct cytopathic effect 
(Lazaro et al., 2007). Of those patients with CHC, between 5 and 25% will develop liver 
cirrhosis (Mattson et al., 1993). The main cause of HCV -induced cirrhosis is the long-
term inflammation and the replacement of injured hepatocytes by connective tissue and 
abnormal hepatic tissue nodules (Pol et al. , 2004). The resulting cirrhosis is the cause of 
approximately 50% of orthotopic liver transplants (OLT) (Prieto et al. , 1998). 
Furthermore, approximately 5% of cirrhotic patients will eventually develop 
hepatocellular carcinoma (HCC) (Llovet, 2005; Thomas and Seeff, 2005). The genotype 
ofHCV appears to play a role in disease outcome in that those infected with genotype 1b 
have a consistently greater risk of developing HCC (Bruno et al. , 1997). As well, those 
infected with genotype 3 are at higher risk for steatosis (Rubbia-Brandt et al. , 2000). 
While genotype is a major predictor of antiviral treatment success, studies have found no 
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clear relationship between genotype and liver disease progression (Poynard et al., 1997; 
Puoti et al., 1997). 
1.2.1. Global Prevalence and Endemic Areas 
It is estimated that 170,000,000 people worldwide (Wasley and Alter, 2000) and 
approximately 300,000 individuals in Canada with symptomatic HCV infection 
accompanied by CHC (Fischer et al. , 2006). Egypt has the highest prevalence for HCV 
infection with up to 20% of the population being chronically afflicted (Mohamed et al., 
1996; Habib et al., 2001 ). This unusually high rate of infection is believed to be due to 
parenteral antischistosomal mass-treatment campaigns which were discontinued in the 
1980's. This may represent the greatest incident of iatrogenic transmission of a blood-
borne pathogen worldwide (Frank et al., 2000). 
As mentioned in Section 1.2.1, HCV is classified into 6 major HCV genotypes and 
over 1 00 subtypes according to variations in the nucleotide sequence of the genome 
(Simmonds, 1999; Ramia and Eid-Fares, 2006). In terms of classification, nucleotide 
sequences ofHCV strains of the same subtype can differ by as much as 5% to 15%, while 
differences between subtypes range from 10% to 30% and genotypes by 30% to 50% 
(Hoofnagle, 2002). HCV genotypes are known to have a geographical distribution 
(Mellor et al., 1995; Wasley and Alter, 2000). Genotypes 1 through 3 can be found 
worldwide, although 1 b is the most common strain overall (Simmonds, 2004 ). Genotype 
la is the main virus type prevailing in Europe and North America, while 1 b is 
predominant in Japan (Greene et al., 1995; Simmonds et al., 2005). Genotype 2 is mainly 
occurring in the Mediterranean, Western Africa, and the Far East (Mellor et al., 1995; 
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Simmonds, 2004). Genotype 3 is found in Southeast Asia, India and Australia, whereas 
genotype 4 is the predominant strain in Egypt, northern Africa and the Middle East 
(Ramia and Eid-Fares, 2006). In South Africa, genotype 5 is the most prevalent, while 
type 6 occurs in Southeast Asia and Australia (Mondelli and Silini, 1999; Simmonds, 
2004; Simmonds et al. , 2005). Previously, at least 11 genotypes have been described 
(Bukh et al., 1993; Simmonds, 1999), but these genotypes were later re-classified into 6 
major genotypes due to the similarity in nucleotide sequences (Simmonds et al., 2005). 
1.2.2. Transmission Routes and Risk Factors 
HCV is a highly infectious blood-borne virus. The major route of transmission is by 
blood-blood contact (Conry-Cantilena et al., 1996) and the major risk factor associated 
with HCV transmission is intravenous drug use (IDU) (Alter et al., 1999). It is estimated 
that as much as 80% of new HCV infections are due to IDU (Law et al. , 2003) and in 
active IDU, the prevalence ofHCV can be as high as 95% (Fischer et al., 2004). Sexual 
contact has been found to be a risk factor for HCV transmission, although less than 3% of 
monogamous partners of HCV -infected individuals in the United States have been found 
to be infected (Terrault, 2002). Other risk factors include intranasal cocaine use, 
hemodialysis, tattooing, piercing and needlestick injuries (Kiyosawa et al. , 1991; Eyster 
et al., 1991; Niu et al., 1993; Thomas et al., 1995; Conry-Cantilena et al. , 1996; Lavanchy 
et al. , 1999; Firestone et al., 2007). Available data for the United States collected by the 
CDC's Sentinel Counties Study of Viral Hepatitis between 2001 and 2004, list the 
following risk factors: IDU (39%), occupational exposure (4%); household exposure 
(3%), transfusions (2%), sexual transmission (16%) and no indentified risk (33%) leading 
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to HCV infection (Weinbaum, 2009). Mother-to-infant transmission ofHCV has been 
found in 4 to 7% of cases of babies born to mothers with a high level of viremia although 
the mode oftransmission is unknown (Roberts and Yeung, 2002). 
1.3. Flaviviridae Family 
The Flaviviridae family of viruses includes the Flavivirus, Hepacivirus and Pestivirus 
genera. The Flaviviridae family consists of viruses which have positive-sense, single-
stranded RNA genomes ranging from 9.5 kilobase (Kb) to 12.5 Kb that are translated as a 
single polyprotein. Virion particles of the Flaviviridae family are enveloped and 
spherical (Lindenbach et al., 2007b ). The Flavivirus genera is made up of viruses such as 
dengue virus, West Nile encephalitis virus, tick-borne encephalitis virus, Murray Valley 
encephalitis virus, St. Louis encephalitis virus, Japanese encephalitis virus, and yellow 
fever virus (Lindenbach et al. , 2007b ). The Pestivirus genera includes viruses such as 
bovine viral diarrhea virus, border disease virus and classical swine fever (hog cholera) 
virus (Collett et al., 1988). HCV is the sole member of the Hepacivirus genera 
(Lindenbach et al., 2007b ). It has been postulated that Flaviviridae viruses use the low 
density lipoprotein receptor (LDLR) to enter host cells (Agnello et al., 1999). 
1.4. HEPATITIS C VIRUS 
1.4.1. Genome Organization 
HCV is comprised of a 9.6-Kb RNA genome which is flanked by highly structured 3'-
and 5' -untranslated regions (UTR) (Figure 1.1.). The 5' -UTR contains an internal 
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ribosomal entry site (IRES) for initiation of viral protein translation and structured RNA 
elements required for virus replication and viral protein translation (Honda et al., 1996; 
Lindenbach et al., 2007b ). 
1.4.2. HCV Lifecycle 
1.4.2.1. Entry and Uncoating 
HCV particles circulate in the blood in association with lipoproteins (Burlone and 
Budkowska, 2009). The viral E1 and E2 envelope glycoproteins are necessary for virus 
entry (their functions will be discussed in detail in Section 1.4.3) (Suzuki et al., 2007). 
HCV binding and entry is thought to be mediated by a number of molecules such as: (1) 
LDLR, which has been shown to enhance infection of normal human hepatocytes with 
serum-derived HCV in vitro (Agnello et al. , 1999; Molina et al. , 2007); (2) 
Glycosaminoglycans (GAG), which have been found to be involved in the binding of 
serum-derived HCV to vero cells (Germi et al. , 2002); (3) Scavenger receptor B 1 
(SRB 1 ), a molecule that binds to soluble HCV E2 proteins in vitro (Scarselli et al., 2002) 
and is required for the in vitro entry ofHCV pseudoparticles (HCVpp) (described in 
Section 1.9.2.2.) (Bartosch et al., 2003c) and particles derived from a genotype 2a 
Japanese fulminant hepatitis (JFH)-1 HCV isolate (JFH-1 isolate described in 
Sectionl.9.2.3) (Catanese et al., 2010); (4) CD81 , a tetraspanin that has been shown to 
bind with high affinity to recombinant HCV E2 glycoprotein and to viral particles from 
HCV -infected patients in vitro (Pileri et al. , 1998; Petracca et al. , 2000) and (5) Claudin-
1 and occludin, which are tight junction proteins found on hepatocytes that have been 
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Figure. 1.1. HCV genome organization. The HCV genome is a single-stranded RNA of 
approximately 9.6 Kb. It contains one long open reading frame that encodes a large 
polyprotein precursor of - 3000 amino acids (AA). The polyprotein is translated after 
initiation via the internal ribosomal entry site (IRES) found in the 341 bp 5'-untranslated 
region (UTR). The HCV polyprotein is co- and post-translationally cleaved by host and 
viral proteases to yield 10 structural and nonstructural (NS) proteins. These proteins are: 
core (C), envelope 1 (E1) and envelope 2 (E2), p7, NS2, NS3, NS4A, NS4B, NS5A and 
NS5B. At theN-terminus ofthe E2 region, from amino acid 384 to 410, there lies a 
hypervariable region (HVRl ). As well, in the NS5A region, the putative interferon 
sensitivity determining region (ISDR) located at amino acids 2209 to 2248, has been 
recognized. The 3'-UTR is located at the C-terminus of the HCV genome, contains a 
poly(U) sequence and is thought to have a role in the initiation of minus strand RNA 
synthesis. Putative functions of individual viral proteins are indicated. 
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seen to play a role in the entry of JFH-1 and HCVpp into murine cells and human 
hepatoma cell lines in vitro (Evans et al. , 2007; Ploss et al., 2009). 
HCVpp and JFH-1 particles have been observed to be internalized in clathrin-coated 
pits by clathrin-mediated endocytosis in vitro (Blanchard et al., 2006). The fusion of 
HCVpp and JFH-1 particles with the cellular membranes ofHuh-7 cells in vitro has been 
found to occur in the early endosome, a process that is thought to be driven by the 
acidification of these vesicles (Blanchard et al., 2006). When fusion is completed, 
uncoating and release of the HCV genome in the cytoplasm takes place (Dubuisson et al., 
2008). 
1.4.2.2. Polyprotein Translation and Processing 
Translation of the HCV long open reading frame yields a single polyprotein of 
approximately 3,000 amino acids (Choo et al., 1991). During this process, in the first 
step, the HCV RNA genome binds to the ribosome. Translation is a cap-independent 
process mediated by an IRES located in the domains II through IV ofthe 5' -UTR 
(Bartenschlager et al. , 2004). The generated polyprotein is then targeted to the 
endoplasmic reticulum (ER) where it is co- and post-translationally cleaved by host and 
viral proteases to yield 1 0 viral structural and nonstructural (NS) proteins. These proteins 
are: core (C), envelope 1 and envelope 2 (El and E2), p7, NS2, NS3, NS4A, NS4B, 
NS5A and NS5B (see Figure 1.1.) (Bartenschlager et al. , 2004; Penin et al. , 2004). 
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1.4.3. Functions of Viral Proteins 
The HCV virion is made up of structural proteins which include core, El and E2. The 
core or capsid protein is released from the polyprotein by host signal peptidases yielding 
the mature protein which binds RNA and is targeted to the cytoplasmic surface of the ER 
(Dubuisson, 2007). E1 and E2, which are also released from the polyprotein by host 
signal peptidases, are transmembrane glycoproteins that constitute the virus envelope and 
are required for viral entry into cells. E2 has been found to bind to many putative HCV 
receptors (see Section 1.4.2.1.). The E2 protein sequence contains a hypervariable region 
(HVR) which is a target for neutralizing antibodies and variations in this region are 
thought to be responsible for virus immune escape (also see Section 1.8.2)(McAllister et 
al., 1998). p7 is a short membrane peptide which is cleaved from the polyprotein by host 
signal peptidases and appears to have ion channel features (Pavlovic et al., 2003). It is 
thought to be required for HCV infectivity in chimpanzees (Sakai et al., 2003), as well as 
being required for assembly and release of infectious virions (Steinmann et al., 2007a). 
The 3-dimensional structure of p7 has recently been revealed and this protein is thought 
to be a viroporin (Luik et al., 2009). Additionally, the introduction of mutations in the 
coding region of p7 has led to inhibited replication of HCV in Huh-7 cells as well as 
HCV particle release from the same cells (Steinmann et al. , 2007b). Unlike the structural 
proteins, the NS proteins are cleaved from the polyprotein by the NS2-3 and NS3-4 viral 
proteases. NS2 is a membrane spanning protein (Santolini et al. , 1995) and in the HCV 
genotype 2a JFH-1/Huh-7-based cell culture system, which will be described in detail in 
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Section 1.9.2.3, it has been shown that adaptive mutations in the NS2 alone can lead to 
enhanced production of HCV (Russell et al., 2008). 
The NS3 protein includes a serine protease domain, which is located at theN-terminus 
of the protein, and a helicase domain, at the C-terminus. The serine protease is known to 
cleave the HCV polyprotein at the NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B sites. 
NS4A is the smallest of the HCV NS proteins and is part of the NS3-4A protease, 
which is involved in cleavage of the polyprotein (Lindenbach et al., 2007a). The NS4B is 
an integral membrane protein that associates with the ER membranes. Data has shown 
that the expression ofNS4B induces the formation of the membranous web within the 
cytoplasm which is involved in HCV replication (Penin et al., 2004). Replication-
enhancing mutations have been identified in NS4B in the JFH-1-based cell culture system 
(HCVcc) which will be described in Section 1.9.2.3 (Pietschmann et al., 2009). 
The NSSA protein is a membrane-associated phosphorylated multidomain protein that 
has been found to play a role in HCV replication (Lindenbach et al., 2007b ). In the JFH-
1 Huh-7 system, adaptive mutations in NSSA confer more robust HCV replication 
(Dubuisson, 2007). As well, NSSA has been shown to contain an interferon sensitivity 
determining region (ISDR) found at amino acids position 237-276. Mutations in this 
region can result in higher interferon sensitivity and lower HCV RNA loads in hepatoma 
cell lines in vitro (Fukuma et al. , 1998). 
The NSSB protein is an RNA-dependent RNA polymerase (RdRp), the enzyme which 
drives HCV replication. NSSB is post-translationally inserted into the ER membrane, an 
association that has been found to be required for RdRp activity. Because of its well 
determined role in HCV replication, NSSB is a target for potential HCV -specific antiviral 
12 
therapies (Pockros et al., 2008; Kneteman et al., 2009), which will be discussed in greater 
detail in Section 1.1 0.2. 
1.4.4. Replication Strategy 
Plus-stranded RNA viruses, such as polio virus (Bienz et al., 1992), mouse hepatitis virus 
(Gosert et al., 2002) and flaviviruses (Westaway et al., 1999), are known to reproduce via 
a replication complex which is comprised of viral proteins, replicating RNA and altered 
cellular membranes. The existence of an HCV replication complex has been clearly 
shown in cell culture models ofHCV (Gosert et al., 2003). Studies employing the 
replicon system have shown that in HCV -transfected Huh-7 cells, all of the HCV NS 
proteins, as well as HCV RNA plus-strand, coexist in the cytoplasm in association with a 
specific membrane ultrastructural alteration, referred to as the membranous web (Gosert 
et al., 2003). HCV propagation occurs via synthesis of the HCV RNA negative strand, 
which serves as a template for synthesis of the HCV RNA positive strand. Therefore, the 
detection of this strand is accepted as an indicator of actively progressing replication. 
The HCV RdRp, discussed above, is the enzyme responsible for this process (Lohmann 
et al., 1997; Moradpour et al., 2003). Due to the lack of 3'-exonuclease proofreading 
activity, the RdRp inserts mutations into the genome during replication (Bartenschlager 
and Lohmann, 2000). The HCV quasispecies, defined as a swarm of closely related but 
genetically distinct variants, is a direct consequence of a high rate (1 012 virions per day) 
of error-prone replication which results in the generation of a multiplicity of viral 
variants. Thus, the error rate of HCV during replication is 1.5-2 x 1 o-3 base substitutions 
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per genome site per year (Neumann et al., 1998). The role ofthe HCV quasispecies in 
viral immune evasion will be discussed in detail in Section 1.8.2. 
1.4.5. Virion Ultrastructure and Biophysical Properties 
The virion of HCV is a spherical 40-60-nm particle that is made up of a detergent-
sensitive lipoprotein envelope with spike-like projections. This envelope encapsulates a 
spherical nucleocapsid that exhibits polyhedral symmetry (Kaito et al., 1994; Heller et al., 
2005). The non-enveloped HCV nucleocapsid ranges in size from 25-50 nm and have 
been seen to band at approximate 1.24 g/mL in a sucrose gradient and 1.33 g/mL in 
cesium chloride (Miyamoto et al., 1992; Kanto et al., 1994; Trestard et al., 1998; Maillard 
et al., 2001) . The density of enveloped HCV virions has been found to be heterogeneous 
with reported densities ranging from 1.04 to 1.11 g/mL in a sucrose density gradient and 
between 1.18 and 1.25 g/mL in a cesium chloride gradient (Hijikata et al., 1993; Kanto et 
al., 1994; Diaz et al. , 2006). Low density particles have been shown to be associated 
with lipoproteins (Diaz et al., 2006), while high density particles, with immunoglobulins 
(Hijikata et al., 1993). 
1.5. NATURAL HISTORY OF HCV INFECTION 
1.5.1. Acute Hepatitis 
The first 6 months following HCV invasion is considered as the acute phase of infection. 
During this time period, viral RNA titers rise rapidly with the viral load doubling as 
quickly as every 10.8 hours (Glynn et al., 2005). HCV RNA can be detected in the serum 
within 7-21 days after exposure using polymerase chain reaction (PCR)-based assays 
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(Farci et al., 1991), while it takes on average 50 days for HCV-specific antibodies to be 
detected (Orland et al., 2001; Cox et al., 2005). In the majority ofHCV-infected patients, 
acute infection is asymptomatic and frequently not diagnosed (Marcellin, 1999). In 15-
30% of HCV -infected patients, symptomatic acute hepatitis (AH) is identified (Busch and 
Shafer, 2005). The symptomatic phase is thought to occur between 2 and 12 weeks after 
exposure and can last up to 12 weeks thereafter (Orland et al., 2001). During AH, serum 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, which 
indicate hepatocyte injury, can be as high as 10 times the normal level (Thomas and Seeff, 
2005). The HCV RNA load in patients during AH has been seen to range from 104 to 10 7 
genome copies or virus genome equivalents (vge) /mL (Alter M.J et al, 1992; Glynn et al. , 
2005). In patients who experience symptomatic acute infection, the frequency of 
spontaneous, apparent complete clearance of viremia is higher than that in those with 
asymptomatic infection (Gerlach et al. , 2003; Santantonio et al., 2003). 
1.5.2. Spontaneous Resolution of Hepatitis C 
AH can be spontaneously resolved in 15-25% of cases (Thimme et al., 2001 ; Cox et al. , 
2005). In children, this clearance can occur in as few as 6% ofHCV RNA-seropositive 
individuals, as was seen in a study of224 European children (Jara et al. , 2003). In terms 
of immunological determinants, a robust and vigorous response including HCV -specific 
CD4+ and CD8+ T cell reactivity against multiple viral epitopes is associated with 
spontaneous recovery (Thimme et al. , 2001 ; Gerlach et al., 2003; Santantonio et al. , 
2003). Among genetic factors, a single nucleotide polymorphism upstream of the 
interleukin (IL)-28B gene encoding the type III interferon (IFN-3 or IFN-A.), has been 
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recently found in individuals with European and African backgrounds to be associated 
with enhanced resolution of hepatitis C (Thomas et al., 2009). The rates of spontaneous 
clearance in IDU who have been re-infected can be as high as 83%, further emphasizing 
the role of the adaptive immune response in apparent complete resolution of viremia 
(Osburn et al. , 201 0). It has also been found that patients infected with genotype 3 have a 
greater frequency of resolution of hepatitis C than those afflicted with genotype 1 
(Lehmann et al. , 2004). 
1.5.3. Chronic Hepatitis 
Chronic hepatitis Cis characterized as HCV RNA persistence in serum (plasma) for 6 
months or longer post-exposure and can occur in up to 85% of patients infected (Thomas 
and Seeff, 2005). During chronic symptomatic infection in adults, HCV RNA loads are 
lower than in AH and they generally plateau at levels between 104 and 106 IU/mL 
(approximately 5x104 and 5x106 vge/ mL) (Fabrizi et al., 2000). In a proportion of 
patients, serum HCV RNA and AL T levels can fluctuate (Ingles by et al., 1999). Patients 
with CHC can be asymptomatic for many years although some may experience fatigue, 
right upper quadrant pain, nausea, dark urine, itching and anorexia (Hoofnagle, 1997). In 
CHC, the measure of disease progression is the degree of liver necroinflammatory 
lesions, which is characterized by portal and intralobular lymphomononuclear cell 
infiltration, hepatocyte necrosis and fibrosis, as determined by histological examination 
of liver biopsy. 
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1.5.4. Factors Affecting Progression to Liver Disease 
Factors affecting the progression of CHC and cirrhosis in individual patients appear to be 
both host and virus related. In a study which examined development of liver disease in 
2235 HCV-infected patients by examining the META VIR score (a standardized scoring 
system which measures both the degree of inflammation and fibrosis), the median rate of 
progression to fibrosis was 0.133 fibrosis units per year, with fibrosis progression per 
year being defined as the ratio between fibrosis stage in META VIR units and the time-
span of infection (Poynard et al., 1997). Several independent host factors have been 
found to be associated with a faster rate of liver injury progression, such as: (1) male sex 
(possibly related to a protective effect of estrogen) (DiMartino et al., 2004); (2) alcohol 
consumption (greater than 50 g/day) (Schiff and Ozden, 2003), and (3) age of acquisition 
of infection (those who are infected after the age of 40 show more severe disease). The 
median time from the acquisition of HCV infection to cirrhosis is estimated to be 30 
years. However, men infected after the age of 40 have been seen to progress to cirrhosis 
with a median of only 13 years, while women who did not consume alcohol progress to 
cirrhosis in a median of 42 years (Poynard et al. , 1997). 
Additional factors promoting progression of CHC include duration of infection, 
immunosuppressive therapy and low CD4+ T cell count due to human immunodeficiency 
virus (HIV) infection, HBV infection or schistosomiasis coinfection, non-alcoholic 
steatohepatitis and non-responsiveness to antiviral therapy (Thomas and Seeff, 2005). 
Excessive iron load in the liver has also been suggested to accelerate progression to 
cirrhosis. Mutations in the hemochromatosis gene, which causes higher ferritin and serum 
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iron in heterozygous patients, has been seen to be an independent risk factor for 
progression to liver fibrosis and, subsequently, cirrhosis in HCV-infected patients 
(Erhardt et al., 2003; McCaughan and George, 2004). 
Considering virus-related factors, it has been postulated that the expression ofHCV 
proteins can affect the degree of liver fibrosis and disease progression. For example, 
HCV core protein has been shown to induce oxidative stress, alter mitochondrial function 
and increase the production of reactive oxygen species, which in turn promote apoptosis 
(Okuda et al., 2002). It has been reported that increased expression of activated caspases, 
which are mediators of apoptosis, in sera of patients with CHC, is associated with a 
higher degree of fibrosis in these patients. (Bantel et al. , 2004). 
Coinfection with HIV has been shown to augment progression to fibrosis in patients 
with CHC and is accompanied by higher serum levels ofHCV RNA (Thomas et al., 
1996; Benhamou et al., 1999). At the same time, evidence has shown that certain 
antiviral therapies can slow the progression of CHC to cirrhosis. HIV /HCV co infected 
patients treated with protease inhibitors experienced a significantly lower rate of cirrhosis 
than patients not receiving this treatment (Poynard et al., 1997; Benhamou et al., 2001; 
Feld and Liang, 2006). 
Nonetheless, so far, it is still not possible to accurately predict the rate of progression 
of CHC to fibrosis for individual patients based on known virus and host factors (Feld 
and Liang, 2006). 
For children, as compared to adults, the course of CHC seems to be more mild and the 
rate of progression to fibrosis is much slower (Broide et al., 2004). Most children are 
diagnosed incidentally and rarely have symptoms. As well, children with CHC 
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spontaneously resolve hepatitis less frequently and rarely develop cirrhosis or 
hepatocellular carcinoma as well as extrahepatic complications. The explanation for a 
milder course of infection and slower progression to fibrosis could be related to an 
apparent immune tolerance ofHCV at birth or early in life (Garcia-Monzon et al. , 1998). 
1.5.5. Occult Persistence 
The introduction of highly sensitive nucleic acid amplification assays capable of 
detecting below 10 vge/mL or 2 IU/mL has changed our understanding of the natural 
history of HCV infection. These assays have allowed for the detection of very low levels 
ofHCV RNA positive and negative (replicative) strands in individuals who have resolved 
CHC either spontaneously or due to antiviral therapy with IFN and RBV (Pham et al. , 
2004). 
Presently, standard clinical laboratory assays have sensitivities which range between 
30 and 1000 vge/mL or 9.6 and 615 IU/mL (Pham and Michalak, 2008). Commonly, the 
predominant test being used in clinics is the VERSANT HCV RNA version 3.0 assay 
from Bayer with a sensitivity of approximately 1000 vge/mL or 615 IU/mL. The most 
sensitive of these tests involve transcription mediated amplification (TMA) assays such 
as the VERSANT HCV® RNA assay that can achieve a sensitivity of ~30 vge/mL or 9.6 
IU/mL. However, this assay is not yet routinely used for clinical evaluation. 
The detection ofHCV RNA positive strands in the serum, and both positive and 
negative strands in peripheral blood mononuclear cells (PBMC) and/or liver of 
individuals who have been found to be repeatedly HCV RNA non-reactive by standard 
clinical laboratory tests and have repeatedly normal AL T levels is defined as occult 
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infection (OCI) (Pham et al., 2004; Radkowski et al., 2005a; Laskus et al., 2007; 
Michalak et al., 2007; Pham et al., 2008). This finding was first reported by this 
laboratory (Pham et al., 2004) and confirmed by other groups (Castillo et al. , 2004; 
Radkowski et al., 2005a; Castillo et al. , 2006). It has been found that applying sensitive 
detection techniques (sensitivity of 10 vge/mL or 2 IU/mL) uncovers HCV replication for 
years after apparent complete spontaneous or therapeutically-induced resolution of 
hepatitis (Pham et al. , 2004). Additionally, HCV RNA has been reportedly detected in 
patients with elevated liver function tests of unknown etiology (Castillo et al., 2004). 
Furthermore, HCV RNA positive and negative strands have been detected in CD4+ 
and CDS+ T cells, B cells and monocytes in individuals after clinically apparent 
resolution of hepatitis Cas well as the appearance of distinct HCV variants in their 
immune cells (Pham et al. , 2008). 
In terms of duration of OCI, HCV RNA positive and negative strands have been 
detected in liver biopsy samples taken from patients that had apparently clinically cleared 
the virus up to 8 years earlier (Radkowski et al., 2005a). At this point, due to limited 
follow-up periods, it is not known whether occult HCV infection occurs for the entire 
life, like other persistent viruses, such as HBV (Michalak et al., 1994) and Epstein-Barr 
virus (EBV) (Babcock et al., 1998). It has been suggested that a major clinical 
consequence of occult infection are the public health implications in that patients, without 
clinical markers of infection, may carry a risk to the community with respect to blood 
donation and organ transplantation (Pham et al., 2004; Feld and Liang, 2005). 
The presence of residual virus that has the ability to replicate may lead to HCV 
reactivation after apparent successful antiviral treatment. The rates of HCV recurrence, 
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after sustained virological response (SVR), which is defined as serum HCV RNA 
negativity by standard clinical laboratory RT-PCR assays for a minimum of 6 months 
after completion of antiviral treatment, have been reported to be as high as 20% (Di 
Liberto et al., 2006). A study following 97 HCV infected subjects after a response to 
IFNIRBV, in which testing for HCV RNA was carried out every 6 months over a 7 year 
follow-up period, revealed that 11ofthese patients (corresponding to 11.3%) showed 
viral recurrence (Ciancio et al., 2006). Viral reactivation has also been observed in HCV 
RNA- negative patients who were recipients of liver, kidney (Melon et al., 2005; Savas et 
al., 2007) or bone marrow transplants (Zekri et al., 2004), and it is suggested to occur as a 
result of immunosuppressive therapy (Lee et al., 2005). 
The challenges to estimating the numbers of patients that experience HCV recurrence 
after SVR are: (1) The lack of sufficiently sensitive standard clinical HCV RNA 
detection assays; (2) The infrequency of testing of serial serum samples of patients after 
SVR and (3) Testing is limited to serum or plasma but not including PBMC or liver 
tissue. 
Factors which can enhance the detection of OCI include testing of larger volumes of 
plasma or serum after ultracentrifugation (Bartolome et al., 2007) and stimulation of 
PBMC with mitogens if the nai've cells were found to be HCV non-reactive (Pham et al. , 
2005). In studies carried out in this lab in which both the sera and PBMC compartments 
were tested in individuals after resolution of hepatitis, HCV RNA positive and in some 
cases negative strands were detected in at least one compartment (either serum or PBMC) 
in the majority of cases tested (Pham et al., 2004). In later studies, it was also found that 
serial sampling of sera and lymphoid cells augmented the degree of detection of residual 
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virus (Pham et al., 2007). As well, a recent study examining 276 individuals with no 
indication of hepatic disease (HCV antibody and plasma HCV-RNA negative with 
normal liver enzyme levels) found that 3.3% of these patients carried HCV-RNA in their 
untreated PBMC (De Marco et al., 2009), supporting the notion of sampling multiple 
compartments when testing for HCV RNA. 
Occult HCV persistence has been suggested to be responsible for HCV -specific 
cellular immune responses in the absence of clinical markers of viremia (Quiroga et al. , 
2006). To that end, it has been speculated that occult HCV persistence may be helpful to 
the host in that there is maintained antigenic stimulation in the host and by constant 
stimulation of HCV -specific T cells (Pham et al. , 2008). The idea that residual HCV 
replication contributes to ongoing liver pathology was addressed by Castillo and 
colleagues in a study that found virus in 57 of 100 patients who had no detectable virus 
by standard clinical assays (Castillo et al. , 2004). They also found that the same 
individuals who had residual viral replication also had persistently elevated liver enzymes 
and were more likely to have liver fibrosis and mild inflammation (Castillo et al., 2004). 
At the same time, in 172 HCV antibody-positive, HCV RNA-negative patients who had 
apparently resolved viremia and had normal liver functions, liver biopsies revealed that 
82% had fibrotic changes with CD8+ T cell infiltrates that were similar to that seen in 
viremic patients. These findings support the notion that a large number of patients that 
have been clinically found to have resolved CHC continue to carry HCV in the liver 
(Hoare et al. , 2008). 
From this laboratory, studies indicate that sensitivity of HCV detection assays should 
be <1 0 vge/mL and testing should include samples of all 3 compartments of virus 
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occurrence (i.e., plasma, PBMC and liver) and preferably serial samples (Michalak et al., 
2007). 
1.5.6. Extrahepatic Non-Lymphatic System Manifestations 
Studies have shown an association of HCV with several diseases of organs other than the 
liver and the lymphatic (immune) system (which will be reviewed in Section 1.6.1). 
Membranoproliferative glomerulonephritis (MGN) has been associated with chronic 
HCV infection (Johnson et al., 1993; Davda et al. , 1993). Although factors leading to the 
development of HCV -related MGN are unclear, deposition of immune complexes 
containing HCV antigens, immunoglobulin (Ig)G or lgM class antibodies to those 
antigens in the renal glomeruli are most likely the pathogenic factor (Johnson et al., 
1993). It has also been suggested that B cell activation and antibody production, which 
will be discussed in Section 1.6.1., are a possible mechanism of the development of this 
pathology (Johnson et al., 1993). The notion that HCV may have a role in the 
development ofMGN is supported by the fact that interferon alpha (IFN-a.)-based 
antiviral therapy leading to a reduction ofHCV RNA load in patients has also been 
shown to result in histological improvement of renal pathology (Y amabe et al., 1995). 
Vasculitis, a potentially fatal disease characterized by the inflammatory destruction of 
blood vessels, veins and or arteries (McMurray and Elbourne, 1997), has been found in 
some cases to be associated with HCV infection (Marcellin et al., 1993). HCV -related 
vasculitic lesions have been observed in such places as the skin, muscle, lungs and 
intestine. The mechanism of development of HCV -related vasculitis is likely the same as 
MGN. Treatment ofHCV-related vasculitis with immuosuppressive agents, such as 
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rituximab (an anti-CD20 antibody used to deplete B cells), has been shown to reduce 
pathology in 67% of patients although up to 95% of patients experience clinical recovery 
when rituximab was coupled with IFN/RBV therapy (Terrier et al., 2009). As well, all 
relapses ofvasculitis in the rituximab/IFN/RBV-treated patients were associated with a 
failure of antiviral therapy to control HCV infection. 
Increased development of insulin resistance and type 2 diabetes mellitus have been 
observed in patients with HCV (Mehta et al., 2003; Romero-Gomez, 2006). A 
retrospective study of patients with diabetes found that 4.2% of diabetic patients, were 
infected with HCV, however, 29% of those HCV-positive patients carried the genotype 
2a virus (Mason et al., 1999). The mechanism of HCV -related insulin resistance is 
unclear. A study by Kawaguchi and colleagues (2004) found that increased fasting 
insulin levels were associated with the presence of HCV core in serum, liver fibrosis, and 
decreased expression of insulin signaling molecules, insulin receptor substrate (IRS) 1 
and 2 respectively. In an in vitro study of human hepatoma cells expressing HCV core 
and in HCV core-transgenic mouse livers, it was found that expression of HCV core 
leads to degradation ofiRS1 and IRS2. Resolution ofHCV infection has been seen to 
improve insulin resistance and increase expression of IRS 1 and IRS2 (Kawaguchi et al., 
2005). While diabetes development has been seen to be related to liver fibrosis stage, it 
has been suggested that the association between stage of fibrosis and insulin resistance 
may be indirect in that factors that promote insulin resistance may also promote 
development to fibrosis (Negro, 2006). Additionally, in a study of 28 non-diabetic HCV 
patients, increased insulin resistance was observed, as measured by an increased 
homeostasis model assessment of insulin resistance (HOMA-IR) value, as well as greater 
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insulin secretion at baseline (Lecube et al. , 2006). Higher levels of pro-inflammatory 
cytokines, such as tumour necrosis factor alpha (TNF-a) were found in patients with 
HCV, which suggests that this cytokine may be mediating insulin resistance. 
Thyroid disorders, such as Hashimoto's thyroiditis (Agmon-Levin et al., 2009), 
autoimmune thyroid disease (Pateron et al. , 1992) and hypo- or hyperthyroidism, have 
also been found at increasing rates in patients with CHC. The mechanism of 
development ofthyroid disease in CHC is unknown (Femandez-Soto et al. , 1998). 
However, IFN-a treatment in patients with CHC who show thyroid disease, can lead to 
further thyroid gland dysfunction (Femandez-Soto et al., 1998). 
Porphyria cutanea tarda (PCT) is a disease caused by reduced uropophyrinogen 
decarboxylase activity and leads to cutaneous lesions, skin fragility, iron overload and 
chronic liver disease (Fargion et al. , 1992). PCT has been found to be strongly associated 
with HCV infection (Herrero et al., 1993; Decastro et al. , 1993). In a study of20 
Japanese patients with PCT, 85% were found to be HCV infected (Tsukazaki et al. , 
1998). The role ofHCV in the development ofPCT is unclear, although it is thought that 
infection triggers the development of the disease in genetically predisposed individuals 
(Zignego et al. , 2007). 
Other extrahepatic manifestations that occur with a greater frequency in HCV -infected 
individuals include lichen planus (Nagao et al. , 2000), Sjogren's syndrome (Agmon-
Levin et al., 2009) and chronic polyarthritis (Zignego et al., 2007). 
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1.6. HCV L YMPHOTROPISM 
HCV lymphotropism refers to the propensity of HCV to infect and replicate in the 
cells of the immune system. HCV has been shown in several studies to infect lymphoid 
cells as evidenced by the detection of HCV RNA positive strand and its replicative 
intermediate, HCV RNA negative strand. Data exists indicating that in the absence of 
detectable HCV RNA in the serum, virus may be detected in the PBMC (Pham et al., 
2004; Pham et al., 2005; De Marco et al., 2009; Pham et al., submitted). 
Reports oflymphotropism include HCV infection ofT cells and B cells (Shimizu et 
al., 1992; Zignego et al., 1992; Navas et al., 1994; Goutagny et al., 2003; Radkowski et 
al., 2004; Pham et al., 2004; Pham et al., 2005; Pal et al., 2006; Pham et al., 2008). HCV 
replication in lymphoid cells has been described during CHC as well as years after 
apparent complete therapy-induced or spontaneous resolution of hepatitis C (Pham et al., 
2004; Radkowski et al., 2005a; Pham et al., 2008). 
In a study which measured the presence ofHCV RNA positive and negative strands in 
lymphoid cell subsets in patients with CHC and OCI, it was found that HCV was able to 
replicate in CD4+ and CDS+ T cells as well as in B cells (Pham et al., 2008). 
Additionally, in the same study, HCV NS5A protein was detected in the same cell subsets 
and HCV variants distinct from those occurring in plasma were also identified. 
In terms ofthe HCV RNA loads in lymphoid cells, it has been shown that between 
100 and 1000 vge/1 0 7 cells can be detected in approximately 30% of patients with OCI 
who have apparently resolved hepatitis, while approximately 104 vge/1 0 7 cells can be 
detected in patients with CHC (Pham et al., 2007). Meanwhile, HCV RNA levels 
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comparable to those occurring in immune cells from patients with CHC can be detected 
in -10% of patients with OCI (Pham and Michalak, 2008). It is presently unclear 
whether HCV persists for life in the lymphatic system, but it is currently known that virus 
can linger in immune cells for at least 9 years after apparent complete recovery from 
hepatitis C (Radkowski et al., 2005a; Pham et al., submitted). 
Whether or not HCV found in lymphoid cells represents a lymphotropic strain or 
whether HCV replication in the immune cell environment selects for specific viral 
variants is presently unclear. However, HCV viral sequences detected in lymphoid cells 
have been found to be distinct from the wild-type virus in circulation (Shimizu et al., 
1997; Pham et al., 2004; Radkowski et al. , 2005a). Replication ofHCV in the lymphatic 
system has been proposed as a reservoir for reinfection of liver grafts post transplantation 
(Pal et al., 2006). HCV lymphotropism and extrahepatic replication has been implicated 
as the underlying cause ofB celllymphoproliferative disorders (Blackard et al., 2006) 
which will be discussed in detail in Section 1.6.1. In terms of impairment of lymphoid 
cell function, HCV -infected T cells and B cells have been found to be functionally 
impaired and this will be discussed in Sections 1.6.2 and 1.6.3, respectively. In this 
thesis, the lymphotropic nature and replication of HCV in T lymphocytes was 
investigated and will be discussed in detail in Chapters 2, 3 and 4. 
1.6.1. B Cell Dysfunctions and Related Pathology 
Disorders associated with HCV infection involving B lymphocytes include type II mixed 
cryoglobulinemia (MC)(Pawlotsky et al., 1995) and B-cell non-Hodgkin's lymphoma 
(Zignego et al., 1997; Ferri and Mascia, 2006). 
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1.6.1.1. Mixed Cryoglobulinemia 
Approximately 80% of patients with type II mixed cryoglobulinemia are also infected 
with HCV (Agnello et al. , 1992). This disease is associated with the accumulation of 
cryoglobulins, which are immunoglobulins that form solid deposits at 4°C. It has been 
found that up to 5% of patients with HCV -related cryoglobulinemia will develop 
vasculitis (Vassilopoulos and Calabrese, 2002). The mechanism of cryoglobulinemia in 
HCV infection is not clear, but is thought to be related to unregulated B cell proliferation. 
B cells have been shown to be stimulated to undergo proliferation and IgM production by 
direct stimulation ofCD81 by HCV E2 glycoproteins (Fearon and Carroll, 2000; Curry et 
al. , 2003). As well, in HCV infected patients with fibrosis and end stage cirrhosis, there 
is an expansion ofCD5+, CD81+ B cells in the liver (Curry et al. , 2003). The contribution 
ofHCV to the appearance ofMC is supported by the resolving effect that antiviral 
therapy has on this condition. Thus, it has been observed that treatment with IFN/RBV 
results in clinical recovery from HCV-associated MC in up to 67.5% of patients, 
suggesting that resolution ofMC is linked to a decreased level of viremia (Saadoun et al. , 
2006). 
1.6.1.2. B Cell Non-Hodgkin's Lymphoma 
Lymphotropic HCV infection, identified by the detection of HCV RNA in circulating 
lymphoid cells, has been found in the majority of HCV patients with non-Hodgkin 
lymphoma (Ferri et al., 1997). B-cell non-Hodgkin' s lymphoma is defined as an 
uncontrolled proliferation of B lymphocytes associated with a high incidence of 
circulating monoclonal B cells. As mentioned in Section 1.6.1.1 , it has been suggested 
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that the interaction between HCV and CD81 on B cells may result in stimulation of B 
cells, leading to uncontrolled B cell proliferation. 
1.6.2. T Cell Dysfunctions 
As will be discussed in Section 1.7.3, HCV clearance is associated with a robust and 
multi-specific CD4+ and CD8+ T cell response. In patients chronically infected with 
HCV, T cells have been found to be functionally exhausted and display defects in 
production of interferon-gamma (IFN-y) and IL-2 (Semmo et al. , 2007), as well as 
impaired proliferation in response to stimulation with HCV -specific antigens (Golden-
Mason et al., 2009). In T cells, exposure to HCV in vitro resulted in impaired IFN-y 
signaling in that in HCV -infected T cells, Stat-1 and T bet mRNA levels were suppressed 
after stimulation with IFN-y compared to uninfected T cells (Kondo et al., 2007). An 
additional functional defect observed in T cells of patients with CHC is reduced 
cytotoxicity (Thimme et al., 2001). A possible mechanism ofT cell exhaustion is the 
higher expression of certain inhibitory receptors compared to healthy counterparts. In 
this regard, programmed death receptor-1 (PD-1) is a major inhibitory receptor on T 
cells. Binding of PD-1 by its ligand programmed death receptor-ligand 1 (PD-L 1) results 
in the inhibition ofT cell proliferation and cytokine production (Blank et al. , 2005). It 
has been demonstrated that PD-1 expression on total T cells and CD8+ T cells in the 
peripheral blood and in the livers of patients chronically infected with HCV is 
significantly higher than that of those who spontaneously resolve (Golden-Mason et al. , 
2007). It has been further shown that blocking the PD-1/PDL-1 interaction with 
antibodies to PD-L1 and/or PD-L2leads to recovery of proliferation, IFN-y secretion and 
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IL-2 production in previously dysfunctional, HCV-specific CTLs (Golden-Mason et al., 
2007; Nakamoto et al., 2008). In addition to PD-1 , T cell immunoglobulin and mucin 
domain-containing protein 3 (TIM-3) interaction with its ligand galectin-9 has been 
implicated as another possible mechanism ofT cell exhaustion in CHC. The binding of 
TIM-3 to galectin-9 has been found to result in negative regulation ofT-helper type 1 
(THl) responses and the induction of peripheral tolerance (Sabatos et al., 2003; Zhu et 
al., 2005). In this regard, in HIV infection, expression ofTIM-3 has been found to be 
elevated on both CD4+ and CD8+ T cells compared to uninfected individuals or those 
who were able to control infection (Jones et al., 2008). As well, it has been shown that 
TIM-3 expression is upregulated on CD4+ and CD8+ T cells in CHC patients (Golden-
Mason et al., 2009). Further, the greatest proportion ofPD-1/TIM-3-dual expressing T 
cells was found in the liver ofCHC patients. Blocking ofTIM-3 and TIM-3 ligand 
interaction rescued proliferation ofT cells and IFN-y production (Golden-Mason et al., 
2009). 
1.6.3. HCV-Related Dysfunction ofNK Cells 
Natural killer (NK) cells belong to the first line of defence against viral infections and are 
rapidly activated to acquire cytotoxic activity and to produce inflammatory cytokines 
such as IFN-y and TNF-a (Biron, 1999). The innate immune response is characterized by 
a considerable amount of cross-talk between NK cells, NK T cells and DC (Biron, 1999; 
Heath et al., 2004; Kanto and Hayashi, 2007). It is thought that during HCV infection, 
the failure of the host immune response may be due to virally inhibited cross-talk 
between these cells which leads to decreased priming of the adaptive immune response. 
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As mentioned previously, HCV particles and recombinant HCV E2 proteins bind to 
CD81 (Pileri et al., 1998). In vitro, ligation of CD81 by HCV E2 protein has been 
shown to directly block NK cell function, as evidenced by inhibited IFN-y and TNF-a. 
production, as well as diminished cytotoxic granule release and decreased CD25 
expression (Crotta et al., 2002; Tseng and Klimpel, 2002). 
1.6.4. Factors Augmenting HCV Replication in Immune Cells 
Coinfection with other viruses may augment HCV replication in lymphoid cells. For 
example, Molt-4 cells infected with murine retroviruses have been shown to be more 
readily infected with HCV as compared to their counterparts who were free of 
retroviruses. Active replication in these cells was evidenced by the detection of HCV 
RNA negative strand (Shimizu et al., 1992). In patients coinfected with HCV and HIV, 
circulating levels of HCV RNA in the sera have been found to be higher than in HCV-
mono infected patients (Thomas et al., 2001) suggesting that perhaps HCV RNA levels in 
the PBMC may also be higher. 
In addition, the removal of certain PBMC subsets, such as IFN-y-producing CD8+ T 
cells, has been shown to increase HCV replication in CD8+-depleted PBMC compared to 
those not depleted of the T cell subset (Li et al., 2005b ). This is thought to be due to the 
anti-viral properties ofiFN-y as the addition of CD8+ T cell-conditioned medium to Huh-
7 cells has been shown to result in decreased HCV replication (Li et al. , 2004). As well, 
addition ofCD8+ T cells to CD8+ T cell-depleted PBMC led to inhibition ofHCV 
replication (Li et al. , 2005b ). Mitogens such as phytohemagluttinin (PHA), concanavalin 
A (Con A) and poke weed mitogen (PWM), have been utilized to augment HCV 
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replication in PBMC from individuals with OCI (Pham et al., 2005). Mitogen treatment 
led to increased HCV replication and, in consequence, virus genome detection in 
circulating immune cells (Pham et al., 2004; Pham et al., 2005). 
1.7. HCV-INDUCED IMMUNE RESPONSES 
1.7.1. Innate Immunity 
1. 7.1.1. Cellular Components 
1.7.1.1.1. Natural Killer Cells 
NK cells are part of the first line of defence against HCV (Kanto and Hayashi, 2007). 
Under normal circumstances, the interaction ofNK cells with DC leads to IFN-y 
production and NK-mediated cytolysis (Yu et al., 2001). In HCV infection, the function 
ofNK cells appears to be impaired in terms of decreased cytolysis and IFN-y production. 
In vitro, in human hepatic cell lines, such as Huh-2, Huh-7 and Huh-7-derived lines, NK 
cell-conditioned medium high in IFN-y has been shown to inhibit HCV replication, while 
incubation ofNK cells with anti-CD81 antibodies resulted in decreased IFN-y production 
and a lessened anti-HCV effect (Li et al. , 2004). NK cells from CHC patients have also 
been seen to secrete immunosuppressive cytokines, such as IL-l 0, and transforming 
growth factor~ which can downregulate DC functions (Zignego, 2004). In HCV-
infected individuals, proportions ofNK cells in circulation has been found to be similar 
in numbers, as compared to uninfected patients, however, the cells cytolytic activity is 4-
fold lower than that of healthy individuals (Corado et al. , 1997). As well, the same study 
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showed that in vitro infection ofPBMC with HCV resulted in decreased NK cell 
cytotoxic capacity. Further, successful antiviral therapy in patients chronically infected 
with HCV leads to recovery ofNK cell function (Bonavita et al., 1993). 
1. 7.1.1.2. Natural Killer T Cells 
During the normal response to viral infection, NKT cells are thought to activate DC and 
NK cells through secretion ofiFN-y. It has been observed that NKT cells in chronic 
HCV infection are biased towards Th2-type response (Kanto and Hayashi, 2007). As 
well, it has been identified that the proportion ofValpha24Nbeta11 double positive NKT 
cells are lower in chronically infected patients compared to controls (Lucas et al., 2003). 
1. 7.1.1.3. Dendritic Cells 
The role ofDCs in the innate response to viral infection involves the detection, 
processing and presentation of viral antigens. The major DC subsets are myeloid DC, 
which mainly secrete IL-12 and TNF-a and drive a Th1 response. On the other hand, 
plasmacytoid DC secrete IFN-a and drive a Th2 response (Liu, 2001). DC in patients 
with CHC, have an impaired response to HCV antigens, such as HCV core and El, while 
maintaining their ability to respond to non-HCV antigens, such as tetanus toxoid (Sarobe 
et al., 2002). Additionally, DC from HCV-infected patients are unresponsive to 
exogenous IFN-a in vitro (Kanto and Hayashi, 2007). 
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1.7.1.2. Interferon Induction 
Innate immune components are the first responders in a virally infected host. The innate 
response is triggered by the recognition of a pathogen-associated molecular pattern 
(P AMP), which binds its specific P AMP receptor. In HCV infection, double-stranded 
RNA is bound by two P AMP receptors, Toll-like receptor (TLR) 3 and retinoic-acid-
inducible gene I (RIG-I). Engagement ofPAMP receptors result in the downstream 
activation of interferon regulatory factors (IRF), such as IRF-3, IRF-5 and IRF-7, as well 
as nuclear factor 1Cl3 (NFKB) (Malmgaard, 2004). This results in the secretion ofiFN-
beta (IFN-~), which binds to the IFN-a/~ receptor leading to JAK-STAT signaling and 
subsequent activation ofiFN-stimulated genes (ISG). In the chimpanzee model ofHCV 
infection, the expression of interferon response genes involved in the type 1 IFN 
signaling pathway can be induced as early as 2 days after infection (Bigger et al. , 2001; 
Thimme et al., 200 I). The observed early induction of IFN does not appear to be related 
to or predict resolution of hepatitis (Thimme et al., 2001; Thimme et al., 2002) which 
may be explained by subversion of the IFN response by viral components, a topic that 
will be discussed in Section 1.8.1. 
1.7.2. Adaptive Immunity 
1.7.2.1. Humoral Immunity 
On average, by 50 days after HCV exposure, patients seroconvert and produce antibodies 
against HCV proteins (anti-HCV) (Orland et al., 2001; Cox et al. , 2005). These 
antibodies are not thought to be broadly neutralizing, which may be attributed to the high 
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sequence variation in the HCV genome and the generation of escape mutants (Farci et al. , 
1994). The role ofthe humoral response in the clearance ofHCV is not clear as apparent 
HCV clearance has been observed in the absence ofHCV-specific antibody production 
(Post et al. , 2004). The appearance of anti-HCV antibodies in patients and in 
experimentally infected chimpanzees does not appear to protect against reinfection with 
the same strain or a heterologous strain of HCV (Farci et al., 1992). However, using 
chimeric mice with humanized livers as a model ofHCV infection, human monoclonal 
antibodies against HCV E2 have been identified to be able to protect against challenge 
with a heterologous HCV quasispecies. In vitro, this antibody was able to neutralize 
HCV particles released from Huh-7 cells in vitro infected with JFH-1 (system described 
in Section 1.9.2.3) and HCVpp expressing E1 and E2 from several HCV genotypes (Law 
et al. , 2008). Recent studies have confirmed this finding with anti-E2 antibodies showing 
neutralizing abilities against pseudoviruses carrying E1 and E2 glycoproteins from 
genotypes 1a, 1 b, 2b, 3a and 4a (Broering et al., 2009). 
1.7.2.2. Cellular Immune Responses 
Throughout the course of HCV infection, spontaneous decline in viremia in the acute 
phase is associated with strong, HCV -specific, CD4+ and CD8+ T cell responses, directed 
against multiple HCV epitopes (Gerlach et al., 1999). 
HCV -specific CD4+ T cell reactivity that develops in the acute phase of infection are 
associated with a sustained Th1 response, characterized by the induction of type 1 
cytokines, such as IFN-y and TNF-a, and with viral control (Gerlach et al., 1999). CD8+ 
cytotoxic T cells (CTL) contribute to viral elimination in HCV infection through direct 
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killing of infected cells and the induction of antiviral cytokines, such as IFN-y and TNF-
a. Both CD4+ and CD8+ T cell activation is typically required for resolution of hepatitis 
(Rehermann and Nascimbeni, 2005), a finding that has been very well documented in the 
chimpanzee model. In one such study, CD4+ T cells were depleted by antibody before 
infection of chimpanzees. In the presence of a functional memory CD8+ T cell response, 
the elimination of CD4+ T cells resulted in poor viral control and persistent viremia 
(Grakoui et al., 2003). In another study, chimpanzees that had been shown to control 
HCV challenge and clear the viremia in two previous HCV infections, were depleted of 
CD8+ T cells before a third exposure to virus. Even in the presence of previously primed 
CD4+ T cells, the absence of CD8+ T cells resulted in prolonged viremia until CD8+ T 
cells recovered (Shoukry et al., 2003). 
CD4+ and CD8+ T cell responses in chimpanzees infected with HCV are seen to be 
delayed with the approximate time to intrahepatic, HCV -specific T cell activation being 4 
to 8 weeks after onset of viremia (Thimme et al., 2001; Thimme et al., 2002). As well, 
the induction of HCV -specific peripheral blood T cell responses in chimpanzees appears 
to be delayed until 8 weeks, reflecting that seen in the liver (Shin et al. , 2008). 
Meanwhile, in chimpanzees, the appearance ofHCV-specific T cell responses and IFN-y 
production occurs directly before a decline in serum HCV RNA load (Thimme et al., 
2001). 
In terms of epitopes recognized by HCV -specific T cells, in HLA-A2, HCV -infected 
patients, several CTL epitopes, in regions such as core, E2, NS3, NS4 and NS5, have 
been identified. Although no clear immunodominant epitopes have been found, it has 
been shown, using MHC-class 1 tetramers, that a CTL epitope within NS3 (1073-81) is 
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frequently recognized in HLA-A2 positive patients (Takaki et al., 2000). NS3 (1073-81)-
specific T cell responses are found to be associated with control of virema (Takaki et al., 
2000), although recognition of this epitope alone is thought to be inadequate for viral 
control (Urbani et al., 2005). HCV-specific CD4+ T cell epitopes have been uncovered 
and, in the case ofNS3 (1248-1261), they can be recognized by patients with at least 5 
different HLA-DR backgrounds (Diepolder et al., 1997). In IDU, CD4+ T cell responses 
were investigated in terms of the magnitude and the HCV epitopes targeted in infected 
patients that spontaneously cleared viremia versus those who developed CHC. It was 
observed that there is a slight, non-statistically significant difference in the magnitude of 
HCV -specific CD4+ T cells between the patient groups although patients that went on to 
resolve hepatitis had CD4+ T cell responses mainly directed to the non-structural 
proteins, while those acquiring CHC were observed to have CD4+ T cell responses 
predominantly targeting the HCV core protein (Ruys et al., 2008). 
As far as a memory T cell response to HCV infection, patients who were exposed to 
HCV eighteen years earlier and have undetectable anti-HCV antibodies, continued to 
have HCV -specific CD4+ and CD8+ T cell responses (Takaki et al. , 2000), although this 
control could be due to the presence of OCI (Pham and Michalak, 2008). As well, in 
chimpanzees, prior exposure to HCV has been shown to result in a shorter course of 
infection with reduced peaks of viremia in re-challenged animals (Bassett et al. , 2001). 
In humans, in studies examining re-infection ofiDU with continuing exposure to HCV, 
those who had previous HCV infection followed by spontaneous resolution of hepatitis, 
had a 4-fold reduced likelihood of developing viremia following re-exposure (Grebely et 
al., 2006). At the same time, HCV -specific CD4+ and CD8+ T activation appears to occur 
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in all recovered patients as such responses have been observed in both patients who have 
spontaneously resolved hepatitis as well as those who have achieved an SVR after 
IFNIRBV therapy (Klade et al., 2009). 
Regulatory T cells (Tregs) are known to maintain self-tolerance and control 
deleterious immune responses (Sakaguchi et al. , 2006). The role ofTregs in the immune 
response to HCV infection remains unclear. In vitro, co-culture of HCV -specific CD8+ T 
cells with CD4+CD25+ Tregs led to decreased IFN-y production (Sugimoto et al. , 2003). 
It has been observed that removal of CD4+CD25+ Tregs from peripheral blood resulted in 
rescued HCV-specific CD4+ and CD8+ T cell proliferation and IFN-y production 
(Cabrera et al., 2004). However, in the chimpanzee model, there appeared to be no 
difference in the quantities of Tregs in the liver and circulation in animals that had 
chronic hepatitis as compared to those that resolved hepatitis (Manigold et al., 2006). 
1.8. 
1.8.1. 
HCV ESCAPE FROM ANTIVIRAL IMMUNE RESPONSES 
Interference with the Innate Immune Response 
As mentioned earlier, there is a strong innate activation due to recognition ofHCV 
double-stranded RNA that leads to the stimulation of the interferon pathway resulting in 
the induction ofiSG. As well, propagation of subgenomic replicons and full-length HCV 
clones have been shown to be inhibited in the presence ofiFN-a in vitro (Frese et al. , 
2001; Lindenbach et al. , 2005). However, early induction ofiFN-a in the chimpanzee 
model of hepatitis C does not predict viral clearance (Thimme et al. , 2001). This 
observation has led to studies of the ability of HCV proteins to directly or indirectly 
interfere with the interferon induction cascade. As outlined in Section 1.7.1., IRF-3 is part 
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of the signalling cascade implicated in the innate response to HCV RNA. NS3/4A 
protease was found to be an antagonist of this response and blocks IRF-3 activation 
through cleavage of the adaptor protein TRIF (Ferreon et al., 2005; Li et al. , 2005a). 
NS3/4A protease has also been shown to block RIG-I signaling and subsequent IRF-3 
activation via cleavage of the adaptor protein IFN promoter-stimulator 1 (Loo et al. , 
2006). As well, HCV is known to disrupt the IFN-a signaling pathway through 
disruption of protein kinase R (PKR) signaling. The HCV E2 and NS5A proteins can 
both bind and inhibit PKR-PKR phosphorylation (Gale et al., 1997; Taylor et al. , 1999), 
although it has been shown that expression ofNS5A alone can lead to cells becoming 
resistant to the effects ofiFN-a against viruses, such as interferon-sensitive 
encephalomyocardititis virus (Polyak et al., 1999). An additional viral strategy of evasion 
of the IFN response is through the production of IL-8, which is induced by the interaction 
ofHCV NS5A protein with 2' -5 ' oligoadenylate synthetase (OAS) (Polyak et al., 2001). 
As discussed in Section 1. 7 .1.2, ligation of the IFN -a/~ receptor during the host response 
to the detection of double-stranded viral RNA, leads to JAK-STAT signaling and 
subsequent activation of ISG. HCV core protein has been shown to induce the 
expression of suppressor of cytokine signalling (SOCS) proteins 1 and 3, which blocks 
JAK-STAT signaling through the IFN-a/~ receptor and inhibits downstream ISG 
expression (Bode et al. , 2003; Vlotides et al., 2004). 
1.8.2. Quasispecies Expansion and Immune Escape 
Host selective immune pressure has been shown to drive HCV quasispecies expansion 
(Manzin et al., 2000). One of the examples is that patients that are immunosuppressed 
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have a less evolved viral population (Lawai et al., 1997). Immune pressure on HCV is 
exerted by: (1) the humoral response which includes neutralizing antibodies directed 
specifically against the dominant neutralizing epitope contained in the HVR1 of the E2 
and (2) the cellular response, in which CTLs are directed against conserved regions of the 
genome, such as the NS3 protein. In a study of children with perinatal HCV infection, it 
was observed that HCV-infected newborns, in the presence ofhigh levels ofviral 
replication, had a single dominant variant or a small number of closely related viruses 
that remained stable for several weeks while the humoral and cytotoxic host immune 
responses were immature. The quasispecies in these newborns was observed to diverge 
and expand around 6 to 7 months of age. In contrast, acutely infected adults are seen to 
have rapid viral evolution after infection, likely due to the presence of an active virus-
specific immune response (Manzin et al., 1998; Manzin et al. , 2000). 
Studies have shown that the CTL response can "select" for HCV variants that have 
mutations in the conserved regions which can render the virus unrecognizable to virus-
specific CTLs. These changes in viral sequence are known as virus escape mutants 
because they can evade or subvert host immunosurveillance (Weiner et al. , 1995). These 
mutations, however, can occur at the expense of virus fitness in that the mutated viruses 
may be less replication competent. Thus, the survival of such mutations and their 
subsequent stabilization hinges on whether the immune escape mutants will be able to 
replicate efficiently. If the mutated virus is as fit or replication competent as the wild-
type virus, it may be 'fixed' in the quasispecies in the absence of immune pressure. 
However, if the escape mutant has reduced replication efficiency, in the absence of host 
immune pressure, the wild-type virus, which replicates more robustly will prevail and 
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will drown out the escape mutant. This event is known as reversion. In this regard, in 
chimpanzees, virus isolated from an animal in the acute phase ofHCV infection was used 
to infect an HCV -na"ive animal and the presence of neutralizing antibodies in the plasma 
of the infected animal was evaluated over an 11-year period against the virus used for 
inoculation. While plasma obtained 2 years after infection neutralized the original 
inoculum, plasma taken from the same animal 11 years after inoculation was no longer 
neutralizing for this same inoculum. This suggested that the quasispecies had gone 
through significant evolution with respect to the virus in the original inoculum (Farci et 
al., 1994). 
In humans, mutants in the HCV NS3 region have been found that confer escape from 
CDS+ T cell responses in patients with HLA-BS background (Timm et al. , 2004). 
Interestingly, when virus carrying the BLA-BS-associated escape mutation was 
transmitted to an HLA-BS negative individual, the mutation was subsequently lost, 
suggesting a reversion of mutations in the BS-associated epitope to the fitter wild-type in 
the absence ofHLA-BS restricted CTL pressure 
1.9. MODELS OF HCV INFECTION 
1.9.1. Animal Models 
The main challenge in the attempt to understand the natural history and pathogenesis of 
HCV infection is the lack of a convenient and reliable animal model. Some of the 
models currently employed are: (1) Chimpanzees (Farci et al. , 1992); (2) the Scid-
AlbluP A mouse (K.neteman et al., 2006; Kneteman et al., 2009); (3) the HCV trimera 
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mouse (Eren et al., 2006; Galun et al., 2007); (4) the Tupaia belangeri; (5) the NOD/Scid 
mouse model, and (6) transgenic mice expressing HCV proteins. Each of the above 
mentioned animal models have advantages and disadvantages which are related to: (1) 
differences in the course of disease compared to humans; (2) the reproducibility of the 
model; (3) the availability of animals, and (4) the cost ofthe model. Specific aspects of 
the most widely used animal models are discussed below. 
1.9.1.1. The Chimpanzee Model 
The chimpanzee has been used to study the course of HCV infection, the pathogenesis of 
HCV as well as prevention and management strategies against HCV. Chimpanzees have 
been employed to investigate several aspects ofhepatitis C immunopathogenesis 
including: (1) the role ofCD4+ and CD8+ T cells in viral clearance (Shoukry et al., 2003; 
Grakoui et al., 2003); (2) the lack of immune protection following reinfection (Farci et 
al., 1992); (3) the efficacy of vaccination (Esumi et al., 1999; Puig et al., 2006; Roilier et 
al., 2007; Elmowalid et al., 2007), and (4) the infectivity oflymphocyte-derived virus 
(Shimizu et al., 1998). It has been demonstrated that approximately 20 copies of HCV 
can transmit infection to chimpanzees (Katayama et al., 2004a). Chimpanzees produce 
virions at high levels, i.e. 105 to 107 vge/ mL (Bukh, 2004). In experimentally infected 
chimpanzees, development of chronic hepatitis has been observed to occur in 
approximately 60% of animals (Bigger et al. , 2004), which is comparable to that seen in 
humans. In terms of reproducibility, the course of infection in each chimp, similar as in 
humans, cannot be predicted (Rosenberg, 2001 ). The use of chimps is very limited due to 
high costs of animal maintenance (approximately $30,000 per animal), restricted 
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availability and ethical issues tied to the fact that these animals are endangered. With 
these issues in mind, most studies including chimpanzees have very few animals. There 
are a wide variety of tools available to examine the immunopathogenesis of infection and 
to test the efficacy of antivirals in the chimp model due to the fact that many human 
reagents, i.e. antibodies, oligonucleotide primers and assays, are directly applicable to 
investigations in chimpanzees. However, the chimpanzees are not an optimal choice to 
test classical antiviral agents, such as IFN-a. Thus, in studies using IFN-a with or 
without ribavirin, as well as adenovirus-based gene therapy to upregulate expression of 
IFN-a in the liver, treatment failed to decrease HCV load despite the fact that high levels 
ofiFN-a were found to be circulating in treated animals (Lanford et al., 2006). On the 
other hand, there are studies showing that the HCV-NS5B inhibitor A-837093 
successfully inhibited HCV replication in the chimpanzee model (Wagner et al., 2006) 
although due to availability of very few animals, dose-dependent studies are difficult. 
1.9.1.2. The Scid-Aib/uP A Mouse Model 
The beige Scid-Alb/uPA mouse is the most successful small animal model ofHCV 
infection. In this model, severe combined immunodeficient (SCID) mice are generated 
that express a urokinase plasminogen activator transgene driven by the albumin promoter 
(Alb/uP A). The damaged mouse livers are then repopulated with a xenograft of human 
hepatocytes that are functional and produce human albumin. Repopulated livers can 
then be infected with HCV (Mercer et al., 2001 ). The Scid-AlbluP A mouse has been 
utilized in the testing of antiviral therapies, such as IFN-a and inhibitors blocking NS3 
protease or NS5B polymerase activities (Kneteman et al., 2006; Kneteman et al., 2009). 
43 
However, due to the fact that these mice are immunodeficient, this is not a model for 
testing HCV vaccines. Another restriction is that the mice are susceptible only to HCV 
doses greater than or equal to 105 copies per mouse (Mercer et al., 2001 ), which makes it 
infeasible to test the infectivity of low-copy numbers of virus occurring in OCI. Finally, 
while this animal model is less expensive than the chimpanzee model, it is labour 
intensive and requires the availability of high quality human hepatocytes for mouse liver 
repopulation. 
1.9.1.3. The Scid-BNX Trimera Mouse Model 
The Scid-BNX "trimera" mouse is a chimeric mouse model in which beige/nude/X-
linked immunodeficient (BNX) mice were sublethally irradiated and reconstituted with 
bone marrow from Scid mice. The animals are then able to accept fragments of HCV-
infected liver from patients with chronic HCV. The trimera mouse model has been 
employed to test the efficacy of neutralizing antibodies in inhibiting HCV infection in 
human liver grafts (Eren et al. , 2006; Galun et al., 2007) and antiviral agents (Ilan et al., 
2002). The limitations of the Scid-BNX mouse model is that only approximately 50% of 
mice become infected with HCV after grafting and that this infection only lasts for 10-50 
days post-transplant (Galun et al., 1995). 
1.9.1.4. The Nod/Scid Mouse Model 
The NOD/Scid mouse is a model in which NOD/SCID mice are engrafted with human 
liver tissue which can then be subsequently infected with HCV from infected patients. 
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When infection is successful, viremia can last for up to 4 weeks. However, this model 
suffers from a low rate of infection (Maeda et al., 2004). 
1.9.1.5. The Tupaia Belangeri Model 
The Tupaia belangeri has been shown to be susceptible to HCV infection (Xie et al. , 
1998). In vitro, primary hepatocytes from the tupaia have been infected with HCV and 
are capable of producing virions that can de novo infect HCV -naive hepatocytes (Zhao et 
al., 2002). In a study looking at the role of SRBI, in vitro pre-incubation of primary 
Tupaia hepatocytes with anti-SRBI antibodies led to inhibition ofHCV particle or E2 
protein binding, suggesting this model can be useful in investigating the interaction 
between E2 and SRBI (Barth et al., 2005). In this model, in vivo susceptibility of the 
tupia to HCV is greater after whole-body irradiation, which would make vaccine studies 
unlikely (Xie et al., 1998). 
1.9.1.6. Transgenic Mice 
Several laboratories have generated transgenic mice expressing HCV proteins, such as 
core, E1, E2, NS3, NS4 and NS5A either alone (Kawamura et al., 1997; Majumder et al. , 
2002; Kawamura et al., 2006; Chang et al. , 2008) or together (Pasquinelli et al. , 1997; 
Matsuda et al., 1998; Frelin et al., 2006). These mice have been used to investigate the 
role of HCV proteins in the immunopathogenesis of liver injury in the induction of 
steatosis, the development of HCC, and modulation of apoptotic cell death. Using this 
model, several observations on the affects of viral proteins on liver pathology were made, 
among others that HCV core protein can induce lipid accumulation in hepatocytes and 
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that the expression of this protein may result in the development of cancer (reviewed in 
(Barth et al., 2008). 
1.9.2. Cell Culture Models 
1.9.2.1. The Replicon Systems 
The replicon system is an in vitro virus culture method that was first described in 1999 
(Lohmann et al., 1999). This approach was based on the transfection of cloned selectable 
viral RNA which replicates autonomously in the target cells. Replicons have been 
developed for several viruses, such as HCV, bovine diarrhoea virus, Lassa virus and 
Sindbis virus (Frolov et al., 1997; Behrens et al., 1998; Hass et al., 2004). The HCV 
subgenomic replicon was first created with a 5' -HCV IRES, a neomycin 
phosphotransferase gene, which determines G418 resistance, a second IRES from 
encephalomyocarditis virus, which directs processing of the polyprotein, and the HCV 
sequence from the beginning ofNS2 or NS3 to the end of the 3 ' - UTR (Lohmann et al. , 
1999). Cell culture adaptive mutations indentified in the non-structural gene encoding 
regions, such as in the interferon sensitivity determining region found in the NS5A, 
which increased replicative ability of the replicon (Blight et al. , 2000). As well, adaptive 
mutations in the NS5B gene improved the efficiency of colony formation (Lohmann et 
al., 2001). In general, the replicon systems have advanced our understanding of the role 
of individual viral proteins in virus and served as a tool for the testing of antiviral 
therapies potentially targeting HCV. Among others, the first clinically tested NS3 
protease inhibitor BILN 2061 was tested in Huh-7 cells carrying the HCV 1 b subgenomic 
replicon (Lamarre et al., 2003). 
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1.9.2.2. Pseudoparticle System 
The HCV pseudoparticle (HCVpp) system is a cell culture system employing retroviral 
and lentiviral core particles expressing HCV E1 and E2 glycoproteins This system can be 
used to study infectivity and the early stages of viral infection (Bartosch et al., 2003b ). 
Due to packaging of the particle with a green fluorescence protein (GFP) marker gene, 
this system has been employed to show that primary hepatocytes and hepato-carcinoma 
cells were infected in vitro and that this infection required the presence of El and E2 
proteins, and was neutralized by anti-E2 monoclonal antibodies (mAb) (Bartosch et al., 
2003a; Owsianka et al., 2005). In addition, HCVpp have been employed to investigate 
putative HCV co-receptors, such as LDLR (Bartosch et al., 2003b), CD81 (Cormier et al., 
2004; Owsianka et al., 2006), SRB 1 (Voisset et al., 2005), claudin-1 (Evans et al., 2007) 
and occludin (Ploss et al., 2009). In addition, the HCVpp system is a tool to indentify 
factors which may enhance infectivity such as addition of apolipoprotein C 1 to target 
cells (Meunier et al., 2005). 
1.9.2.3. The HCVcc System 
The JFH-1 strain ofHCV was isolated from a 32 year old Japanese male with fulminant 
hepatitis. It is a genotype 2a strain of virus which replicates efficiently and supports 
secretion of infectious viral particles in cell culture, known as (HCV cc ), after transfection 
of full-length JFH-1 RNA into a human hepatoma (Huh)7.5 cell line, without requiring 
cell culture adaptive mutations (Zhong et al., 2005; Lindenbach et al., 2005; Wakita et al. , 
2005). The major improvement of this strain over the previously described HCV replicon 
system is that the JFH-1 viral clone is able to support virus assembly and the secretion of 
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infectious particles into culture supernatant enabling the study of the full HCV life cycle. 
The generated particles, which bind to anti-core, El and E2 antibodies, display 
biophysical properties of complete HCV virions of 50-65nrn in diameter and a buoyant 
density of 1.01 to 1.17 g/mL with the peak of infectivity between 1.09-1.11 g/mL in 
sucrose (Zhong et al., 2005; Lindenbach et al. , 2005; Wakita et al., 2005). JFH-1-derived 
virus has been shown to propagate in primary human hepatocytes although the level of 
replication observed is presently unclear (Molina et al. , 2008). On the other hand, it has 
been observed that JFH-1 particles do not infect or replicate in primary lymphocytes, 
which the authors suggest may be due to the fact that, unlike virus particles found in 
patient sera, JFH-1 is a cloned virus without quasispecies properties, and may therefore 
lack the presence of lymphotropic variants (Marukian et al., 2008). JFH-1 particles have 
in vivo infectivity in chimpanzees, although infection was associated with low virus titres 
of approximately 103 vge/mL, a transient 9-week course of viremia, and no 
seroconversion (Kato et al., 2008). However, in the above described, JFH-1-infected 
chimpanzees, adaptive mutations in NS2 developed that resulted in greater virus 
replication. Although not thought to be required for replication, cell culture adaptive 
mutations have been described in the NS2 and p7 proteins that independently lead to 3 to 
4 log higher virus titres in in vitro infected Huh-7 .5 cells (Russell et al. , 2008). 
Originally, only the JFH-1 HCV strain was able to infect and propagate in Huh-7.5 
cells which are deficient in RIG-I and TLR3, limiting this system to the study of the full 
cycle ofHCV genotype 2a infection in this specific hepatoma line (Zhong et al., 2005; 
Lindenbach et al. , 2005; Wakita et al., 2005). However, infectious strains of full length 
virus have been developed that are intergenotypic and intragenotypic chimeras of JFH-1 
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nonstructural proteins with structural elements from other 2a virus strains and other HCV 
genotypes including 1a, 1 b 2a, 3a as well as the J6CF 2a strain (Pietschmann et al., 2006; 
Mateu et al., 2008). These HCV chimeras replicate at different efficiencies in Huh-7 
cells with some requiring adaptive mutations for infectivity (Yi et al., 2007). Chimeric 
viruses also have different specific infectivities suggesting that the presence of JFH-1 
non-structural proteins alone does not confer robust replication, rather there is an 
interaction between structural and non-structural elements which determine replication 
and particle formation. 
1.9.3. In Vitro Infection of Primary Hepatocytes 
In vitro infection of primary human hepatocytes with serum-derived HCV has been 
described in some studies (Fournier et al. , 1998; Lazaro et al. , 2007; Buck, 2008). The 
potential benefit of such a system is testing the susceptibility to infection with different 
genotypes (Lazaro et al. , 2007). In vitro infection of chimpanzee hepatocytes with wild-
type HCV has also been reported (Lanford et al., 1994). Compared to the replicon 
system, which is restricted to specific virus sequences and employs hepatoma-derived 
Huh-7 cells, this system can employ wild-type virus and allows for investigation of the 
early steps of HCV infection and replication (Fournier et al. , 1998). Nonetheless, the 
data reporting the use of primary hepatocytes as HCV targets are limited due to 
difficulties in obtaining primary human hepatocytes and challenges in maintaining 
hepatocytes in culture. 
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1.10. 
1.10.1. 
THERAPY OF HCV INFECTION 
Approved Therapies and Treatment Strategies 
From the initial observation that IFN-a could be employed in the treatment of non-A, 
non-B hepatitis (Hoofnagle et al., 1986), antiviral therapy for HCV has been advanced. 
Numerous multicenter studies evaluated the efficacy of treatment with different 
preparations of IFN-a and in treatment regimes with and without RBV (McHutchison et 
al., 1998; Poynard et al. , 1998; Manns et al. , 2001; Fried et al. , 2002). This led to the 
presently accepted treatment for CHC with IFN/RBV. Thus, IFN is administered 
intravenously as pegylated IFN-a2a (180 )lg/week) or pegylated IFN-a2b (1.5 
)lg/kg/week). RBV is administered orally at doses of0.8 to 1.2 g/day depending on body 
weight (Heathcote et al., 2000; Fried et al., 2002). The current treatment efficacy is 
approximately 80% in patients with genotypes 2 and 3 infection and approximately 45% 
in patients with HCV genotype 1 infection (Heathcote et al., 2000; Manns et al. , 2001; 
Fried et al., 2002; Hadziyannis et al., 2004). Therefore, identification of the HCV 
genotype prior to therapy is a key element in determining the course of antiviral 
treatment. Since genotypes 1, 4, 5 and 6 are less responsive to IFN/RBV therapy, the 
treatment for these patients is 48 weeks, whereas for those carrying genotypes 2 and 3 the 
treatment is 24 weeks long. Monitoring the reduction in serum HCV RNA allows for 
determination of the response to therapy very early in treatment. Data has shown that the 
kinetics of the reduction of viremia is biphasic (Zeuzem, 1999). Phase 1 consists of the 
first 24 hours after administration ofiFN/RBV. In this period, there appears to be a rapid 
dose-dependent reduction in serum viral load. In Phase 2, which is the time period 
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beyond day 2, a slower decline in viremia is observed. The response in this phase can 
predict overall treatment outcome and the possibility of an SVR (Zeuzem et al., 2001 ). 
HCV RNA testing at week 4 and week 12 after treatment initiation is used to determine 
whether an early virological response (EVR), which is defined as a 2-logtO viral reduction 
or apparent complete clearance of HCV RNA at 12 weeks, or rapid virological response 
(RVR), defined as undetectable serum HCV RNA at week 4, has occurred. Measurement 
of the RVR and EVR allows for early prediction of antiviral treatment efficacy and 
decisions of whether to stop or continue the treatment. Data have shown that the course 
ofiFNIRBV therapy for patients who achieve an RVR can be shortened to between 12 
and 16 weeks for genotypes 2 and 3 and to 24 weeks for genotype 1 (Heathcote, 2007; 
Poordad et al., 2008). If a patient carries genotypes 1, 4, 5 or 6, and the HCV load does 
not drop by 2 log10 or more by 12 weeks of therapy, then the patient has only a 0-3% 
chance of achieving SVR after 48 weeks of treatment. In the case of patients who 
respond poorly to IFN/RBV therapy in the first 4 weeks of administration, a prolonged, 
72-week course of treatment has been shown to increase SVR rates (Heathcote, 2007). 
1.10.2. Future Therapies 
There are several challenges in the development of future HCV therapies. These 
challenges include: (1) A need to develop modalities targeting HCV (they include agents 
specifically directed against HCV enzymes, such as HCV protease, helicase and RNA 
dependent RNA polymerase); (2) Improving treatment efficacy (this may require agents 
targeting sites of extrahepatic virus replication; (3) Minimalization of the side effects of 
therapy and (4) Management of resistant viruses (this may include development of 
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antivirals against resistant HCV strains which are unresponsive to the current IFN-a/RBV 
therapy (Pawlotsky, 2004; Koike, 2006). 
The development of HCV -specific therapies is an important area of research and 
several promising agents are under development. Among them, VX-950, also known as 
telaprevir, which is an oral HCV protease inhibitor that has been shown to decrease the 
HCV load in patients who had previously not responded to classical IFN-a/RBV therapy 
(Reesink et al., 2006; Hezode et al. , 2009). In 2003, Larnmare and colleages developed 
an HCV NS3 protease inhibitor, BILN 2061 , which showed a potent effect on HCV 
replication as evidenced by the sharp virus load decline observed in patients treated with 
this drug. The study of the efficacy of this drug was halted in phase II clinical trials due 
to cardiac cytotoxicity (Lamarre et al., 2003). Reports have also shown that SCH 
503034, a potent oral HCV protease inhibitor, when given in combination with PEG-IFN-
a-2b, is able to reduce viremia in hard to treat non-responders (Sarrazin et al., 2007). 
Polymerase inhibitors, such as HCV 796 and R1262 (Pockros et al. , 2008; Kneteman et 
al., 2009), which target the activity of HCV NS5B, have also been generated and have 
shown some efficacy in suppressing viral replication. One of the main challenges of 
antiviral treatment is adherence to therapy (Broers et al. , 2005) which can be poor in 
patients receiving IFNIRBV therapy due to side effects. In a study treating patients who 
had failed traditional IFN-a treatment, an altered form ofiFN-a, albumin-interferon alpha 
(Albuferon) was recently employed. This drug combines the potency of IFN-a and the 
stability of human serum albumin, with the half-life of Albuferon being 18 times longer 
than IFN-a and its clearance rate is 140 times slower. In patients treated, none 
discontinued therapy due to side-effects of the drug (Balan et al. , 2006). 
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The issue of the emergence or selection of resistant viral strains is an important 
consideration in the development of new antiviral treatments. In a study comparing 8 
patients treated with telaprevir alone to 8 patients receiving combination therapy of 
telaprevir and IFN-a over a period of 14 days, resistant viral variants were found in 6 of 
the 8 patients on the monotherapy regime while only 2 of 8 patients on combination 
therapy showed them. This suggests that combination therapy may be necessary to 
prevent the development of drug resistance (Kieffer T et al, 2006). However, while the 
combination oftelaprevir and IFN-a are effective in suppressing HCV replication, 
whether this will result in an SVR remains unknown (Lang, 2007). 
1.10.3. Orthotopic Liver Transplantation and Recurrence 
Cirrhosis resulting from HCV -induced CHC, and HCC, are the main causes in 
approximately 50% of liver transplantations (L T) in Western countries (Prieto et al., 
1998). High-level HCV viremia occurs almost invariably by one month after liver 
transplant (Gretch et al. , 1995; Testa et al., 2000). Progression to fibrosis has been 
observed with up to 50% of patients developing chronic active hepatitis in liver allografts 
during the first year following OLT (Gretch et al., 1995; Berenguer et al., 2000). 
Explanations for increased progression to fibrosis after LT appear to be related to: (1) the 
age of the liver donor; (2) differences in the virus virulence; (3) genetic differences 
between recipients, and 4) the amount of immunosupression or alcohol consumption 
following L T (Berenguer et al., 2000). With respect to faster progression to fibrosis, it 
has been clearly shown that the use of immunosuppressive therapies, such as 
cyclosporine and tacrolimus, is associate with higher HCV replication. In recent years, 
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the immunosuppressive agents used following L T has changed from cyclosporine to 
tacrolimus, in some treatment regimes, although studies show little or no difference in the 
level of recurrent HCV observed regardless of the agent (Ghobrial et al. , 1999; Martin et 
al., 2004; Hilgard et al. , 2006). 
1.11. PURPOSE OF THE STUDY 
Prior to these studies, it was known that HCV RNA positive and negative (replicative) 
strands and HCV proteins can be detected in the lymphocytes of patients chronically 
infected with HCV, as well as in those who have achieved a clinically apparent SVR. 
However, the infectivity of virus replicating in and the biophysical and ultrastructural 
properties of virions secreted by lymphocytes of patients with progressing symptomatic 
or clinically resolved HCV infection, remains unknown. Replication of HCV in cells of 
the immune system, similarly as in other long-term viral infections, could have 
implications in terms of viral interference in immune responses, immune escape and 
HCV persistence. 
It has also been previously shown that HCV replication in lymphoid cells of patients 
who resolved CHC can be significantly upregulated after mitogen stimulation. Based on 
our hypothesis that mitogen stimulation may both enhance HCV replication efficiency, as 
well as increase lymphocyte susceptibility to virus infection, we designed a preliminary 
study testing this possibility. In these preliminary experiments, unstimulated lymphoid 
cells were compared to those stimulated with a T cell mitogen. We found that stimulated 
cells could be more readily infected with wild-type HCV than non-stimulated cells. 
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Therefore, using these pre-treated lymphoid cell targets, the central objectives of the 
current studies were: 
1. To establish an in vitro infection system in which plasma or lymphoid cell-derived 
HCV can be used as an inoculum and normal human lymphoid cells as infection targets, 
and in which infectious HCV virions will be propagated. Specifically, we will explore 
the in vitro susceptibility of virus-naiVe, mitogen-pre-treated, total PBMC to infection 
with molecularly unmodified HCV, their ability to support HCV replication, to express 
viral proteins, and the assembly of complete HCV virions. We will test whether virion 
particles released in cell culture by de novo infected lymphoid cells can transmit HCV 
infection to naive cells, and whether HCV replication can be inhibited by treatment with 
IFN-a 2b and prevented by antibodies directed against the HCV envelope or a postulated 
virus receptor, CD81. Finally, we will investigate ultrastructural properties ofHCV 
particles released into culture supernatant by in vitro infected lymphoid cells. 
2. To assess whether exposure ofT cells to wild-type HCV influences the cell 
phenotype, proliferation, and cell survival in in vitro cultures. In this regard, we will 
examine modifications to the CD4+ to C08+ ratio following exposure to HCV and 
changes to the proliferative capacity and susceptibility to apoptosis of CD4-positive and 
COS-positive T cells. We will also test whether in vitro exposure of naive lymphocytes 
to HCV may have an effect on the expression profile of selected cytokines in these cells. 
3. To determine whether small amounts ofHCV lingering in the circulation long after 
therapeutically-induced clinically apparent resolution of CHC remain infectious. For this 
purpose, we will employ the in vitro HCV replication system established in aim 1. HCV 
de novo infection will be identified by detecting HCV RNA negative strand, 
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intracytoplasmic NS5A protein and the appearance of HCV variants in infected T cells. 
Also, neutralization of infection will be assessed using anti-E2 mAb, blocking with anti-
CD81 mAb, and treatment of the target cells with IFN-a 2b. We also will compare 
biophysical properties, i.e., buoyant density and sedimentation velocity, of the virus 
produced by in vitro infected cells with those of virions occurring in the plasma or 
released by patients' PBMC and used as inocula. Finally, an attempt will be made to 
visualize HCV virions circulating in patients with persistent asymptomatic HCV infection 
as well as those secreted by de novo infected T cells using immunoelectron microscopy. 
The establishment of a system for in vitro infection of normal, non-tumorous human 
cells with molecularly unmodified, wild-type HCV, will be of significant importance for 
studies of the complete cycle of H CV replication, identification of factors determining 
host's susceptibility to HCV, particularly molecules serving as HCV receptors, and for 
investigations on possible cytopathic consequences of wild-type HCV infection. Such a 
system will also be applicable for pre-clinical testing of the potential suitability of novel 
agents against HCV. 
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Chapter Two: De Novo Infection and Propagation of Wild-
Type Hepatitis C Virus in Human T Lymphocytes In Vitro 
This study has been published in Journal of General Virology in December, 2006, 
volume 87, pp. 3577-3586. 
2.1. SUMMARY 
While exploring previous findings that ex vivo treatment oflymphoid cells from HCV-
infected individuals with T cell-stimulating mitogens augments detection of the residing 
virus, an in vitro HCV replication system was established, in which mitogen-induced T 
cell-enriched cultures served as HCV targets and the derived T cells multiplied virus 
during repeated serial passage. HCV replication was ascertained by detecting HCV RNA 
positive and negative strands, HCV NS5A and E2 proteins, release of HCV virions and 
nucleocapsids (confirmed by imrnunoelectron microscopy) and de novo infection of 
mitogen-induced T cells prepared from healthy donors. Further, affinity-purified normal 
human T lymphocytes were also susceptible to HCV infection in vitro and HCV 
replication was detected in pure T cells isolated from a patient with chronic hepatitis C. 
These results documentthat T cells can support propagation ofHCV both in vivo and in 
vitro. The infection system established offers a valuable tool for in vitro studies on the 
entire cycle ofHCV replication, virus cytopathogenicity and evaluation of antiviral 
agents against wild-type HCV in the natural host-cell milieu. 
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2.2. INTRODUCTION 
Hepatitis C virus is a single-stranded RNA virus with a genome of9,600 base pairs in 
length which encodes for a single polypeptide subsequently co-translationally and post-
translationally cleaved to at least ten structural and nonstructural proteins (Bartenschlager 
and Lohmann, 2000). HCV is thought to propagate via synthesis of the so-called 
"negative strand". Although considered to be primarily hepatotropic, accumulated 
evidence indicates that HCV also replicates in the lymphatic system (Lerat et al. , 1996; 
Shimizu et al., 1997; Laskus et al., 1998). Its replicative intermediate has been 
demonstrated in PBMC from patients with progressing CHC (Laskus eta!., 1998; Okuda 
et al., 1999; Willems eta!., 1994) and individuals with apparent complete resolution of 
the disease (Pham et al., 2004; Pham et al., 2005; Radkowski et al., 2005a; Radkowski et 
al., 2005b ). HCV replication has been documented in T lymphocytes (Zignego et al., 
1992), B cells (Zignego et al. , 1992; Morsica et al. , 1999; Bare et al., 2005), monocytes 
(Radkowski et al., 2004), and dendritic cells (Goutagny et al. , 2003) in CHC patients. In 
addition, recent studies from this laboratory have shown that ex vivo mitogen treatment of 
PBMC from patients with CHC or those with occult HCV infection augmented HCV 
replication in this compartment (Pham et al. , 2004; Pham et al. , 2005; Pham and 
Michalak, 2006). 
Further support for the notion that lymphotropism is a natural propensity of HCV has 
stemmed from work with transformed or immortalized lymphoid cell cultures. For 
instance, HCV propagation has been demonstrated in EBV -transformed B cells isolated 
from PBMC of patients with CHC (Sung et al., 2003). The presence ofHCV RNA and 
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proteins has also been reported in in vitro infected human T cell lines, such as MOLT -4 
coinfected with human T celllymphotropic virus (Shimizu et al., 1992). However, many 
of these investigations relied on the target cells being co infected with other viral 
pathogens and overall, were difficult to reproduce. The lack of an adequate understanding 
of the mechanisms of HCV infection and a possible role of co-infecting viruses in 
promoting lymphoid cell susceptibility to HCV raises a concern that the initiation of 
HCV infection and propagation of the virus in these systems might have been altered. 
Considerable efforts to establish HCV replication in hepatocyte cultures have recently 
succeeded with the system in which transfection of Huh-7 hepatoma cells with a full-
length HCV RNA led to secretion of infectious viral particles (Zhong et al., 2005; 
Lindenbach et al., 2005; Wakita et al., 2005). However, this system is presently robust 
only for replication of HCV genotype 2a viral clones. 
The present study was undertaken in an effort to establish an in vitro infection system 
in which: (1) plasma or lymphoid cell-derived wild-type HCV can be used as an 
inoculum; (2) virus-transformed or -immortalized cells will not be used as infection 
targets, and (3) infectious HCV will be propagated. Over the course of this work, we 
designed conditions allowing for infection of human T cell-enriched cultures with wild-
type HCV and for its productive replication in the derived T cells. The system created 
should be of value for studies on the complete cycle of HCV replication, factors 
determining the host's susceptibility to HCV, and cytopathic consequences of wild-type 
HCV infection. It could also be utilized for testing the efficacy of anti-HCV agents in the 
natural host cell milieu. 
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2.3. MATERIALS AND METHODS 
2.3.1. Plasma-Derived HCV inocula 
Plasma from patient N07/M with serologically and histologically documented CHC was 
used as the main source ofwild-type HCV. This inoculum, designated HCV N07/M, 
carried HCV genotype 1aat 1x105 vge/mL, as determined by real-time RT-PCR (Pham et 
al., 2004). To establish whether the inoculum would be able to infect lymphoid cells, 
PBMC isolated from N07/M were examined and found to be positive for both HCV RNA 
strands by RT-PCR/nucleic acid hybridization (RT-PCRINAH) assays (Pham et al., 
2004). The estimated HCV load was approximately 105 vge per 107 cells. Plasma 
samples from five CHC patients were also used as sources of wild-type HCV: N08/M 
plasma contained HCV genotype 1 b at 5x 106 vge/mL; C07 IF, genotype 1 a at 
1.6x105 vge /mL; C32/M, genotype 1a at8.5x106 vge/mL; C34/M, genotype 1a at 
2.6x106 vge/mL; and N23/M, genotype lb at 1.9x104 vge/mL. HCV replication in PBMC 
was evident in these patients (not shown). The study was approved by the local Human 
Investigation Committee and samples were collected after informed consent had been 
obtained. 
2.3.2. Preparation of Lymphoid Cells 
Lymphoid cells serving as HCV infection targets were isolated from a healthy donor 
(AIM) with no clinical history or molecular indication of HCV exposure, as confirmed by 
RT-PCRINAH assay (sensitivity of ~10 vge/mL) (Pham et al., 2004), and who was 
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seronegative for anti-HCV (enzyme immunoassay; Abbott Diagnostics). For some 
experiments, lymphoid cells from two other HCV RNA- and anti-HCV -negative 
individuals, B/M and C/F, were utilized. For direct infection or serial passage ofHCV, 
PBMC were isolated from 40 mL blood. Monocyte-depleted cells were resuspended in 
culture medium at 1x106 cells/mL (Pham et al. , 2004). For some experiments, T 
lymphocytes were affinity-purified from PBMC of donor AIM. In parallel, T cells from a 
CHC patient (N09/F), who carried genotype 1 a at 2x 106 vge/mL, were isolated by 
negative selection using MACS magnetic beads (Miltenyi Biotec) (Pham et al., 2005). T 
cells were 97% pure by flow cytometry. 
2.3.3. Direct Infection with Plasma-Derived HCV 
Monocyte-depleted lymphoid cells were exposed to 5 Jlg phytohaemagglutinin (PHA; 
ICN Biomedicals)/mL for 48 hprior to inoculation with HCV (Pham et al., 2004). For 
direct infection, PHA-treated cells (lx106 cells/mL)were exposed to 250 J..LL heat-
inactivated (30 min at 56°C) plasma containing approximately 2.5x 104 vge. In parallel, 
the cells were exposed to 250 J..LL plasma from donor B/M for mock infection. Inocula 
were removed after 24 h, then the cells were washed and cultured with 20 U recombinant 
human interleukin-2 (IL-2; Roche Diagnostics)/mL for 72 h (phase A). At 4 days post-
infection (p.i.), supernatant was collected and the cells were cultured with 5 J..Lg PHA/mL 
and 20 U IL-2/mL (designated PHAIIL-2) for the next 72 h (phase B). At 7 days p.i., 
supernatant was harvested and the cells were again cultured for 3 days in medium with 
IL-2 (phase C). The culture supernatant collected at 10 days p.i. was centrifuged at 400 x 
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g for 30 min and used as the source of HCV for the serial-passage experiment. In a 
supplementary experiment, affinity-purified T cells from donor NM were infected with 
N07/M or N08/M inoculum and cultured for 10 days p.i. as described above. 
2.3.4. Serial Passage of HCV in T Cell Culture 
PHA-stimulated target cells were incubated with clarified supernatant after phase C from 
the direct infection, normally containing approximately 105 vge HCV. After 24 h, the 
cells were collected, washed and stimulated with IL-2 or PHNIL-2 (phases A, B and C) 
as described above. At day 10 p.i., supernatant was harvested and cells were cultured for 
96 h with PHNIL-2(phase D). The culture ended at 14 days p.i. withcollection ofthe 
supernatant and cells. A sample of the phaseD supernatant was preserved for analysis, 
whereas the remainder was used to infect fresh PHA-induced lymphoid cells. This was 
repeated 14 consecutive times, spanning a total of28 weeks. The phaseD supernatants 
were examined for completeness of cell removal by phase-contrast microscopy. 
Randomly selected phaseD supernatants were amplified for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) by using primers and PCR conditions reported previously 
(Hodgson and Michalak, 2001) and no signals were detected. To determine whether 
HCV produced after the multiple passage in NM T cells could infect cells from other 
healthy donors, PHA-pretreated lymphoid cells from B/M and C/F were incubated with 
pooled supernatant after phases A-C of passage 11 and cultured as described for the 
direct-infection experiment. 
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2.3.5. Blocking of HCV Infection in T cells with Anti-CD81 
The experiment was carried out with anti-CD81 mAb JS81 (Pharrningen) at 1 : 20 and 1 : 
100 dilutions in 50 J..LL containing 5x 106 mitogen-induced AIM T cells by using a 
previously published protocol (Zhong et al., 2005). T cells preincubated with an isotype-
control mAb and inoculated with the same HCV served as controls. The cells were 
cultured for 14 days before analysis. 
2.3.6. Treatment with Alpha Interferon (IFN-a). 
To reaffirm that active HCV replication was established in T cells, the cells were treated 
in triplicate with 1000, 100 or 10 U recombinant human IFN-a 2b (Research 
Diagnostics )/mL at the time of HCV inoculation. The same IFN- amounts were added to 
the culture each time that the medium was changed (phases A-D). The cells were 
cultured for 14 days as described above. IFN -a concentrations were non-toxic to 
lymphoid cells in an MTT [3-( 4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide] assay (data not shown). Cells inoculated with HCV, but not treated with IFN-a 
served as controls. 
2.3.7. Ultracentrifugation and Buoyant Density Gradients 
To determine HCV RNA in T cell culture supernatants, samples (5 mL) were centrifuged 
at 400 x g for 30 min and then at 150 000 x g for 22 hat 4 °C in an SW50.1 rotor 
(Beckman Instruments). RNA was extracted from the pellets and analysed by RT-
PCR/NAH. To examine ultrastructural features of the released viral particles, samples 
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(5 mL) of passage 5, 8 and 11 supernatants were clarified, ultracentrifuged and analysed 
by electron microscopy. As controls, the supernatant from AIM cells not infected with 
HCV, but cultured under identical conditions, was prepared. To analyse properties of 
HCV RNA reactive particles further, 15 mL pooled supernatant obtained after phases A-
C from passage 8 was clarified and ultracentrifuged as described above. The resulting 
pellet was resuspended in 800 11L 10 mM Tris/HCl buffer (pH 7 .2) with 0.15 M NaCl and 
10 mM EDT A and overlaid onto a 12 mL discontinuous gradient of 1.1- 1.6 g caesium 
chloride (CsCl)/mL prepared in the same buffer. In parallel, plasma samples (800 11L) 
from patient C26/F carrying 1.1 x 106 vge/mL and from a healthy donor were fractionated. 
After centrifugation at 200 000 x g for 48 hat 10 °C in a Beckman SW41 rotor, fractions 
(750 11L) were collected from the top of each gradient and analysed for HCV RNA and by 
electron microscopy. 
2.3.8. RNA Extraction and RT -PCRINAH. 
Total RNA was extracted by using TRizol (Invitrogen) from 1x107 cells (which usually 
yielded approx. 15 11g RNA) or from 100 11L of the pellet suspension obtained by 
ultracentrifugation of culture supernatants. RNA was also isolated from samples 
(650 11L) ofthe CsCl fractions by usingTRizol LS (Invitrogen). RNA (1--41-lg) was 
transcribed with Moloney murine leukemia virus (MML V) reverse transcriptase for HCV 
RNA positive-strand detection or with recombinant Tth DNA polymerase for virus RNA 
negative-strand detection (Pham et al. , 2004). PCR was carried out by using primers and 
conditions reported previously (Pham et al. , 2004). A water sample and a mock-treated 
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test RNA were always included as contamination controls. Complementary DNA 
(eDNA) from PHA-treated AIM cells exposed to BIM plasma(mock infection) and 
cultured as the infected cells served as a negative control, whilst 1 0-fold dilutions of 
recombinant HCV UTR-E2 fragment (rHCV UTR-E2) acted as quantitative standards. 
Specificity of the detection and validity of controls were confirmed routinely by Southern 
blot hybridization (Pham et al., 2004). Detection ofHCV synthetic RNA (sRNA) 
positive and negative strands was not affected by the presence of cellular RNA from 
healthy PHA-stimulated lymphoid cells. HCV RNA in plasma was quantified by real-
time RT-PCR using LightCycler Fast Start Master hybridization probes (Roche 
Diagnostics) (Pham et al., 2004). 
2.3.9. Detection of HCV NSSA and E2 Proteins 
For Western blotting, proteins ofT cells infected with HCV and recovered after passages 
3, 11 and 14 were separated on 10% sodium dodecyl sulfate-polyacrylamide gels and 
blotted as reported previously (Michalak et al. , 2000). Blots were probed with anti-HCV 
NS5A mAb (Biodesign) or anti-HCV E2 (ALP98) mAb (provided by Dr A. Patel, 
Institute of Virology, University of Glasgow, UK). HCV replicon cell line AB12-A2FL, 
containing full-length HCV genotype 1 b (provided by Dr C. Richardson, Ontario Cancer 
Institute, University of Toronto, Canada), was used as a positive control. AIM T cells not 
exposed to HCV, but cultured under the same conditions, were a negative control. 
Reactions were visualized by a horseradish peroxidase-conjugated secondary antibody 
and chemiluminescence. To assess intracellular expression ofHCV E2 protein in in vitro-
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infected T cells, confocal immunofluorescence microscopy was carried out by using 
AB12-A2FL Huh-7 cells, naiveHuh-7 cells and HCV-naive T cells as controls. Cells 
were grown overnight on poly lysine-coated 16-well glass slides (Nalge Nunc 
International), fixed with 4% paraformaldehyde and permeablized with 0.5% Triton X-
100. HCV E2 protein and tubulin were identified with anti-HCV E2 (AP33) mAb and rat 
anti-tubulin (Chemicon), respectively. Cy2-labelled donkey anti-mouse or Cy5-labelled 
donkey anti-rat antibodies (both from Jackson ImmunoResearch) were used in the second 
layer. Cells were examined in a Fluo View FV300 confocal system (Olympus). 
2.3.10. Transmission and Immune Electron Microscopy 
For routine microscopy, aliquots of the pellets recovered after ultracentrifugation or 
fractions from CsCl gradients and respective controls were applied onto Formvar-carbon-
coated 200-mesh microscopic grids. The grids were washed and stained negatively with 
1% phosphotungstic acid (PTA). To precipitate HCV cores, aliquots of the pellets were 
incubated with 20 !Jg anti-HCV core lgG2a mAb (Virogen)/mL or with an isotype-
control mAb for 1 h at ambient temperature and then overnight at 4 °C. Precipitates were 
loaded on grids. Alternatively, grids were incubated with anti-HCV core mAb or a 
control mAb for 10 min, washed, incubated with test samples for 10 min and washed. All 
grids were counterstained with PTA. To confirm that HCV virions were secreted by T 
cells, immunogold staining of the pellets recovered by ultracentrifugation from selected 
culture supernatants was done by using anti-E2 (AP33) mAb, as described by Owsianka 
et al. (2001). This was followed by incubation with anti-mouse lgG conjugated with 
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12 run gold particles (Jackson ImrnunoResearch) and counterstaining with 1 %PTA. 
Examinations were carried out with a JEM 1200 EX (JEOL) microscope. 
2.4. RESULTS 
2.4.1. Selective Expansion ofT Cells in Culture 
Anticipating that the intracellular environment supportive ofHCV replication elicited by 
PHA (Pham et al., 2004) may also enhance lymphoid cell susceptibility to virus, 
monocyte-depleted cells were PHA-treated prior to HCV exposure. After 48-h culture, 
the cells expanded by 20% to 45%. Approximately 64% of them were CD3-positive (T 
cells), with a CD4- to CD8-positive cell ratio of 2.4:1 (Fig. 2.1 ), 24% were CD40-
reactive (B cells, macrophages and/or dendritic cells), 16% were CD19-positive (B cells), 
and <1% CD14-positive (monocytes) (data not shown). After alternating stimulation of 
both virus-na"!"ve and HCV -exposed cells with PHA and/or IL-2 for 14 days, 96.6% of the 
cells were CD3-positive (Fig. 2.1 ). Interestingly, while the ratio of CD4-positive to CD8-
positive cells was 2:1 for uninfected T cells, that for the infected was 1 :3 .4. Less than 1% 
CD19-reactive cells were detected in HCV-infected cultures (data not shown). These 
data showed that T cells were essentially the only cell type supporting HCV propagation 
at the phase D of the passage from which supernatant was used to transmit infection. 
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Figure. 2.1. Phenotypic characterization of lymphoid cells before and after infection 
with HCV. Monocyte-depleted lymphoid cells from donor AIM were untreated (Naive 
untreated), treated with PHA for 48 h (Naive day Of or cultured for 14 days after PHA 
treatment (Naive day 14). In addition, AIM cells recovered following 11 passages with 
HCV N07/M inoculum were examined (HCV-infected 14 days p.i.). Cells were incubated 
with fluorescein isothiocyanate (FITC)-anti-CD3 or with phycoerythrin (PE)-anti-CD4 
or - anti-CD8 mAb, or with an appropriate immunoglobulin isotype control, and analysed 
by flow cytometry. Gates were set up on isotype controls. Percentages indicate positive 
cells. 
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2.4.2. HCV Genome Expression During De Novo Infection and Serial 
Passage in T Cell Cultures. 
As shown in Figure 2.2A, HCV RNA positive strand was detected in both cells and 
culture supernatant after the direct infection with HCV N07/M, while the mock-infected 
cells were negative. HCV load was -105 vge/107 cells. Comparable results were 
obtained when HCV -positive plasma from C32/M, C34/M and N23/M patients were used 
for direct infection of AIM cells (Figs 2.2C and 2.2D). These results implied that 
infection of the T cell cultures was not related to the origin ofHCV inoculum. Heat 
inactivation of plasma did not influence HCV infectivity, although it occasionally 
improved cell survival. Estimated levels of HCV RNA positive strand in T cells after 
passages 2, 4, 9 and 11 (Fig. 2.2A) ranged between 105 and 106 vge per 107 cells, while 
the amount of HCV released during each serial passage was - 104 vge/mL. Taken 
together, the total HCV produced during the entire passage experiment was estimated to 
exceed 107 vge. Given that the HCV N07/M inoculum carried 2.5 x 104 vge and that 1.4 
x 104 vge was recovered in culture medium after the inoculation, at least 1 000-fold 
enrichment in the virus was achieved. Also, HCV RNA negative strand was found in T 
cells collected after direct infection and all passages analyzed, but not in phaseD 
supernatants (Fig. 2.2B). Semi-quantitatively, there were - 104 vge of the negative strand 
for 1 0 7 cells. 
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Figure. 2.2. Detection of HCV RNA positive and negative strands in T -cell cultures after 
direct infection and during serial passage ofHCV. In (a) and (b), AIM T cells (C) and 
their culture supernatants (S) were obtained after direct infection (D.I.) or indicated 
passages of HCV N07 /M inoculum. AIM T cells exposed to normal human plasma and 
cultured as infected cells (mock inf~ction) served a~ a negR~i,, e control. Synthetic HCV 
RNA (HCV sRNA) positive and negative strands were used to confirm specificity of the 
detection and as quantitative standards. DU, Density units. In (c) and (d), AIM T cells 
were exposed to HCV-positive plasma from different CHC patients, or T cells from 
healthy donors AIM, B/M and C/F were inoculated with cell-free supernatant (S) 
obtained after passage 11 shown in (a). HCV RNA-positive (a, c) and -negative (b, d) 
strands were detected by specific RT-PCRINAH. Water instead of eDNA amplified in 
direct (DW) and nested (NW) reactions, as well as a mock-treated test RNA (M), were 
included as contamination controls. Positive samples show the expected 244 bp 
amplicons. 
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To determine whether the virus obtained after multiple serial passages in NM T cells 
could infect T cells of other healthy individuals, PHA-treated cells from donors B/M and 
CIF were exposed to pooled supernatants from passages 11 and 12. After the direct 
infection, cells from B/M carried HCV RNA positive strand at ~ 105 vge/1 07 cells and 
negative strand at~ 104 vge/1 07 cells. Interestingly, although cells from C/F proliferated 
to the same extent as those from NM and B/M donors, they remained HCV RNA 
negative (Figs. 2.2C and 2.2D). This variation might be of biological significance and 
will be investigated in the future. 
2.4.3. HCV Protein Display in In Vitro Infected T Lymphocytes. 
To determine whether HCV infection was accompanied by synthesis of viral proteins, 
the presence ofHCV NS5A and E2 proteins was examined by Western blotting. A 
protein band of ~56 kDa was detected in T cells after passages 3 and 11 when probed 
with anti-NS5A mAb (Fig. 2.3A). Also, a band of approximately 70 kDa, representing 
the E2 protein, was evident in passage 14 (Fig. 2.3B). Bands of comparable molecular 
sizes were detected in Huh-7 cells transfected with HCV AB12-A2FL replicon, but not in 
naive Huh-7 cells or in normal T cells cultured under identical conditions as infected T 
cells. A confocal microscopic analysis suggested that the E2 protein has intracytoplasmic 
and plasma membrane-associated localization in infected T cells (Fig. 2.3C). 
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Figure. 2.3. Detection of HCV NSSA and E2 proteins in in vitro-infected T cells. AIM 
T cells after passages 3, 11 and 14 ofHCV N_i)JIM inoculum were lysed, then proteins 
were separated at 30 J.lg per lane and probed with (a) anti-NSSA or (b) anti-E2 (ALP98) 
rnAb. The 56 kDa NSSA and 70 kDa E2 protein bands are marked on the right and 
molecular mass markers on the left. AIM cells not exposed to HCV, but cultured as 
infected T cells, and naive Huh-7 cells were used as negative controls. In (c), T cells 
after direct infection with HCV N23/M inoculum were double-stained with anti-E2 
(AP33) and anti-tubulin rnAbs and analysed by confocal microscopy. Huh-7 cells 
transfected with the HCV AB 12-A2FL replicon served as a positive control. 
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2.4.4. Inhibition of HCV Infection by Anti-CD81 and Treatment with 
IFN-a 
Pre-incubation ofT cells with two concentrations of anti-CD81 mAb, but not with an 
isotype control, blocked HCV RNA expression (Fig. 2.4). To provide further evidence 
that active HCV replication was supported by T cells and to recognize applicability of our 
system for testing susceptibility of wild-type HCV to antivirals, the effect ofiFN- a on 
the outcome of de novo infection in T cells was examined. The results showed a dose-
dependent antiviral effect ofiFN-a (Fig. 2.5). HCV replication was abrogated in cells 
treated with 1000 U/mL, but not inhibited uniformly by lower doses. 
2.4.5. HCV Infection in Affinity-Purified T Cells 
To further confirm natural susceptibility ofT cells to HCV infection, affinity-purified T 
cells from healthy AIM donor were infected with HCV N07/M or HCV N08/M. In 
parallel, pure T cells from N09/F patient with CHC were cultured exactly as those from 
AIM donor. At 10 d.p.i., HCV RNA positive strand was detected at - 105 vge per 107 T 
cells infected with N07/M and N08/M inocula (Fig. 2.6A). Interestingly, T cells purified 
from N09/F patient carried HCV RNA positive strand at a similar level as those infected 
with HCV N07/M (Fig. 2.6A). The level ofHCV RNA negative strand was - 104 vge/107 
cells infected with N07 /M and N08/M inocula, and in T cells from N09/F patient (Fig. 
2.6B). 
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Figure. 2.4. Inhibition of HCV infectivn in T cells with anti-CD81 rnA b. AIM P.cells 
pre-treated with anti-CD81 mAb at 1 : 20 or 1 : 100 were exposed to HCV -positive 
N23/M plasma (see Methods) and, after 14 days culture, were examined for HCV RNA. 
T cells pre-treated with an appropriate isotype control (ISO) at 1 : 20 served as controls. 
For (a), other controls were as described in the legend to Fig. 2.2 (b) Plot presentation of 
densitometric values obtained for (a). 
(a) Anti-CD81 
(b) 
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Figure. 2.5. Effect of IFN-a treatment on detection of HCV RNA in in vitro-infected T 
cells. AIM T cells were exposed to HCV N07/M inoculum in the absence (HCV-UT) or 
presence of indicated concentrations of IFN-a in triplicate and cultured for 14 days. RNA 
was analysed for HCV RNA positive (a) and negative (b) strands by RT-PCR/NAH 
assays. Specificity and contamination controls were as described in the legend to Fig. 2.2. 
(a) IFN-cx (units ml- 1) 
1 0 100 1000 HCV-UT rHCV 
DW NW M 1 2 3 1 2 3 2 3 1 2 UTR-E2 
-244 bp 
(b) 
10 100 1000 HCV-UT HCV sRNA 
DWNW M 2 3 1 2 1 
+-244 bp 
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Figure. 2.6. Expression of HCV RNA in affinity-purified T lymphocytes infected with 
HCV either in vitro or in vivo. Affinity-purified T cells from donor NM pre-treated with 
PHA were exposed to HCV N07/M or HCV N08/M inoculum and cultured (see 
Methods). In parallel, purified T cells from patient N09/F (CHC) were cultured under 
similar conditions. RNA was analysed for HCV RNA positive (a) and negative (b) 
strands. RNA from affinity-purified T cells of donor AIM, which were not exposed to 
the virus but cultured similarly, was included as a negative control (H). Contamination 
and specificity controls and quantitative standards were as described in the legend to Fig. 
2.2. 
:; . 
Figure. 2.7. Isopycnic banding ofHCV RNA in the supernatant obtained after eight 
consecutive passages of HCV N07/M inoculum in T cells. An aliquot of the concentrated 
supernatant pool from passage 8 (see Methods) and plasma from patient C26/F (CHC) 
and a healthy AIM donor were centrifuged through 1.1- 1.6 g CsCl/mL gradients; 750 ~L 
fractions were collected. HCV RNA was examined by RT-PCR/NAH. Depicted are 
HCV RNA levels (vge) in fractions from the passage 8 supernatant (e) and plasma of a 
chronic HCV carrier (0), and the CsCl density values (A; g/mL). An arbitrary scale from 
-(absence) to+++ (several dozen particles per microscopic grid) was used to estimate 
the number of HCV virion (VP) and core (CP) particles encountered in individual 
fractions by electron microscopy. NT, Not tested. 
.---------------- - --- --------
(a) rHCV UTR-E2 
OW NW M H NOS/M N07/M N09/F 10° 101 102 103 104 105 
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2.4.6. Buoyant Density of HCV RNA-Reactive Particles Released by In 
Vitro Infected T Cells. 
To recognize properties of HCV particles produced by T cells, culture supernatant 
obtained after passage 8 was subjected to isopycnic centrifugation. The fractions 
collected were examined for HCV RNA by RT-PCR!NAH and virus particles by electron 
microscopy. As shown in Figure 2.7, the main peak ofHCV RNA reactivity was 
identified at buoyant densities 1.16- 1.19 g/mL (fractions 5 to 7; peak 1). There was also 
a peak at 1.26- 1.32 g/mL (fractions 9 to 11; peak 2) and some minor increase in HCV 
RNA positivity at other densities. The greatest HCV copy numbers estimated were 1.4 x 
105 vge/mL for fraction 6 (density 1.18 g/mL) of peak 1 and 0.75 x 105 vge/mL for 
fraction 9 (density 1.26 g/mL) of peak 2. Analysis ofthe fractions from C26/F plasma 
also showed HCV RNA peaks of distinct buoyant density (Fig. 2.7), confirming that the 
gradient was capable of separating a heterogenous population of HCV particles. Similar 
analysis of the supernatant from non-infected but cultured NM T cells did not reveal 
viral signals (not shown). 
2.4.7. Ultrastructural Features ofHCV Particles Produced by T Cells. 
The vast majority ofHCV particles detected by electron microscopy after direct 
ultracentrifugation ofT cell culture supernatants were nonenveloped cores (Fig. 2.8A i-
iii). Their diameters ranged between 25 and 50 nm (mean 36.5 nm). These particles 
could be precipitated with anti-HCV core mAb (Fig. 2.8A, iv-vii), but not with an isotype 
control mAb (not shown). Fractions collected after a CsCl gradient showed the presence 
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Figure. 2.8. Ultrastructural identification of HCV virion and core particles in culture 
supernatants obtained after serial passage of HCV in T cells. (a) HCV core particles 
recovered after direct centrifugation of supernatants after passages 5, 9 and 11 of HCV 
N07 /M inoculum. (i- iii) Examples of HCV core particles after passages 5 and 11 . (iv-
vi) Nucleocapsid particles from passage 9 detected by immunoelectron microscopy using 
anti-core rnAb. Note visible spikes given by extended antibody molecules. (vii) 
Aggregates of HCV core particles immunoprecipitated with anti-core antibody. Bars, 50 
nm. (b) HCV virion-like particles detected in fraction 6 (density, 1.18 g/mL) after CsCl 
gradient fractionation of the culture supernatant from passage 8 (i- iii) and C26/F plasma 
(iv- vi). Bars, 100 nm. (c) Detection of HCV virions produced by in vitro-infected T cells 
by immunoelectron microscopy with anti-HCV E2 (AP33) rnAb. (i- iv) Single HCV 
virions decorated with colloidal gold particles in C32/M plasma (i- ii) and in the T -cell 
supernatant pooled after passages 10 and 13 of HCV N07 /M (iii- iv). (v- vi) Examples of 
the medium-size (v) and large (vi) aggregates of HCV virions. The same culture 
supernatant pool exposed to the isotype-control rnAb served as a negative control (vii). 
Bars, 100 nm. Preparations were counterstained with 1 % PTA. 
(a) (b) 
(c) 
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ofboth virion-like structures and non-enveloped cores (see Fig. 2.7). Virion-like 
particles were heterogeneous in diameter, which ranged between 51 and 74 nrn (mean 
67.4 nrn), and envelope thickness between 6 to 15.6 nrn (mean 11.4 nrn). Figure 2.8B 
illustrates examples ofHCV virion-like particles after CsCl fractionation of the passage 8 
supernatant (Fig. 2.8B, i-iii) and C26/F plasma (Fig. 2.8B, iv- vi). Diameters of these 
virions were 62- 85 nrn (mean 77.6 nrn) and the envelope thickness ranged from 9 to 27 
nrn (mean 20.6 nrn). To further ascertain that HCV virions were released by the in vitro 
infected T cells, pellets recovered after ultracentrifugation of the T cell culture 
supernatants or C32/M plasma were stained by immunogold with anti-HCV E2 mAb. 
Singular enveloped virions dressed with gold particles were detected both in control 
C32/M plasma (Fig. 2.8C; i and ii) and in the pooled T cell culture supernatants 
recovered after passages 10 and 13 (Fig. 2.8C; iii and iv). Aggregates of gold-coated 
virions were also detected (Fig. 2.8C; v and vi). There were a few gold particles not 
associated with virions in the same supernatant after incubation with an isotype control 
mAb (Fig. 2.8C, vii). 
2.5. DISCUSSION 
In this study, lymphoid-cell cultures, established by ex vivo treatment ofPBMC from 
healthy individuals with aT cell-inducing mitogen, were susceptible to wild-type HCV 
and capable of supporting its complete cycle of replication. Productive HCV replication 
was documented by detection ofHCV RNA positive and negative strands, ofNS5A and 
E2 proteins and by secretion of complete virions, which could infect T cells from healthy 
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donors de novo. The results also showed that circulating T cells in clinically evident 
HCV infection are an extrahepatic site of virus replication. 
Data from the present and previous works (Pham et al., 2004; Pham et al., 2005), 
indicate that activation of lymphoid cells, which characterizes functioning, dividing and 
immature progenitor lymphoid cells, predisposes cells to HCV recognition and promotes 
an intracellular microenvironment supportive of virus replication. This may explain why 
HCV has been more readily identifiable in lymphoid-cell cultures or in PBMC from 
patients coinfected with other viral pathogens (Beld et al., 1998; Laskus et al., 2004) and 
why mature, mitogen-untreated lymphoid cells are poorly permissive to HCV infection in 
vitro. Our data raise a possibility that lymphoid organs, which embrace the most active 
proliferative expansion of lymphoid cells in adulthood, are sites of HCV propagation and 
long-term persistence of virus. The notion of lymphotropism is supported by data 
demonstrating HCV RNA in bone marrow, lymph nodes or spleens from patients with 
CHC or co infected with human immunodeficiency virus type 1 (Laskus et al., 1998; 
Radkowski et al., 2000). 
In our system, passage of HCV by infection ofT cell cultures freshly prepared each 
time was associated with consistent detection of both HCV RNA positive and negative 
strands in the cells and of the positive strand in culture supernatants from all passages 
tested. The potency of the virus to infect the cells did not decrease during serial passage 
and the estimated amount of the virus produced appeared to be proportional toT cell 
proliferation. On average, I 05 vge were detected per I 07 infected T cells at the end of 
each passage. Interestingly, a comparable rate of approximately 1 05 vge per 10 7 cells was 
detected forT cells affinity-purified from patient N09/F with CHC. 
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HCV in de novo-infected T cells was susceptible to IFN-a. treatment, with complete 
inhibition of virus replication observed at 1000 U/mL. This result resembles that 
reported for primary human hepatocytes infected in vitro with wild-type virus (Castet et 
al., 2002). In addition, as was shown for the JFH-1 full length viral clone in Huh-7 cells 
(Zhong et al., 2005), anti-CD81 mAb was able to inhibit HCV infection in our system. 
To ascertain further that in vitro-infected T cells supported HCV replication and that 
the virus was assembled, ultrastructural characteristics of viral particles released by the 
cells were examined after either direct ultracentrifugation or fractionation in CsCl 
gradients. It was found that non-enveloped core particles were predominantly detected in 
the supernatants after direct centrifugation, whereas HCV virions were mainly seen in 
those fractionated throughout the density gradient, particularly in the fractions enriched 
with HCV RNA. These findings suggested that concentrating the virus without applying 
density equilibrium led to dissociation of viral particles and thus implied erroneously that 
HCV cores, but not complete virions, were mainly produced by infected T cells. In fact, 
depending on which method ofHCV concentration is employed, separation ofthe viral 
envelope from the nucleocapsid has been observed (Fujita et al., 2001). Nevertheless, the 
HCV nucleocapsids detected in our T cell supernatants displayed the expected size and 
were immunoprecipitated with anti-HCV core mAb, as observed by others (Kaito et al., 
1994; Maillard et al., 2001 ). Similarly, HCV virion-like particles detected after isopycnic 
banding showed heterogeneous properties, as reported previously (Hijikata et al., 1993; 
Kanto et al., 1994; Fujita et al., 2001; Pumeechockchai et al., 2002). Specificity of these 
particles was confirmed by immuno-gold staining with anti-E2 mAb, and both single, 
complete virions and immune-aggregates of virions were detected. These results 
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documented conclusively that viral particles with physical and structural properties of 
complete HCV virions were released by in vitro-infected T cells. 
Overall, our results from a multiparametric analysis demonstrated that mitogen-
induced normal human T cells can support the complete cycle ofHCV replication and 
produce infectious virions. This suggests that they are equipped not only with 
appropriate molecules capable of recognition and uptake of HCV, but also with the 
machinery to multiply the virus. This system should be of value for studies on 
recognition of cytopathic mechanisms ofHCV infection, investigation of host factors 
determining susceptibility and the efficiency of virus replication, and for testing antiviral 
agents against wild-type HCV propagating in the natural host-cell milieu. 
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Chapter Three: Exposure of Lymphocytes to Wild-Type HCV 
In Vitro Inhibits CD4+ but not CDS+ T Cell Proliferation 
3.1. SUMMARY 
HCV has been shown to replicate in cells ofthe immune system Previously, we 
established a culture system in which wild-type HCV productively propagates in 
mitogen-stimulated primary T cells. The aim of the current study was to determine 
whether exposure to HCV can lead to changes in T cell proliferation and eventually 
induce apoptosis, which may result in cell phenotypic changes in comparison to cells not 
exposed to virus. For this purpose, PBMC from a single healthy donor provided naive T 
cells. The cells were exposed to HCV inocula from 3 patients with CHC carrying 
genotypes 2b, 3a and a mixture of 1a and 1 b or to normal human plasma (NHP). Cells 
were analyzed prior to and up to 10 days post-exposure for HCV RNA positive and 
negative strands by specific RT-PCRINAH assays. In addition, T cell proliferation was 
measured by the carboxyfluorescein succinimidyl ester (CFSE) assay, apoptosis by flow 
cytometry-based annexin-V/7-actinomycin D assay, and T cell phenotype determined by 
staining for CD3, CD4 and CD8 followed by flow cytometry. Two of three HCV inocula 
examined produced quantifiable intracellular HCV RNA signals, while HCV RNA 
negative strand, indicative of virus replication, was detected following exposure to one of 
the inocula. Two inocula containing HCV genotype 2b and 3a led to a shift in the T cell 
phenotype from predominantly CD4-positive towards CDS-positive at the end of the 10-
day culture period. Interestingly, cultures exposed to these two inocula had the highest 
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levels of intracellular HCV RNA expression. This change in T cell subset distribution 
was associated with a statistically significant inhibition of lymphocyte proliferation, 
which appeared to be restricted to CD4+ T cells. Furthermore, there were no significant 
differences in the rate of apoptosis during the 1 0-day culture period between T cells 
exposed or not to HCV. As well, expression of selected cytokines such as IFN-y, TNF-a., 
and IL-2 did not vary noticeably in the cells cultured in the presence of virus or not. 
These results suggest that HCV, regardless of the genotype, may exert a direct effect on 
CD4+, but not CD8+, T lymphocyte proliferative capacity and that this effect may occur 
in the absence of detectable active virus replication within these cells. In consequence, 
this finding may imply that exposure to HCV is sufficient to modify T lymphocyte 
proliferation and to shift the T cell phenotype. 
3.2. INTRODUCTION 
HCV is a single-stranded RNA virus belonging to the Flaviviridae family that infects at 
least 170 million people worldwide (Wasley and Alter, 2000). In HCV -infected patients, 
viral replication, which is revealed through the detection of HCV RNA positive strand 
and the HCV replicative intermediate, the RNA negative strand, has been demonstrated 
in cells of the immune system, such as B cells, monocytes, and CD4+ and CD8+ T cells 
(Pham et al., 2004; Radkowski et al., 2004; Pal et al., 2006; Kondo et al., 2007; Pham et 
al., 2008). In this laboratory, it was demonstrated that primary T lymphocyte cultures, 
generated by ex vivo treatment ofPBMC from healthy individuals with PHA, aT cell-
inducing mitogen, were susceptible to wild-type HCV and capable of supporting viral 
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replication. Furthermore, these cells were able to produce infectious virions that de novo 
infected naYve lymphocytes (Section 2). 
HCV infection leads to chronicity in up to 85% of those afflicted, while acute HCV 
infection is thought to spontaneously resolve in 15-25% of cases (Cox et al., 2005; 
Thomas and Seeff, 2005). Resolution of hepatitis C appears to occur as a result of a 
robust HCV -specific T cell-mediated response. In HCV -infected chimpanzees, the 
closest animal model of human HCV infection, recovery from hepatitis and a drop in 
plasma HCV loads to levels undetectable by clinical RT-PCR assays requires the activity 
of both CD4+ T helper cells and CD8+ cytotoxic T cell cells (Shoukry et al., 2003; 
Grakoui et al., 2003). In patients with CHC, their T cells appear to have markers of 
exhaustion and are defective in their ability to produce IFN-y and IL-2 (Semmo et al., 
2007). PD-1, a major inhibitory receptor on T cells that leads to inhibition ofT cell 
proliferation and cytokine production upon PDL-1 binding, has been found to be 
expressed at significantly higher levels in the PBMC and in the livers of patients with 
CHC compared to those who spontaneously resolve hepatitis C (Golden-Mason et al. , 
2007). Furthermore, TIM-3, a negative regulator ofThl responses, has been found to be 
upregulated on peripheral blood CD4+ and CD8+ T cells in CHC patients (Golden-Mason 
et al., 2009). In vitro, the functional consequences ofT cell infection in Molt-4 and 
Jurkat T cell lines, and primary T cells have been studied to a small extent. Among 
others, it was revealed that in Molt-4 cells, HCV infection suppressed IFN-y signalling 
through STAT -1 pathway (Kondo et al., 2007). 
Stemming from the previous observations that exposure of naYve lymphoid cells to 
HCV in vitro and their subsequent culture can lead to changes in the CD4+ to CD8+ T cell 
94 
ratio (Section 2), in the current work we asked whether and how HCV may alter the 
behaviour of lymphoid cells. This was tested by examining HCV -induced changes to the 
cells' proliferation, apoptosis and phenotype, and expression of selected cytokines. 
We were able to confirm that exposure ofT lymphocytes to HCV indeed caused a 
shift in the CD4+ :CD8+ cell ratio. This appeared to be due to inhibited proliferation of 
CD4+ T cells but not increased apoptotic death of these cells. 
3.3. MATERIALS AND METHODS 
3.3.1. Plasma-Derived HCV Inocula and Target Cells 
Plasma from patients C26/F (CHC-1), C33/M (CHC-2), N28/F (CHC-3) with clinically 
and serologically documented CHC was used as the source of wild-type HCV. These 3 
inocula carried different HCV genotypes and various HCV loads expressed in vge/mL 
(Table 3.1.). Thus, CHC-1 carried a mixture of genotype 1a and 1 bat 1.1 x 106 vge/mL, 
CHC-2 had genotype 3a at ~ 1 x 104 vge/mL, and CHC-3 carried virus of 2b genotype at 
2.4 x 106 vge/mL. Plasma HCV RNA load was determined by HCV-specific real-time 
RT-PCR, as reported previously (Pham et al., 2004). Selection of plasma serving as 
HCV inocula was also based on the finding that PBMC from the cases examined were 
HCV RNA positive strand reactive (Table 3.1 .). Lymphoid cells serving as HCV targets 
for in vitro infection experiments were isolated from a single healthy donor who had no 
clinical history or molecular indication ofHCV exposure, as confirmed by highly 
sensitive RT-PCR/NAH assay (sensitivity of < 10 vge/mL or < 2 IU/mL) (Pham et al., 
2004). 
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3.3.2. In Vitro HCV Infection and Culture Conditions 
In this study, de novo infection of lymphoid cells with HCV was accomplished following 
methodology established in my previous work (Section 2.3.3), in which alternating 
stimulation with PHA in the presence of IL-2 resulted in infection and detection of 
propagating virus (Section 2). The data from this previous study revealed a change in the 
T cell subset distribution in lymphocyte cultures exposed to HCV but not in those non-
exposed to virus (Section 2, Fig. 2.1 ). In examining the cause of this phenotype shift, we 
observed augmented lymphocyte proliferation early after exposure to virus, i.e., at 4 d.p.i. 
We also found at later time points of culture, i.e., 7-10 d.p.i. , a high rate of cell 
proliferation which was accompanied by increased cell apoptosis independent of whether 
HCV was detectable or not in cultured cells (data not shown). This outcome was most 
likely related to the repeated exposure of cells to mitogen (PHA). To minimize this 
effect, which was potentially masking the influence of virus on immune cell proliferation 
and apoptosis, we altered the cell culture protocol in the present study and we stimulated 
lymphoid cells with mitogen only once prior to infection without subsequent repeated 
restimulation. Thus, monocyte-depleted lymphoid cells from a healthy donor were 
treated with 5 J.lg/mL PHA for 48 h prior to infection (Section 2.3.3.). Following 
stimulation, 1 x 107 cells were exposed to 2.7 x 105 vge from CHC-1 or CHC-3 or 500 J.lL 
(- 104 vge) of plasma from (CHC-2) in 9.5 mL of culture medium at a final concentration 
of 1 x 106 cells/mL. In parallel, the same number of target cells was exposed to 500 )lL 
of normal healthy plasma (NHP) from 3 different healthy donors, as negative controls 
(mock infection). As an additional control, target cells were incubated with 9.5 mL of 
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culture medium without adding plasma. At the same time, for investigation of the effect 
of virus exposure on cell proliferation, triplicate 1-mL cultures of 1 x 106 PHA-
stimulated, CFSE-labelled lymphocytes (methodology described in Section 3.3.4) were 
exposed to CHC-1 , CHC-2 or CHC-3, NHP-1 , NHP-2, NHP-3 or NP as indicated above. 
In all cases, inocula were removed after 24 hours and the cells were washed twice 
thoroughly prior to resuspension in 9.5 mL of complete AIM-V medium (Invitrogen), as 
described before (Section 2.3.3.). Culture supernatants were collected at 10 d.p.i. and 
stored at -80°C. Cell pellets were collected at -2, 0, 1, 7, 10 d.p.i. and cryopreserved for 
RNA analysis. Also, at least 2 x 105 lymphoid cells were collected at each time point for 
determination of cell surface phenotype and evaluation of proliferation and apoptosis 
(See below). 
3.3.3. Determination of Cell Phenotype 
To determine the phenotype of immune cells after in vitro exposure to HCV, cells 
cultured in the presence ofNHP or medium alone (NP) and those exposed to virus were 
incubated with a cocktail containing an anti-CD3 antibody labelled with Alexa Fluor 488 
(Alexa 488) (BD Pharmingen), an anti-CD4 antibody bound to peridinin chlorophyll 
protein complex (PerCP) (BD Pharmingen) and an anti-CD8 antibody conjugated to 
allophycocyanin (APC ) (Ebiosciences, San Diego, CA) or with a control staining 
cocktail containing the appropriate isotype controls (Ebiosciences or BD Pharmingen) for 
30 minutes at 4°C. Using forward versus side scatter, lymphocytes (gate R1) (See Fig. 
3.1) were separated from debris by flow cytometric analysis using a F ACSCalibur flow 
cytometer (Becton Dickinson). Then, lymphocytes were sub-gated on Alexa-488-
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positive cells (CD3+ T cells) (gate R2) to determine percentages of CD4+ and CD8+ 
reactive cells by detecting APC-positive cells (CD8+) found in the upper left quadrant 
and PerCP-positive cells (CD4+), located in the lower right quadrant (See Fig. 3.1). 
Quadrant markers were set up on background staining using appropriate isotype controls. 
3.3.4. Flow Cytometry-Based T Cell Proliferation Assay 
To quantify the level of proliferation in HCV -exposed and unexposed lymphocytes, cells 
were stained with carboxyfluorescein succinimidyl ester (CFSE), as previously described 
(Gujar and Michalak, 2005). Briefly, 2.3 x 107 PBMC suspended in 2.3 mL ofPBS were 
stained with CFSE (Molecular Probes, Eugene, Oregon), at the pre-tested optimal 
concentration of 1 mM, at 37°C for 10 min in a 15-mL conical tube. Subsequently, cells 
were washed twice with 10 mL of 5% fetal calf serum (GIBCO-Invitrogen Corporation, 
Auckland, New Zealand) in PBS. To carry out triplicate infections of labelled targets 
with each of the three HCV inocula tested, the three NHP and the NP control, CFSE-
labelled lymphocytes were resuspended in 1 mL cultures of 1 x 1 06 cells in complete 
AIM-V medium (GIBCO) supplemented with 10% FCS in 6-well plates (Becton 
Dickinson). As an additional control to determine the CFSE staining in unstimulated 
cells, CFSE-labelled PBMC cultured with AIM-V medium alone without stimulation 
were included. Proliferation in PBMC from triplicate wells were analyzed at -2, 0, 1, 4, 7 
and 10 d.p.i. using a flow cytometer and using Cellquest Pro (Becton Dickinson) or 
ModFit LT (Verity Software House, Topsham, ME) analysis softwares. Using forward 
versus side scatter, lymphocytes (gate R1) were separated from debris. Proliferation 
represented by the mean percentage CFSE low in triplicate or single cultures measured at 
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different time points throughout the culture period. Percentage CFSE low was based on 
an unstimulated control with cells cultured in medium alone. For triplicate infections, 
cells collected at 4 d.p.i. (in triplicate) and for their singular samples collected at 6, 7 and 
I 0 d.p.i., CFSE-labelled lymphoid cells were stained with anti-CD3-APC, anti-CD4-
PerCP and anti-CD8-PE. Using forward versus side scatter, lymphocytes (gate RI) were 
separated from debris, gated on CD3+ T cells and sub-gated on CD4+ or CD8+ T cells to 
determine the proliferation of individual T cell subpopulations. Proliferation was 
represented by the mean percentage CFSE low ± SEM. Mitogen unstimulated controls 
were routinely included, as described above. Additionally, dilution of CFSE fluorescence 
was analyzed using the proliferation wizard module of ModFit L T software showing 
daughter generations. P.l. (proliferation index) values were determined using 
unstimulated cells to define the parent generation. 
3.3.5. Annexin V-PE-17-AAD Assay for Detection of Cell Apoptosis 
To determine the degree of apoptosis in lymphoid cells after exposure to HCV inocula, 
lymphoid cells were stained with annexin V conjugated with PE, or 7-aminoactinomycin 
D (7-AAD), as previously established (Gujar et al., in press). Briefly, Ix I05 cells were 
washed with annexin buffer containing 10 mM HEPES (Invitrogen), 5 mM NaCl, 5 mM 
KCl and 2 mM CaCh and centrifuged at I ,500 rpm for I 0 min at 4 ° C. Then, a cocktail 
containing 50 ~J.g/mL of 7-AAD (Invitrogen) and 50 ~J.g/mL of annexin-V -PE (Invitrogen) 
were prepared in annexin buffer. Cells were resuspended in I 00 IlL of apoptosis cocktail 
and kept on ice for 30 min. After staining, cells were washed once with annexin buffer, 
centrifuged at 400 x g for IS min and resuspended in 500 !J.L of annexin buffer to be 
IOO 
analyzed by flow cytometry, as described before (Gujar et al. , 201 0). 
3.3.6. Quantification of Cytokine Expression 
In lymphocyte cultures in which numbers of recovered cells permitted, RNA was 
extracted, treated with 2 U of DNase (Sigma) for 10 min at room temperature followed 
by incubation in a stop solution for 10 min at 70 °C. RNA was transcribed to eDNA 
using MMLV-RT (Invitrogen). Due to very limited amounts ofRNA obtained, 
quantification ofthe level of expression ofiFN-y, TNF-a, IFN5a and IL-2 was evaluated 
only. This was accomplished using SYBR Green real-time RT-PCR, the Roche 
LightCycler (Roche Diagnostics), and amplification conditions previously established in 
this laboratory (Pham et al., 2007). Reactions were performed using 50 ng of eDNA in a 
total volume of20 flL using: sense primer 5' -TCAGCTCTGCATCGTTTTGG and 
antisense primer 5'-TGTTTT AGCTGCTGGGCACA for IFN-y, sense primer 5'-
TCTTCTCGA ACCCCGAGTGA and antisense primer 5' -CCTCTGATGGC 
ACCACCAG for TNF-a, sense primer 5' -CAGCCTGAGTAACAGGAGGA and 
antisense primer 5'-GCAGATGA GTCCTTTGTGCT for IFN5a, and sense primer 5'-
CCCAAGAAGGCCACAGAACT and antisense primer 5'-
TGCTGA IT AAGTCCCTGGGTCTT A for IL-2. As a control, actin was amplified using 
eDNA generated from tested samples employing sense primer 5' -
ATCTCCTGCTCGAAGTCC and anti-sense primer 5' -CAACCGTGAGAAGAT 
GACC. Cytokine mRNA expression was normalized against actin. Specificity of 
amplifications was confirmed by a melting curve analysis. 
101 
3.3.7. Statistical Analysis 
The data were analyzed and differences between HCV-exposed cultures and those not-
exposed to virus were determined using GraphPad Prism software (GraphPad Software 
Inc., San Diego, CA). Statistical analyses were performed by applying the Mann-
Whitney, non-parametric, two-tailed test. P values of :S 0.05 were considered as 
statistically significant. 
3.4. 
3.4.1. 
RESULTS 
HCV Expression in Lymphoid Cells Before and after Exposure to 
HCV 
HCV RNA positive strand was detected in T cell cultures following exposure to all 
inocula tested (Table 3.2) but not in the cultures exposed to NHP or medium alone (data 
not shown). The level of HCV RNA detection in the cells examined varied depending on 
inoculum and time of cell collection following exposure to virus. Thus, HCV RNA load 
ranged from <50 vge/!Jg total RNA to >8000 vge/!Jg total RNA (Table 3.2). HCV RNA 
negative strand was detected at 7 and 10 d.p.i. for cell cultures exposed to CHC-1 
inoculum that also induced the highest HCV RNA positive strand loads in lymphocytes 
amongst the inocula tested. It is of note that in the preliminary experiments, the HCV 
RNA loads detected in lymphoid cell cultures subjected to repeated mitogen stimulation 
were consistently greater than those found in lymphoid cells infected after the single 
mitogen stimulation only, as indicated above. Similarly, HCV negative (replicative) 
strand was more frequently indentified in the cells repeatedly mitogen stimulated during 
14-day cultures after exposure to different HCV inocula (data not shown). 
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[ Table 3.~. HCV RN~ Detection in Lymphocytes Expose~ to HCV PoS!~ve Plasma 
I HCV RNA load ("9e/ug RNA) 
Inoculum 1 d.p.i. 7 d.p.i. 
Positi-.e I Negati-.e Positi-.e Negati-.e I 
CHC-1 
CHC-2 
CHC-3 
j strand . strand J strand strand j 
f nt - not te; ted 
1n.d.- not detected 
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10 d.p.i. 
Positi-.e I Negati-.e 
strand 1 strand 
I I 
3.4.2. Phenotype of Lymphoid Cells During Culture after Exposure to 
HCV 
In preliminary experiments and in the study reported in Section 2, exposure ofT cells to 
HCV inocula was followed by their culture in the presence of IL-2 under alternating 
mitogen stimulation. In the presence ofPHA and IL-2, PBMC cultures that were 
originally 45 % CD3-positive became greater than 95% CD3-positive T cells after 14 
days of culture after exposure to virus. Interestingly, at the end of culture period, CD8+ T 
cells became evidently more prevalent than CD4+ T cells in the above cultures (See Fig. 
2.1). Similarly, in this study, PHA-stimulation prior to HCV exposure leads to an 
enrichment in CD3-positive T cells during culture (Fig. 3.1B). Exposure to 2 of 3 HCV 
inocula tested, i.e., CHC-1 and CHC-2, and culture without repeated mitogen stimulation 
resulted in an altered ratio of CD4 to CDS-positive T cells in that CD8+ T cells became 
more prevalent (Figs. 3.1A and 3.1B). As also observed in the preliminary experiment, 
Figure 3.1 A illustrates that the enrichment in CD8+ T cells was evident as early as 4 d. p.i. 
in cells exposed to CHC-1 where the ratio ofCD4+ T cells to CD8+ T cells was 
approximately 2:3. In the remaining cultures exposed to HCV inocula, NHP or medium 
alone, the ratio was close to 2.5:2 at 4 d.p.i. At 7 d.p.i., a change in the T cell subset 
distribution also appeared in cells inoculated with CHC-2. At this time point, the CD4+ 
to CD8+ T cell ratio for CHC-1 was 2:3 and for CHC-2 was 2.5:2.3, while for CHC-3, 
NHP-1, NHP-2, NHP-3 and medium alone, the ratio was close to 3:2. At 10 d.p.i. , the 
CD4+ to CD8+ ratio forT cells exposed to CHC-1 and CHC-2 were 2.8:2.1 and 2.7: 2.2, 
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Figure. 3.1. Phenotypic characteriz~tion of cultured lymphocytes after exposure to 
HCV. Lymphoid cells from the same healthy donor were either exposed to medium 
alone ( no plasma), (NP), 3 normal human plasma (NHP 1-3) or HCV inocula (CHC 1-3). 
Cells collected throughout the culture period at the time points indicated (d.p.i.) were 
stained with anti-CD3 Alexa-4gg, anti-C04-PerCP and anti-COg-APC mAbs (Section 
3.3 .1 . ), or with appropriate immunoglobulin isotype controls, and analysed by flow 
cytometry. (A) Graphical representation of flow cytometry data showing phenotype ofT 
cells for each infection condition tested. C04+ T cells (solid black bars) and CD8+ T 
cells (hatched bars) displayed as percentage of total C03+ T cells at 4 different time 
points throughout the culture period. (i.e., 1, 4, 7 and 10 d.p.i.). The detection of HCV 
RNA positive strand was shown for 1, 7 and 10 d.p.i. For HCV RNA positive strand 
detection, ++ indicates > 1000 vge/J..Lg total RNA, + indicates between 50 and 1000 
vge/J..Lg total RNA, and +/-indicates <50 vge/ J..Lg total RNA. For negative strand detection, 
+ indicates detection of the strand while - indicates no detection. Grey boxes indicate 
cultures in which the CD4+ to cog+ ratio was altered when compared to cultures exposed 
to NP or NHP, n.a.- Not applicable, n.t.- not tested. (B) Determination ofT cell 
phenotype in cell cultures exposed or not to HCV and cultured for 10 days post-exposure. 
Using forward versus side scatter, lymphocytes (gate R1) were separated from cellular 
debris. Lymphocytes were then sub-gated on Alexa-4gg positive C0 3 T cells (gate R2) 
for enumeration of CD4+ and cog+ T cells by detecting APC positive cog+ T cells 
found in the upper left (UL) quadrant and PerCP-positive C04+ T cells in the lower right 
(LR) quadrant. Quadrant markers were set using cells exposed to the appropriate isotype 
controls. Numbers in the UL and LR quadrants indicate percentages of positive cells. 
respectively, while the cultures not exposed to HCV, i.e., NP, NHP-1 , NHP-2 and NHP-
3, as well as those exposed to CHC-3 had very similar CD4+ to CDS+ ratios of 
approximately 3.5:1 (Fig. 3.1A). Finally, exposure ofT cells to CHC-3 inoculum was 
found to have little effect on T cell phenotype. Interestingly, infection with this inoculum 
resulted in a detectable, but unquantifiable, level of HCV RNA positive strand throughout 
the culture period and no detection ofHCV RNA negative strand (Table 3.2.). This 
finding may suggest that the level of HCV RNA expression in T cells was related to the 
observed change in T lymphocyte subset distribution. 
3.4.3. Apoptosis of Lymphoid Cells after Exposure to HCV and During 
Culture 
To determine whether the observed apparent enrichment in CDS+ T cells following 
exposure to HCV was due to enhanced cell apoptosis of CD4+ T cells, we examined the 
degree of lymphoid cell death in triplicate cultures after exposure to a given HCV 
inoculum or to NHP. As seen in Figure 3.2., at all time points examined, the degree of 
apoptosis was similar regardless of whether the lymphoid cells were cultured in the 
presence of medium alone, NHP or wild-type HCV (Figs. 3.2A. and 3.2B.). Thus, under 
the conditions tested, HCV exposure did not appear to enhance apoptosis ofT cells in 
culture. To further examine whether the alteration in phenotype may result from 
selective apoptosis of a certain T cell subset, we also examined the extent of death of 
CD4+ and CDS+ T cells separately. We observed that the degree of apoptosis of CD4+ 
and CDS+ T cells was not altered following exposure to HCV, as shown in Figs. 3.2C. 
and 3.2D., respectively. 
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Figure. 3.2. Determination of degree of lymphoid cell apoptosis by annexin-PE/7-AAD 
flow cytometry assay. (A) Graphical representation of degree of apoptosis detected in 
PHA treated lymphoid cell cultures exposed to NP, NHP l-3 or CHC l-3. Bars indicate 
the percentage of total cells in each phase of apoptosis. Graphs show data from triplicate 
experiments and are shown as mean ± SEM at l , 4, 7 and l 0 d.p.i. Bars with diagonal 
lines represent viable, checkered bars, early apoptotic, bars with horizontal lines, late 
apoptotic and vertical lines, fragmented cells. (B) Flow cytometric determination of 
stage of apoptosis and percentage of cells affected at 10 d.p.i following staining with 
annexin-PE and 7-AAD. Each quadrant represents a different phase of apoptosis. Lower 
left (LL)- viable cells, LR- early apoptotic cells, Upper right (UR)- late apoptotic and 
UL- fragmented cells. (C and D) Graphical representation of degree of apoptosis 
detected in lymphoid cell cultures exposed to NP, NHP or HCV inocula following 
subgating on CD4+ T cells (C) or CD8+ T cells (D). Bars indicate the percentage of total 
cells in each phase of apoptosis. Graphs show data from single experiments at 4, 7 and 
10 d.p.i. 
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3.4.4. Proliferation of Lymphoid Cells after In Vitro Exposure to HCV 
To assess the degree of proliferation ofT cells after exposure to HCV or to control NHP, 
triplicate cell cultures were evaluated for proliferation using the flow cytometry-based 
CFSE proliferation assay. In preliminary experiments using repeatedly mitogen 
stimulated T cell cultures, HCV exposure led to inhibited T cell proliferation at 4 d.p.i 
(data not shown). At later time points, however, very high rates of proliferation in T cell 
cultures which were exposed or not to HCV were observed. This likely reflected aT cell 
response to repeated PHA stimulation, which is known to be a potent T cell stimulating 
mitogen (data not shown). Therefore, in the current study, we stimulated cells with 
mitogen prior to infection only and cultured for the remainder of the time in medium 
without additional PHA or IL-2. Elimination of repeated mitogen stimulation resulted in 
a significant decrease in total lymphoid cell proliferation both in the cultures exposed or 
not to HCV (Fig. 3.3A). Upon further examination of cultures exposed to individual 
HCV isolates, it was found that inhibition ofT cell proliferation occurred after exposure 
to 2 of 3 inocula tested, i.e., CHC-1 and CHC-2 (Figs. 3.3B and 3.3C). Interestingly, 
exposure of cells to the CHC-3 inoculum did not induce inhibition ofT cell proliferation. 
These cells, as indicated before, expressed very low levels of HCV RNA positive strand 
while HCV RNA negative strand was not detected. This may suggest that the level of 
HCV replication within T cells could influence the degree of inhibition of the cell 
proliferation. 
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Figure. 3.3. Measurement of lymphoid cell proliferation after exposure to HCV or 
control normal human plasma. Lymphoid cells from the same healthy donor were stained 
with 111M CFSE prior to PHA stimulation and infection, and proliferation was measured 
by flow cytometry. (A) Summary of proliferation in lymphoid cells exposed to NP, NHP 
1-3 or CHC 1-3. Proliferation represented by the mean percentage CFSE low cells was 
measured in triplicate cultures at 4 time points throughout the culture period, percentage 
CFSE low was based on setting quadrant markers on an unstimulated control cultured 
with medium alone. (B) Graphical representation of lymphoid cell proliferation after 
exposure to HCV or NHP inocula. Lymphoid cells were either exposed to NP, NHP 1-3 
or CHC 1-3. Proliferation was measured by flow cytOJTietry and percentage CFSE low 
was determined based on unstimulated control cells cultured with medium alone. 
Proliferation represented by the mean percentage CFSE low and SEM measured in 
triplicate at 1, 4, 7 and 10 d.p.i. HCV RNA positive and negative strand detection are 
shown above proliferation (n.a.- Not applicable, n.t.- not tested). (C) As an example, 
Flow cytometric determination of proliferation at 7 d.p.i. for lymphoid cells exposed to 
NP, NHP 1-3 or CHC 1-3 using dot plots and Modfit analysis. Using forward versus side 
scatter, lymphocytes (gate R1) were separated from debris. Percentage CFSE low was 
determined based on an unstimulated control cells cultured with medium alone. Lower 
left and lower right quadrants represent cells with CFSE high (no proliferation) and 
CFSE low (ongoing proliferation) reactivity, respectively. Dilution of CFSE 
fluorescence was analyzed with ModFit LT showing daughter generations. P.I. values 
were determined by using unstimulated cells to define parent generation. 
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3.4.5. Proliferation ofT Cell Subsets in Cultures after Exposure to HCV 
To evaluate whether an inhibition in the proliferation of particular T cell subset may be 
responsible for the observed phenotype shift, we measured the proliferation of CD4+ and 
CD8+ T cells separately. When comparing HCV-exposed cultures to those exposed to 
NHP, we saw a significant decrease in CD4+ T cell proliferation rate in cells exposed to 
HCV, while the proliferation of CD8+ T cells was not affected regardless of whether the 
cells were exposed or not to HCV (Fig. 3.4A). Upon further evaluation of the level of 
proliferation ofT cell subsets exposed to individual HCV inocula, it was evident that 
CHC-1 and CHC-2 plasma caused a significant decrease in the levels ofCD4+ T cell 
proliferation compared to those exposed to NHP (Fig. 3.4B). Interestingly, CHC-3 
inoculum did not illicit a similar effect. Overall, no significant differences in CD8+ T cell 
proliferation was seen in cells treated with HCV inocula compared to those exposed to 
NHP (Fig. 3.4B). 
3.4.6. Expression of Cytokines in Cultures Exposed to HCV 
To examine the effects of HCV on cytokine expression in lymphoid cells, we investigated 
the levels of IFN-y, TNF-a, IFN-a5 and IL-2 mRNA in the cells exposed to three HCV 
inocula tested and three NHP. Due to limited RNA availability evaluation of all4 
cytokines in all cell cultures were not always possible. In this preliminary evaluation of 
cells stimulated with PHA prior to infection, there was an upregulation ofiFN-y mRNA 
during the 48-hour 
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Figure. 3.4. Evaluation of CD4+ and CD8+ T cell proliferation after HCV exposure. 
Lymphoid cells from the same healthy donor were stained with CFSE,PHA-stimulated 
and infected as described in Materials and Methods to measure proliferation of CD4+ and 
CD8+ T cell subsets. CFSE-labeled lymphoid cells were triple stained with anti-CD3-
APC, anti-CD4- PercP and anti-CD8-PE, gated on CD3-positive T cells and subgated on 
CD4+ or CD8+ T cells. Proliferation was determined by flow cytometry. (A) Graphical 
representation of proliferation ofT cell subsets after lymphoid cell exposure to three 
different NHP or HCV inocula. Proliferation represented by the mean percentage CFSE 
low ± SEM was measured at four different time points i.e., 4 d.p.i. , in triplicate, and 6, 7 
and 10 d.p.i. (B) Determination of the rate of proliferation in T cell subsets after 
exposure to different inocula. Lymphoid cells from the same healthy donor were CFSE 
stained prior to PHA stimulation and infection were exposed to NP, NHP 1-3 or CHC 1-
3. Cells were stained as above, gated on CD3-positive T cells and sub-gated on CD4-
positive and COS-positive T cells. Proliferation was determined by flow cytometry and 
represented by the mean percentage CFSE low ± SEM measured at 3 different time 
points during the 1 0-day culture. HCV RNA positive and negative strand detection 
displayed above proliferation and is represented as described in the legend for Figure 3.1. 
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Figure. 3.5. Expression levels ofiFN-y, TNF-a and IL-2 mRNA in T lymphocytes 
exposed to HCV-positive or normal human plasma. Lymphoid cells from the same 
healthy donor were treated with PHA for 48hr and exposed either to normal human 
plasma (n=3; NHP-1 to 3) or 3 different HCV inocula (CHC-1 to 3). DNase-treated 
RNAwas transcribed and amplified by real-time PCR using cytokine specific primers. 
IFN-y, TNF-a and IL-2 expression was evaluated at 2 days prior to infection (-2) and at 
0, 1, 7 and 10 d.p.i. Specificity of amplifications was confirmed by a melting curve 
analysis. Recombinant actin gene fragment was amplified in parallel and used as a 
loading control. Cytokine mRNA expression was normalized against actin. 
Contamination controls included water amplified instead of eDNA. 
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stimulation period (Fig. 3.5). After PHA stimulation and until 1 d.p.i., IFN-y induction 
was evident in cells exposed to NHP-2, NHP-3 or CHC-1-3. However, after this time 
point, no differences in expression were seen between cells exposed or not to virus. In 
the case ofTNF-a, it was interesting that the expression of this cytokine was not detected 
at 1 d.p.i. in cultures exposed to CHC-1 and CHC-2 (Fig. 3.5). While the preliminary 
data indicated that there was no significant change in TNF-a expression between cells 
exposed or not to HCV, the two cultures which lacked TNF-a mRNA were also the 
cultures with the greatest level of HCV RNA positive strand detection throughout the 
culture period. In cells exposed to HCV inocula as well as those exposed to NHP, IFN-
a5 expression was not detected by our otherwise sensitive real-time RT-PCR assay 
(sensitivity of200 copies/50J..tg total). In terms ofiL-2 mRNA levels, there appeared to 
be an upregulation in the IL-2 expression at 1 d.p.i. (i.e., 72 hours after PHA stimulation) 
in NHP-1 and NHP-2, although again there were no significant differences between 
cultures that were or were not exposed to HCV (Fig. 3.5). 
3.5. DISCUSSION 
In this study, we examined the effects ofHCV-exposure on the T cell subset 
distribution, proliferative capacity and apoptosis of primary T lymphocytes during a 
prolonged culture period. Evident shifts were found in regard to the T cell phenotype in 
the cultures exposed to two (CHC-1 and CHC-2) ofthree inocula tested. This change 
was characterized by a shift from the predominantly CD4-positive T cell phenotype prior 
to HCV exposure to progressive enrichment of CD8-positive T cells during the 10 d.p.i. 
culture period. In both cases, this CD8+ T cell enrichment was accompanied by a 
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significant reduction in CD4+ T cell proliferation in HCV -positive cultures compared to 
those exposed to NHP or being HCV non-reactive. This effect appeared to be related to 
the level ofHCV RNA positive strand detected in cells exposed, considering the fact that 
the inocula (CHC-1 and CHC-2), that led to the greatest changes in the CD4+ to CD8+ 
ratio, were the cultures that had readily quantifiable cellular levels of HCV RNA (Table 
3.2.). Furthermore, in lymphoid cells exposed to CHC-1 inoculum, in which HCV RNA 
negative strand was detected at 7 and 10 d.p.i., indicating the highest level ofHCV 
replication amongst the cultures examined, the inhibition in CD4+ T cell proliferation 
appeared earlier (i.e., 4 d.p.i.), suggesting that the effect may be mediated by the presence 
of active viral replication. In the case of lymphoid cells exposed to CHC-2 inoculum, T 
cell phenotypic and proliferative changes were observed in the absence of detection of 
HCV replicative intermediates. It is almost certain that viral replication was taking place, 
however at the level that was below the limit of detection of the negative strand detection 
assay. It is of note, that the assay sensitivity for HCV RNA negative strand detection is 
approximately 100-fold less sensitive than our RT-PCR/NAH assay routinely used for 
HCV RNA positive strand identification and that the RNA negative strand occurs in 
infected lymphoid cells at quantities 1 00-fold lower levels than the viral RNA positive 
strand (Pham et al. , 2004). 
In cultures exposed to CHC-3 inoculum, the level of HCV RNA positive strand 
detected throughout the culture period was unquantifiable by a real time RT-PCR assay 
with sensitivity of 50 vge/)..lg total RNA. This indicates that this inoculum did not induce 
infection. Interestingly, there were also no changes in proliferation rate or the 
distribution T cell subsets in comparison to cells exposed to NHP. We have previously 
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observed that not all HCV inocula are able to infect pre-stimulated lymphoid cell targets 
from the same donors (see Section 2.4.2) (MacParland et al., 2009). The factors that 
determine infectivity of wild-type HCV in immune cells have yet to be recognized and 
they are under investigation in this laboratory. 
In early experiments leading to this study, alternating stimulation with PHA and IL-2 
was employed to upregulate lymphoid cell susceptibility to HCV infection and 
replication of virus during culture (Section 2.3.3). In the current work, stimulation with 
PHA after the initial 48 hr treatment was removed to prevent excessive cell activation 
that may mask the pro- or anti-proliferative effects of virus. The removal of this repeated 
mitogen stimulation resulted in a decreased viral replication in cells exposed to HCV 
inocula with reduced detection of both HCV RNA positive and negative strands (data not 
shown). This finding is consistent with previous observations in regard to HCV 
replication in in vitro cultures (Pham et al., 2005) and with findings from in vitro culture 
of other viruses (Chatterjee et al., 1985; Hyypia et al., 1985; Braun and Kirchner, 1986). 
Previously, it has been shown that HCV-specific CD4+ T cell responses in individuals 
chronically infected with HCV are poor or absent (Gerlach et al., 1999). In HCV-
infected patients who transiently control viremia and have fluctuating plasma viral loads, 
including periods of HCV RNA negativity as determined by clinical assays of relatively 
low sensitivity, this apparent viral control is accompanied by increased virus-specific 
CD4+ T cell response (Gerlach et al. , 1999). In patients with CHC, T cells have been 
found to be impaired in the production of IFN-y and IL-2 (Semmo et al., 2007). As well, 
studies investigating CD4+ T cell function during a symptomatic persistent HCV 
infection have shown a significant loss of IL-2 secreting cells compared to individuals 
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who spontaneously resolved viremia, and weak HCV -specific IFN-y production by CD4+ 
T cells upon stimulation (Semmo et al. , 2005). In the later study, HCV-specific IFN-y 
production by CD4+ T cells was rescued after in vitro culture with IL-2, but the effect of 
IL-2 on the proliferative capacity of CD4+ T cells was not measured. These findings may 
suggest that the proliferative impairment in CD4+ T cell observed in our study could be 
due to the impaired IL-2 secretion leading to decreased T cell proliferative capacity. 
Unfortunately, due to limitations in cell numbers, we were not able to perform 
evaluations by ELISA or ELISpot to examine ifthere was indeed impaired IFN-y and IL-
2 cytokine production by CD4+ T cells. Preliminary data obtained in this study indicate 
that there were no significant differences between T cells exposed or not to HCV in terms 
ofiFN-y, TNF-a. and IL-2 mRNA expression. On the other hand, it is possible the levels 
ofHCV replication in the T cell cultures not subjected to repeated mitogen stimulation 
may not have been sufficiently high to induce detectable changed in transcription of these 
cytokines. Further investigations should be carried out to evaluate molecular gene 
expression as well as the level of display of cytokines and their receptors in the T cells 
exposed to HCV in vitro. 
From our findings, we can postulate that HCV infection ofT cells in vitro can lead to 
a cell phenotype shift characterized by an apparent enrichment of CDS+ T cells, which is 
due to a relative decrease in proliferation of CD4+ T cells. This proliferative effect 
appears to be enhanced in the presence of increased HCV replication. Furthermore, HCV 
exposure does not appear to augment apoptotic death of lymphocytes in vitro. It needs to 
be determined whether primary T cells derived from patients with CHC display similar 
characteristics ex vivo. 
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In summary, the results of this study provide further evidence that HCV infection may 
exert direct effects on the behaviour and function ofT cells and raises the possibility that 
HCV may not need to be actively replicating in these cells to cause such effects. 
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Chapter Four: Hepatitis C Virus Persisting after Clinically 
Apparent Sustained Virological Response to Antiviral Therapy 
Retains Infectivity In Vitro 
This study has been published in Hepatology 2009; volume 49 pp.l43l-1441. 
4.1. SUMMARY 
Hepatitis C virus can persist in the liver, lymphoid cells and serum of individuals with 
apparent complete spontaneous or therapy-induced resolution of hepatitis C and can 
replicate in vivo and in vitro in human T cells. The current study aimed to assess the 
infectivity of HCV persisting at very low levels using the previously established HCV 
infection system in human T cells. NaYve lymphoid cells were exposed to plasma and/or 
supernatants from cultured PBMC from 9 individuals with apparent SVR after 
completion of antiviral therapy. Exposed cells were analyzed for HCV RNA positive and 
negative strands and, in selected cases, for HCV NS5A protein, appearance of HCV 
variants, and release of virions by immunoelectron microscopy. The results showed that 
11 of the 12 cultures established became HCV RNA positive strand reactive, while 4 also 
expressed the virus replicative strand. NS5A protein was detected in the de novo infected 
cells and clonal sequencing revealed HCV variants not found in inocula. IEM 
demonstrated enveloped HCV particles in plasma used as inocula and in culture 
supernatant from T cells exposed to that plasma. Overall, HCV carried in 3 of the 9 
individuals studied elicited productive infection in vitro. Conclusion: HCV persisting at 
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very low levels long after therapy-induced resolution of chronic hepatitis C can remain 
infectious. The retained biological competence of the virus might have implications with 
respect to the mechanisms of its persistence and epidemiology of HCV infection. 
4.2. INTRODUCTION 
Hepatitis C virus is a single-stranded RNA virus that chronically infects approximately 
170 million people worldwide. Up to 85% of the infected individuals may CHC. HCV is 
infectious even at trace amounts, with approximately 20 virus copies capable of 
transmitting infection in chimpanzees (Katayama et al., 2004b). Recently, introduction 
of nucleic acid amplification assays detecting HCV genomes with enhanced sensitivity, 
reaching in our laboratory <1 0 vge/mL or <2 IU/mL, revealed that HCV can persist at 
low levels in individuals with apparently complete resolution of hepatitis C either 
spontaneously or due to antiviral therapy (Pham et al., 2004; Radkowski et al., 2005a; 
Castillo et al., 2006; Laskus et al., 2007; Pham et al., 2007; Pham et al., 2008). In 
general, occult HCV infection is considered when small quantities of HCV RNA are 
identifiable in serum (usually below 100 vge/mL), PBMC and/or liver in individuals who 
are repeatedly serum HCV RNA nonreactive by clinical laboratory tests with sensitivities 
ranging between 52 and 1000 vge or 1 0 to 615 IU per mL, and have no clinical or 
biochemical evidence of liver disease (Pham et al., 2004; Radkowski et al., 2005a; 
Laskus et al., 2007; Pham et al., 2007; Pham et al., 2008). In this silent form ofHCV 
infection, detection ofHCV RNA replicative (negative) strand is not uncommon, 
particularly when ex vivo activated PBMC are tested by sensitive HCV RNA negative 
strand-specific reverse transcription-nested polymerase chain reaction combined with 
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nucleic acid hybridization analysis of the resulting amplicons (Pham et al., 2004; Pham et 
al. , 2005). 
While originally thought to be strictly hepatotropic, HCV has been shown in 
numerous studies to also invade and replicate in cells of the immune system (MacParland 
et al., 2006; Pal et al., 2006; Blackard et al., 2006). In our recent work, conclusive 
evidence ofHCV replication in CD4+ and CD8+ T lymphocytes, B cells and monocytes 
was presented (Pham et al., 2008). It has also been shown that the same immune cell 
subsets can be infected in both CHC and persistent low-level HCV infection continuing 
after resolution of CHC (Pham et al. , 2008). Further, primary T lymphocytes from 
healthy individuals have been found to be susceptible to HCV infection in vitro (Section 
2). Along this line, mathematical modeling has independently predicted that HCV 
originating from extrahepatic reservoirs, possibly the immune system, comprises 
approximately 3% of the circulating virus pool in CHC (Dahari et al. , 2005). However, 
analysis ofHCV quasispecies, which is the swarm of genetically related viral variants 
that circulate in HCV -infected individual, occurring in the liver, plasma, PBMC and 
lymphoid tissue of a patient with end-stage liver disease awaiting liver transplant 
demonstrated that extrahepatic variants may constitute more than 50% of those occurring 
in serum (Pal et al., 2006). 
The clinical relevance of low-level HCV carriage, including its potential ability to 
transmit infection, is yet to be determined. Nonetheless, HCV reactivation has been 
reported in patients with HCV RNA clearance confirmed by standard clinical laboratory 
assays prior to liver transplantation (Thomas et al. , 2003; Foms et al., 2003). However, 
the opposite has also been described, albeit no details were given regarding assay 
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sensitivity and the quantity of template analyzed (Everson et al., 2005). Also, HCV RNA 
was identified in anti-HCV reactive patients receiving an HCV -negative bone marrow 
(Zekri et al., 2004) or kidney transplants (Melon et al., 2005). Taken together, a 
possibility exists that occult HCV infection could have both pathogenic and 
epidemiological importance. 
At present, a sustained virological response is defined as serum HCV RNA negativity 
by clinical laboratory assays for at least 6 months after completion of antiviral therapy. 
However, given that the identification oflow-level (occult) HCV infection was only 
made possible by employing research tests of a much greater sensitivity than that of those 
applied for clinical use, it is not surprising that low levels ofHCV RNA are frequently 
escaping detection, giving conflicting results on the occurrence and infectivity of HCV 
persisting at trace levels. Implementation of assays detecting HCV RNA with a greater 
sensitivity (preferably <1 0 vge/mL) for clinical and population-based testing should 
meaningfully contribute to the identification ofthe scope of potential problems associated 
with low-level HCV infection (Michalak et al., 2007). 
An HCV cell culture system allowing for authentic propagation of wild-type HCV in 
primary human T cells has previously been established in this laboratory (Section 2). In 
the current study, this system was employed to assess potential infectivity ofHCV 
persisting at trace quantities for years in patients who achieved SVR after completion of 
IFN-a therapy with or without ribavirin. Our investigation has focussed on randomly 
selected cases which, although repeatedly serum negative by the clinical test, were found 
by RT-PCRINAH to be positive for HCV RNA in sera and in PBMC after their ex vivo 
stimulation (Pham et al., 2004). We uncovered that the residual virus carried by some of 
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the individuals has the capacity to de novo infect and propagate in T cells, strongly 
arguing that the virus persisting as occult infection can retain its biological competence 
and, thus, be potentially infectious. 
4.3. METHODS 
4.3.1. HCV Inocula and Cell Targets 
Nine patients who achieved SVR after completion ofiFN-a or IFN-a/ribavirin therapy, 
as defined by repeated serum HCV RNA negativity by Roche Amplicor HCV version 2.0 
assay (sensitivity 500 IU/mL or 1000 vge/mL; Roche Molecular Diagnostics, Pleasanton, 
CA) and normal liver function tests assessed at 6-12 month intervals, were investigated in 
this study (Table 4.1.). All patients were anti-HCV antibody positive by enzyme 
immunoassay (EIA; Abbott Diagnostics, Mississauga, Ontario, Canada). The follow-up 
period after SVR ranged between 24 to 72 months. All 9 individuals were found to carry 
HCV RNA at the time of this study when total RNA isolated from 500 )lL of serum was 
assayed by highly sensitive RT -PCRINAH (sensitivity of_::: 10 vge/mL_or _::: 2 IU/mL) 
previously established (Pham et al. , 2004). The estimated HCV RNA loads in the 
patients' sera ranged from <40 vge/mL to 400 vge/mL, with the exception of 6/F (59/F), 
who carried as much as 1.6 x 103 vge/mL (Table 4.1.). Also, while PBMC collected from 
the patients were seemingly HCV RNA nonreactive by the same highly sensitive assay, a 
72-hour culture of the PBMC with phytohemagglutinin (PHA; 5 )lg/mL; Sigma, Oakville, 
Ontario, Canada) and recombinant interleukin-2 (IL-2; 20 IU/mL; Roche) (Pham et al. , 
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Table 4.1. Clinical and Virological Clyaracteristics oflndividuals with Occult HCV Infection 
HCV RNA 
folio> -Up 
Antivlrnl P riorl 
Route of Tre~lrnent HCV Aft r SVR Serum load HCV RNA-Positiv 
Infection (W kos) ( n/ ml) ' Slnmd (vg / I• g) 
Unkno~n If (2d) <40 300 
IF R 
2/ § 46/ IVOU (24) Ia 60 400 50 D 
I /R 
3/ t il.3J . ou (tl8) 2a 60 40 < 50 'D 
If / R 
4/ Ft§ 43/F rou (48) Unkn 0 60 0 0 n.a. 
P-IFNf R 
5/ Ft§ 44/ F lnhala ·on (48) a 2 100 100 
p.lf / R 
6/Ft 59/ f Un own {48) lb 36 1.6 X 10' 0 n.a. 
l /R 
7/ ft 48/ F Endemtc ( ) la 24 50 100 
p.lf / R 
8/Ft 33/ F Inhalation ( 8) 24 100 <50 
P-1 / R 
9/ Fi§ 45/ f 11/0U (4 ) 3a .:..50 < 10 + 
Abbrev~a - ns: F, rem e; HCV, hepatilis C Vltus: IFN, in!elfe~on alpha: IL-2. tntelleukln-2: IVDU. antravenous drug use; 1 • • llldle; n.a .. not appll H. nueleac 
acid h tndaa · n; 0. no de ectable; P-IF , pe~a d mterleron "pha; PB .1c, penphe~al blood mononucle r cell; PHA. ph)'lohemagglu mn; R, riba ·nn; RT-PCR, 
re>erse-transtriptlon pol}'mmse chain reaction; S R, sustained \1rologJcal response: ~. vtrus genome equ ·alents. 
'The se111m HCV Rt. A load was dete~mined by teal-ume RT-PCR. 
PB . Cs were stimul ed ""ilh 51'8/ml PHA and 20 IUjml IL-2, lhe HCV Ro A-posatl•e strand was meaSllred by nes ed RT-PCR/ Ali, and tileR A-negati ·e strand 
was measured by S!J'an<kpeclfte RT·PCR,I AH as descnbed in lhe Patients and etllods section. 
Plasma v.as used as !he HCV inoculum 101 me 111 ·cl() inteetlon. 
§The supema~n from PBI> Cs aftef a 72-hour cu re V.11h PHA and IL-2 was used as lhe HCV moculum or tile m tllO In ec on. 
130 
2004) enabled detection of the virus genome in 7 individuals at estimated levels between 
<1 0 and 300 vge/J.lg total RNA (Table 4.1.). Furthermore, HCV RNA negative strand in 
PBMC was detected in 5 cases (Table 4.1.). Plasma from 8 patients was used for in vitro 
infection experiments (see Table 4.1.). In 4 cases (Table 4.1.), supernatant from PBMC 
cultured in the presence of PHA and IL-2 for 72 hours served as an inoculum for in vitro 
infection. Infectivity of both plasma and PBMC supernatants was examined in 3 cases 
(see Table 4.1.). Lymphoid cells serving as in vitro HCV targets were isolated from 
healthy donors who had no clinical history or molecular indication ofHCV exposure, as 
confirmed by RT-PCRINAH assay (Pham et al., 2004) and the absence of anti-HCV 
antibody by EIA (Abbott). 
4.3.2. HCV Infection 
Monocyte-depleted lymphoid cells from a healthy donor were treated with 5 J.lg/mL PHA 
for 48 h (Section 2.3.3.). Following stimulation, 7 x 106 lymphoid cells were exposed to 
500 J.!L oftest plasma in 6.5 mL of culture medium (Section 2.3.3.) or 7 mL of 
supernatant from in vivo infected PBMC which were cultured as indicated above and 
described in detail previously (Section 2.3.3.). In parallel, the same number of target 
cells was exposed to 250 J.!L of plasma from a patient with CHC carrying HCV genotype 
1 b at 7.3 x 105 vge/mL, as a positive control, and to 500 J.!L of plasma from a healthy 
donor, as a negative control (mock infection). Inocula were removed after 24 hours, the 
cells washed and cultured under alternating stimulation with PHA and IL-2 (phases A to 
D) for 14 days, as reported Section 2). It was previously established that after 14 days in 
culture ~98% of the cells were T cells (Fig. 2.1). Culture supernatants were collected at 
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1, 4 (phase A), 7 (phase B), 11 (phase C) and 14 (phase D) days post-infection (d.p.i.) 
and stored at -80 °C, while cells recovered at 14 d.p.i. (phase D) were cryopreserved for 
analysis. 
4.3.3. Modification of HCV Infectivity by Anti-HCV E2, Anti-CD81 and 
IFN-a Treatments 
Neutralization of HCV was carried out by incubating in duplicate 250 JlL of 48/F plasma 
with an anti-HCV E2 mAb (AP33; provided by Dr. A. Patel, Institute of Virology, 
University of Glasgow, Glasgow, UK) for 1 hat 37 °C and then 1 hr at 4 °C prior to 
adding to T cell targets. Inhibition of infection was also done by pre-incubating T cell 
targets with anti-CD81 mAb (Pharmingen, San Diego, CA) before exposure to 44/F or 
48/F plasma, as described previously (Section 2.3.5.). Appropriate isotype-matched 
mAbs were used in control experiments. To further reaffirm that active HCV replication 
was established in T cells, the cells were treated in duplicate with 1000 U/mL 
recombinant human IFN-a 2b (Research Diagnostics, Flanders, NJ) at the time ofHCV 
inoculation, as reported (Section 2.3 .6.). The cells exposed to the same amount of 44/F or 
48/F plasma, but not treated with IFN-a, served as positive controls. 
4.3.4. Ultracentifugation 
To concentrate the virus and to recognize its general biophysical properties, 5 mL of 
plasma or 10 mL of pooled T cell culture supernatants collected after phases C and D, 
which were pre-clarified at 400 x g for 30 min in the presence of protease inhibitor 
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cocktail (1 :200; Sigma), were layered onto 1-mL 30% sucrose cushions and centrifuged 
at 28,000 x g for 2.5 h at 4 °C in the TH641 rotor using Sorvall Discovery 1 OOSE 
ultracentrifuge (Mandel Scientific Company Inc., Guelph, Canada). Based on the 
findings from preceding experiments (data not shown), 8.6 mL was removed from the top 
of each tube and the remaining 2.4 mL collected in 300-~1 fractions (n=8) for evaluation 
ofHCV RNA content and sucrose density. In some instances, two 10-mL samples of 
pooled T cell culture supernatant collected after phases A-D of the same infection 
experiment were concentrated as indicated above and the resulting equivalent fractions 
pooled and used for analysis. 
4.3.5. RNA Extraction and RT -PCRINAH Assays 
Total RNA was extracted with Trizol (Invitrogen Life Technologies, Burlington, Canada) 
from -1 x 107 cells (yielding - 10 ~g RNA) or from 150 ~L ofthe 300-~L sucrose 
fractions. RNA was reversely transcribed using Moloney murine leukemia virus reverse 
transcriptase (RT; Invitrogen). HCV RNA positive and negative strands were detected 
using eDNA derived from 1-2 ~g or 2-4 ~g total RNA, respectively, and primers, 
amplifications conditions, and controls exactly as reported in our previous studies (Pham 
et a!., 2004; Pham et a!. , 2005). A water sample and a mock extraction were always 
included as contamination controls. eDNA prepared from the mock infection served as 
an additional RT-PCR negative control. Recombinant HCV 5'-UTR-E2 fragment (rHCV 
UTR-E2) served as a positive control. Specificity of the detection and validity of 
controls were routinely confirmed by NAH, i.e., Southern blot hybridization, using 32P-
labeled rHCV UTR-E2 as a probe (Pham eta!., 2004). Sensitivity of the RT-PCR assay 
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for HCV RNA positive strand was <10 vge/mL (<2 IU/mL) or 5 vge/~g total RNA, 
whereas that for HCV RNA negative strand detection 25-50 vge/~g total RNA (Pham et 
al., 2004). As a rule, HCV RNA negative strand was tested only in RNA samples from T 
cells which had been found reactive for HCV RNA positive strand. 
4.3.6. Clonal Sequencing 
The nucleotide sequences of 5' -UTR HCV amplicons detected in cultured T cells 
exposed to 44/F or 48/F plasma were compared to those amplified from respective 
plasma and from PBMC isolated from the patients who provided those plasma. The 
amplicons were cloned using the TOPO-T A cloning system (Invitrogen). Ten clones for 
each PCR product were sequenced in both directions using M13 primers and ABI PRISM 
7000 Sequence Detection System (Applied Biosystems, Streetsville, Canada). The 
resulting sequences were aligned with the help of Sequencher software version 4.7 (Gene 
Codes Corp., Ann Arbour, MI) (Pham et a!. , 2008). 
4.3.7. Confocal Microscopy and Flow Cytometry 
To detect HCV NS5A protein in in vitro infected T cells and to estimate the number of 
positive cells, confocal immunofluorescent microscopy and fluorescence activated cell 
sorting (F ACS) were applied. For confocal microscopy, infected cells were fixed with 
4% paraformaldehyde, permeablized with 0.5% Triton X-100, blocked with 10% normal 
goat serum, and double-stained with rat anti-tubulin (Chemicon International, Temecula, 
CA) and with either mouse anti-HCV NS5A mAb (Chemicon) or mouse isotype control 
(Pham eta!., 2008). Then, cells were incubated with Cy2-labeled donkey anti-mouse and 
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Cy5-labeled donkey anti-rat antibodies (both from Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA). Cultured HCV-na'ive T cells, Huh-7 cells, and Huh-
7 cells carrying HCV AB12-A2FL replicon (provided by Drs C. Richardson and J. 
Wilson, Ontario Cancer Institute, Toronto, Canada) stained as above were used as 
controls. Cells were examined in a Fluo View FV300 confocal system (Olympus 
America Inc., Melville, NY). Approximately 1000 cells per each preparation were 
examined and NS5A-positive cells counted. For F ACS analysis, cells were fixed with 
4% paraformaldehyde, permeablized with 0.5% saponin, and double-stained with anti-
NS5A mAb and anti-tubulin, and then with Cy2- and Cy5-labeled secondary antibodies. 
Cells were examined by flow cytometry using a F ACSCalibur cytometer (BD 
Biosciences Pharmingen, San Jose, CA) and the results analyzed by CellQuest Pro 
software (BD Biosciences). 
4.3.8. Immunoelectron Microscopy 
To determine whether complete HCV virions may circulate in individuals with clinically 
apparent SVR and were secreted by de novo infected T cell cultures, 500-)lL of 
unfractionated 48/F plasma and culture supernatant from T cells exposed to that plasma 
was incubated with anti-E2 AP33 mAb, as reported (Section 2.3.10.). In addition, HCV 
RNA-positive fractions 4 and 7 (see Fig. 4.5A) obtained after centrifugation of 44/F 
plasma over sucrose were similarly incubated with anti-E2 mAb. Reacting particles were 
detected with anti-mouse IgG conjugated with 12-nm gold particles (Jackson 
ImmunoResearch) and counterstained with 1% phosphotungstic acid (PTA). 
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Examinations were carried out in a JEM 1200 EX microscope (JEOL Ltd., Tokyo, 
Japan). 
4.4. 
4.4.1. 
RESULTS 
HCV Genome Expression in T Cells Exposed to Plasma from 
Individuals with Clinically Apparent SVR 
Using the previously established system allowing for de novo infection and propagation 
of wild-type HCV in vitro (see Section 2), infectivity of residual HCV occurring in 
plasma of individuals with clinically apparent SVR was tested. Pre-stimulated lymphoid 
cells exposed to plasma from 8 individuals and then cultured under alternate stimulation 
became reactive for HCV RNA positive strand in 7 ofthe cases (Fig. 4.1). HCV RNA 
negative strand, indicative of active virus replication, was evident in 3 of the 7 ( 42.8%) 
cell cultures that were positive for the virus positive strand. The HCV loads were 
estimated to be between 1 x 103 - 5 x 1 04 vge/1 0 7 cells. 
4.4.2. HCV NSSA Protein in In Vitro Infected T Cells. 
To determine whether expression ofHCV RNA in in vitro infected T cells was 
accompanied by synthesis of viral protein, cells exposed to 44/F and 48/F plasma were 
examined for HCV NS5A protein by confocal microscopy. As illustrated in Figure 4.2A, 
HCV NS5A occurred predominantly as granular intracytoplasmic deposits and at the 
plasma membrane of the positive cells. Percentages ofNS5A reactive cells enumerated 
under a confocal microscope were between 0.78% and 1.35%. A flow cytometric 
analysis gave comparable results of 1.05% to 1.52% of HCV NS5A protein positive cells 
(Fig. 4.2B). 
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Figure. 4.1. Detection of HCV RNA- positive and HCV RNA- negative strands 
in T cell cultures after exposure to plasma from patients followed for up 
to 60 months after apparently complete clinical clearance ofHCV. (A) 
HCV RNA- positive strand and (B) HCV RNA- negative (replicative) strand. 
HCV sRNA- positive and HCV sRNA- negative strands were used to confirm' 
the specificity of the detections. Water instead of complementary DNA 
amplified in direct (D/W) and nested (N/W) reactions and a mock 
extraction (M) treated as test RNA were included as contamination 
controls. Positive samples showed the expected 244-bp amplicons. *A 
hybridization signal for 48/M with appropriate controls was overexposed 
to visualize its presence. Abbreviations: HCV, hepatitis C virus; HCV sRNA, 
synthetic hepatitis C virus RNA; rHCV UTR-E2, recombinant hepatitis C 
virus 5' -untranslated region E2 fragment. 
HCV RNA positive strand 
rHCV 
N/W 0/W M 48/M 43/M 43/F 44/F 59/F 48/F 33/F 45/F UTR-E2 
N/W 0/W M 48/M 
* 
HCV RNA negative strand HCV sRNA 
N/W 0/W M 48/M 43/M 43/F 44/F 59/F 48/F 45/F pos neg 
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Figure. 4.2. Expression of HCV NS5A protein in cultured T cells exposed to plasma 
from individuals with SVR. (A) Cultured T cells after exposure to (A,B) 43/M plasma, 
(C-E) 48/F plasma, and (F) plasma from a patient with chronic hepatitis C (positive 
control) were double-stained with anti-HCV NS5A and anti-tubulin mAbs and analyzed 
by confocal microscopy. (G) Cultured T cells exposed to HCV and stained with an 
isotype control antibody served as a negative control. (H) Huh-7 cells transfected with 
HCV AB 12-A2FL full-length HCV replicon served as an additional positive control. 
... 
Images were captured at 60 X magnification. (B) Flow cytometric quantification of HCV 
NS5A-positive T cells exposed to plasma from individuals with therapy-induced SVR. 
Prestimulated cells were incubated with 44/F or 48/F plasma and cultured as described in 
the Patients and Methods section. T cells were stained with anti-NS5A mAb or isotype 
control antibody. Gates were set on the basis of isotype controls. Stimulated, uninfected 
T cells similarly stained with anti-NS5A mAb served as a negative control. Huh-7 cells 
transfected with HCV AB 12-A2FL replicon were used as a positive control. Percentages 
indicate positive cells. Abbreviations: HCV, hepatitis C virus; mAb, monoclonal 
antibody; NS5A, nonstructural protein 5A; SVR, sustained virological response. 
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4.4.3. Inhibition of HCV Infection by Anti-E2, Anti-CD81 and IFN-a 
Pre-incubation ofHCV present in 48/F plasma with anti-HCV E2 mAb, but not with an 
isotype control, neutralized the virus infectivity as evidenced by the absence ofHCV 
RNA negative strand detection in the cells exposed to the treated inoculum (Fig.4. 3A). 
Similarly, pre-incubation ofT cells with anti-CD81 mAb, but not with an isotype control 
mAb, blocked HCV replication, as indicated by a lack ofHCV RNA negative strand 
detection, in experiments in which 44/F or 48/F plasma was used as inoculum (Fig. 
4.3A). Furthermore, treatment with recombinant IFN-a prevented establishment ofHCV 
replication in T cells, as shown in Figure 4.3B. 
4.4.4. Unique HCV Variants in De Novo Infected T Cells 
To assess whether HCV replication in de novo infected T cells led to appearance of 
variants distinct from those present in the plasma used for their inoculation, as it was 
observed in our previous study (see Section 2), 5'-UTR amplicons from 44/F and 48/F 
plasma, PBMC, and from cultured T cells exposed to these plasma were cloned, 
bidirectionally sequenced, and compared. As shown in Figure 4.4, clonal sequence 
analysis of the 147-bp fragment revealed a deletion at position 120 in all clones from 
PBMC and in 8 clones from de novo infected T cells, and a C to T change at position 249 
in all clones from PBMC and in 7 clones from T cells when compared to the sequence 
amplified from 44/F plasma used as inoculum, indicating that unique HCV variants were 
present in the PBMC and, importantly, that the same variants emerged in the T cells 
exposed to the plasma. On the other hand, sequencing ofthe cloned 5'-UTR amplicons 
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Figure. 4.3. Effect of HCV neutralization with anti-E2 mAb, pre-incubation of target 
cells with anti-CD81 mAb, or their treatment with IFN-a. on the replication of HCV in 
cultured T cells. (A) HCV contained in 48/F plasma was pretreated with anti-HCV E2 
mAb in duplicate (ex 1 and ex 2) or an isotype immunoglobulin control mAb and then 
incubated with T cells, or T cell targets were first incubated with anti-CD81 mAb or an 
appropriate isotype control and then exposed to 44/F plasma (ex 1) or 48/F plasma in 
duplicate (ex 1 and ex 2). (B) T cell targets were exposed to 44/F or 48/F plasma in the 
presence or absence (UT) of 1000 U/mL recombinant human IFN-a. 2b in duplicate (ex 1 
and ex 2). RNA was analyzed for HCV RNA-positive and HCV RNA-negative strands 
after 14 days of culture. Specificity and contamination controls were as outlined in the 
legend to Fig. 4.1. Positive samples showed the expected 244-bp amplicons. 
Abbreviations: HCV, hepatitis C virus; HCV sRNA, synthetic hepatitis C virus RNA; 
IFN-a., interferon alpha; mAb, monoclonal antibody; rHCV UTR-E2, recombinant 
hepatitis C virus 5-untranslated region E2 fragment. 
A 
HCV RNA positive strand 
anti·HCV·E2 
48/F 
N/W 0/W M ex1 ex2 ISO 
HCV RNA .negative strand 
anti-HCV-E2 
48/F 
NIW 0/W M ex2 ISO 
anti-C081 
44/F 48/F 
ex1 ISO ex1 ex2 JSO 
anti-C081 
rHCV 
UTR-E2 
44/F 48/F HCV sRNA 
ISO ex2 ISO pos neg 
-----
+-244 bp 
-244 bp 
8 
HCV RNA positive strand 
44/F 48/F 
NJW 0/W M ex1 e.x2 UT ex1 ex2 UT 
HCV RNA negative strand 
44/F 
NIW 0/W M UT 
48/F HCV sRNA 
-UT pos neg 
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Figure. 4.4. Nucleotide sequence alignment of clones derived from HCV 5' -UTR 
fragments amplified from 44/F and 48/F plasma, peripheral blood mononuclear cells, and 
cultured T cells exposed to that plasma. The 5 ' -UTR amplicons derived from each 
sample were cloned, and 10 randomly selected clones were sequenced bidirectionally. 
As a reference, the H_CV genotype la sequence (GenBank accession number M67463) is 
shown on the top line. Nucleotides in the sequences identical to those of the reference 
are shown as dots, deletions are shown as dashes, and differences are shown as letters. 
Numbering of the nucleotides is according to the M67463 HCV genotype la sequence. 
Abbreviations: 5'-UTR, 5'-untranslated region; HCV, hepatitis C virus. 
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derived from 48/F plasma, PBMC and cultured naYve T cells exposed to 48/F plasma 
revealed random single nucleotide polymorphisms. There was no indication of the 
existence of lymphoid cell-specific HCV variants. 
4.4.5. Physically Distinct HCV RNA-Reactive Particles Occur in Plasma 
and Culture Supernatants from T Cells Exposed to That Plasma 
To gain an insight into general biophysical properties ofHCV RNA-reactive particles 
occurring in plasma of individuals with SVR and those released into culture medium by T 
cells exposed to these plasma, samples of plasma and supernatants from the infected T 
cells were ultracentrifuged over sucrose and the 8 bottom fractions collected. The 
analysis of 44/F plasma showed that HCV RNA-reactive particles occurred in fractions 1, 
4 and 7, corresponding to sucrose densities of 1.092, 1.064 and 1.027 g/mL, respectively, 
with apparent HCV RNA peak reactivity in fraction 4 (Fig. 4.5A). In the culture 
supernatant ofT cells exposed to 44/F plasma, HCV RNA-positive particles were found 
in fractions 5-8 at densities between 1.024 and 1.011 g/mL with the peak RNA positivity 
in fraction 5 at density of 1.024 g/mL (Fig. 4.5B). HCV RNA-reactive particles after 
centrifugation of 48/F plasma banded at fraction 4 at sucrose density of 1. 04 7 and in 
fractions 6-7 at densities 1.018-1.013 g/mL (Fig. 4.5C), while those occurring in the 
culture supernatant ofT cells exposed to this plasma in fractions 5-8, having a sucrose 
density of 1.027 - 1.019 g/mL, with the HCV RNA peak reactivity in fraction 5 at 
density of 1.027 g/mL (Fig. 4.5D). 
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Figure. 4.5. Sedimentation velocity of HCV RNA-reactive particles in sucrose. Plasma 
samples from individuals 44/F and 48/F with clinically apparent SVR and supernatants 
from cultured T cells exposed to this plasma were separately layered onto 1-mL sucrose 
cushions and ultracentrifuged. Eight 300-L fractions collected from the bottom of each 
tube were assayed for HCV RNA-positive strands by reverse-transcription polymerase 
chain reaction/nucleic acid hybridization and for sucrose density. (A) 44/F plasma 
collected 3.5 years after SVR was achieved, (B) culture supernatant from T cells infected 
with HCV contained in 44/F plasma, (C) 48/F plasma collected 2 years after clinical SVR 
was achieved, and (D) culture supernatant from T cells infected with HCV contained in 
48/F plasma. On the left side of each panel, the HCV RNA level is expressed in relative 
density units given by hybridization signals shown on the blot under each panel. On the 
blots, contamination and specificity controls are marked as in the legend to Fig. 4.1. 
Abbreviations: HCV, hepatitis C virus; rHCV UTR-E2, recombinant hepatitis C virus 5-
untranslated region E2 fragment; SVR, sustained virological response. 
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4.4.6. Infectivity of HCV Released By PBMC after Clinically Apparent 
SVR 
To assess the infectivity ofHCV found in in vivo infected PBMC of individuals with 
clinically apparent SVR, PBMC from 4 such patients followed for up to 5 years (Table 
4.1.) were stimulated with PHA and IL-2 for 72 hours and the resulting supernatants used 
as inoculum to infect T cells. The data revealed that all cell cultures exposed to the 
PBMC supernatants acquired HCV RNA positive strand reactivity, while HCV RNA 
negative strand was detected in one of the cultures (Fig. 4.6). 
4.4. 7. Ultrastructural Identification of HCV Particles in SVR Plasma and 
Culture Supernatants of De Novo Infected T Cells 
HCV particles were visualized with anti-E2 mAb by IEM (Fig. 4.7). Figure 4.7 A-C 
depicts HCV virions detected in unfractionated (total) plasma obtained from 48/F patient 
24 months after achieving SVR. Figure 4.7. D-F shows HCV particles found in HCV 
RNA-reactive fractions 4 (panel D) and 7 (panels E and F) after fractionation of 44/F 
plasma collected 42 months after SVR. As shown in Figure 4.7. G-K, HCV virion 
particles, either singular or aggregates, were also detected in culture supernatants 
collected from T cells in vitro infected with virus carried in 44/F plasma. Particle sizes 
ranged from 50-75 nm in diameter. 
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Figure. 4.6. Detection of HCV RNA-positive and HCV RNA-negative strands in 
cultured T cells exposed to culture supernatants derived from in vivo HCV -infected, ex 
vivo stimulated peripheral blood mononuclear cells obtained from individuals with 
follow-up of up to 60 months after a clinical SVR. Contamination and specificity 
controls are marked as outlined in the legend to Fig. 4.1. Positive samples show the 
expected 244-bp amplicons. Abbreviations: HCV, hepatitis C virus; HCV sRNA, 
synthetic hepatitis C virus RNA; rHCV UTR-E2, recombinant hepatitis C virus 5-
untranslated region E2 fragment. 
HCV RNA positive strand 
N/W DIW M 46/M 
HCV RNA negative strand 
rHCV 
43/M 44/F 45/F UTR-E2 
HCV sRNA 
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Figure. 4.7. Ultrastructural features of HCV RNA-reactive particles in the plasma of 
individuals with clinical SVR and in the culture supernatant obtained from T cells 
exposed to one of the plasma samples as visualized by immunogold staining with anti-E2 
mAb. (A-C) HCV virion particles in unfractionated plasma of patient 48/F. HCV virions 
in (D) fraction 4 (sucrose density, 1.064 g/mL) and (E,F) fraction 7 (sucrose density, 
1.027 g/mL) of 44/F plasma. (G-K) HCV particles in the supernatant of cultured T cells 
infected with HCV contained in 44/F plasma. (L) The same culture supernatant pool 
shown in panels G to K exposed to the isotype control instead of anti-E2 mAb. 
Preparations were counterstained with 1% phosphotungstic acid. Bars indicate 1 00 nm. 
Abbreviations: HCV, hepatitis C virus; mAb, monoclonal antibody. 
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4.5. DISCUSSION 
These findings provide in vitro evidence that trace quantities of HCV persisting in the 
circulation for a long time after therapeutically induced resolution of CHC can remain 
infectious. The transmission ofHCV infection was exemplified by detection ofHCV 
RNA negative strand, NS5A protein and emergence of unique HCV variants in cultured 
T cells exposed to plasma from individuals with long-term follow-up after SVR. 
Furthermore, HCV replication in T cells was prevented following neutralization of virus 
with anti-E2 mAb, blocking with anti-CD81 mAb, and by treatment of the cells with 
recombinant human IFN-a 2b. In addition, HCV residing in PBMC after clinical 
resolution of infection was also found to be infectious. HCV virion particles specifically 
recognized by anti-E2 mAb were uncovered in plasma of these individuals and in the 
supernatant derived from de novo infected T cell cultures exposed to the plasma. 
Similarly as in CHC (Pham et al. , 2008), circulating lymphomononuclear cells have 
been found to be the site of active HCV replication in low-level infection continuing after 
resolution of hepatitis C, although ex vivo activation of the cells is usually required to 
uncover the virus presence (Pham et al., 2004; Pham et al., 2005). Among circulating 
immune cells, CD4+ and CD8+ T lymphocytes, B cells and monocytes were identified to 
be infected to a varying degree with HCV, but with overall viral loads greater in CHC 
than in occult infection (Pham et al. , 2008). As with PBMC from occult infection, ex 
vivo stimulation ofT cells affinity-purified from patients with low-level infection also 
significantly augmented HCV replication allowing for more ready detection of the 
residing virus, as the recent study showed (Pham et al. , 2008). 
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It was also previously discovered that mitogen-activation of normal human T 
lymphocytes predisposes the cells to infection by wild-type HCV of different genotypes 
(MacParland et al., unpublished observations) (see Fig. 2.2). Productive replication of 
HCV in such treated cells, after exposure to either plasma from patients with CHC or 
culture supernatants from serial passage of wild-type HCV in T cell-enriched cultures, 
was shown by methods comparable to those used in the current study. Namely, by 
detection ofHCV RNA negative strand, virus proteins (NS5A and E2) and HCV variants 
distinct from those occurring in respective inocula, and by identification of secreted 
complete virions, as evidenced by isopycnic banding and ultrastructural examinations 
(Section 2). In the present work, employing the same HCV replication system and 
similar evaluation criteria, it became evident that the virus occurring at low levels in 3 of 
8 plasma collected 2 to 5 years after SVR (cases 43/F, 44/F and 48/F; Table 4.1.), was 
able to establish active HCV replication in vitro. In addition, HCV derived from in vivo 
infected lymphoid cells obtained from one (case 44/F) of 4 patients induced de novo 
infection in the culture system. Taken together, HCV carried by 3 out of the 9 
individuals investigated in this study established infection in vitro which was confirmed 
by at least one criterion of active HCV replication, i.e., the appearance of HCV RNA 
negative strand. However, the infection initiated by the virus originating from two (cases 
44/F and 48/F) of these 3 convalescent individuals was also confirmed by detection of 
viral protein, secretion of HCV RNA-reactive particles physically distinctive from those 
occurring in inocula, and identification of complete virions by IEM. 
HCV RNA-reactive particles occurring in 44/F and 48/F plasma and those secreted by 
T cells exposed to that plasma displayed different sedimentation profiles after 
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ultracentrifugation over sucrose implying distinct biophysical properties. This further 
supported the conclusion that the virus released originated from the de novo infection 
process. In general, although the plasma virions, as confirmed by IEM, predominantly 
banded at higher sucrose densities (1.047-1.064 g/mL), those released from in vitro 
infected T cells tended to sediment at densities not exceeding 1.027 g/mL. Considering 
that HCV virions in plasma of patients with CHC have been shown to be ofheterogenous 
densities, particularly when associated with immunoglobulins and lipids (Hijikata et al., 
1993; Kanto et al., 1994; Diaz et al., 2006), that the majority of plasma virions should or 
do originate from infected hepatocytes, and that the viral particles found in culture 
supernatants in the current study were of low density and were exclusively produced by T 
cells, a possibility exists that virions assembled in hepatocytes and lymphoid cells could 
be biophysically distinct due to association with different host proteins and/or lipids 
giving, in consequence, different sedimentation profiles. Studies have yet to compare the 
biochemical properties of plasma virus in CHC and in persistent low-level HCV 
infection, as well as of virions produced by lymphoid cells in CHC and occult infection. 
Infectivity of HCV traces persisting during the naturally acquired occult HCV 
infection has not yet been investigated. The present study, to our knowledge, is the first 
attempt in this regard. However, in early studies in chimpanzees, diluted plasma from a 
patient with acute post-transfusion hepatitis containing approximately 10 virions was 
capable of inducing infection which was characterized by elevated serum AL T and liver 
inflammation (Feinstone eta!., 1981 ). More recently, as few as 20 copies of HCV RNA 
prepared by dilution of serum obtained during the pre-acute phase of hepatitis C of an 
infected chimpanzee has been demonstrated to cause HCV RNA-positive infection in the 
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absence of ALT elevation (Katayama et al., 2004b). However, since the sensitivity ofthe 
PCR assay used for detection of serum HCV RNA in the latter study appeared to be 
between 100 and 250 copies (Katayama et al., 2004b ), a possibility remains that lower 
doses of HCV may also transmit infection in this model. Our present findings reveal that 
HCV circulating in some individuals with resolved hepatitis C is capable of inducing 
productive infection in vitro at doses of 20 to 50 copies. This can be interpreted as a 
strong indication of potential virus infectivity in vivo. In future studies, it would be of 
interest to determine the molecular mechanisms as to why HCV circulating in some 
individuals, but not in others, was infectious to T cells despite comparable levels of virus 
present. 
In summary, the current study provides the first experimental evidence that HCV 
RNA detectable at low quantities for years after apparent complete resolution of CHC 
reflects the existence of traces of biologically competent virus, which in some situations, 
can retain infectivity. 
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Chapter Five: General Discussion 
The main purpose of this project was to establish an in vitro system in lymphoid cells 
capable of supporting the complete replication cycle of wild-type HCV. We aimed to 
uncover conditions supportive of replication and confirm that this system was truly able 
to facilitate the entire HCV replication cycle by testing, among others, the ability of 
lymphoid-derived virus to de novo infect healthy lymphoid cells; and to determine the 
molecular and biophysical properties of virions produced by lymphoid cells de novo 
infected in culture. A further goal was to assess whether exposure of initially virus-naive 
T lymphocytes to HCV in culture may alter the T cell phenotype, proliferative capacity, 
degree of apoptosis and expression of selected cytokines. Finally, we endeavoured to 
evaluate the infectivity of virus lingering in patients after apparently complete clinical 
recovery from infection following either spontaneous resolution of hepatitis C or 
achievement of a clinical SVR following antiviral therapy. 
The system for in vitro infection ofPBMC with wild-type HCV was based on 
previous findings that activated lymphoid cells are more capable of supporting 
propagation of HCV (Pham et al., 2005). The uniqueness of our studies in relation to 
previously reported work aiming at establishing with HCV infection in vitro lies in the 
fact that we utilized primary, normal human lymphocytes as the target cells and wild-
type, molecularly intact HCV as the inoculum, while other studies have employed cloned 
recombinant and cell culture-adapted viruses (Marukian et al., 2008) and transformed or 
immortalized lymphocyte-derived cell lines as virus targets (Shimizu eta!., 1992; Sung et 
al., 2003). The importance of using wild-type virus and primary lymphoid cells to study 
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in vitro infection is that, comparing to other HCV culture methods, this best mimics what 
would take place in vivo in an HCV -infected individual. In circulation, wild-type HCV 
exists as a swarm of genetically related viral variants. Recombinant cloned viruses, such 
as the JFH-1 viral clone, will gain the ability to mutate once they are replicating using the 
HCV NS5B polymerase but initially require transfection into Huh-7 cells as a single 
cloned viral sequence. In the current studies, we were interested in exposing our target 
cells to the entire quasispecies population existing naturally in an HCV -infected 
individual with the aim of sampling variants with different replicative abilities and 
possibly different lymphoid cell tropisms. 
Many previous studies showing in vitro susceptibility of cultured cells to HCV 
infection have made use of cell lines either transformed by cancer, such as B cell lines 
from patients with non-Hodgkin's B-celllymphoma (Sung et al. , 2003), co-infected with 
other viruses, such as Molt-4 T cells co- infected with murine retroviruses (Shimizu et al. , 
1992), or hepatoma cell lines, such as Huh-7 and Huh-7.5 cells (Zhong et al., 2005; 
Lindenbach et al. , 2005; Wakita et al. , 2005). For the purposes of our investigations, we 
thought it important to look at primary lymphocytes as the targets. Previously, we and 
others have observed that persistent hepatitis viruses can replicate in lymphocytes in 
patients or animals without known co-infection with other viruses or the existence of 
cancers (Michalak et al. , 1994) and we hypothesized that the same could be true for 
HCV. 
The existence of HCV lymphotropism has ignited debate with the main question being 
whether detection of HCV reflects the existence of cell surface adhered free virus or truly 
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intracellular replicating virus. We investigated this question by examining if de novo 
infection of lymphocytes can lead to detectable production ofthe HCV genome 
replicative intermediate, the HCV RNA negative strand, and if protein components of the 
replication complex, i.e., the HCV non-structural proteins, can be detected along with 
HCV RNA. We further investigated whether secretion of enveloped virions is taking 
place and examined their presence in supernatants of in vitro infected cells and by serial 
passage of released virus in naive PBMC-derived T cells. We also confirmed active 
replication of HCV in de novo infected cells via treatment with interferon alpha. 
Another question of high importance is whether virus infection of lymphoid cells can 
lead to pathological outcomes and modify the function of immune cells. It has been 
suggested that HCV infection can cause B cell dysfunction, as it has been found that 
close to 80% of patients with mixed cryoglobulinemia, characterized by an accumulation 
of cryoglobulins, are also chronically infected with HCV (Agnello et al., 1992). The 
notion of HCV -induced lymphocyte abnormalities is further supported by the finding that 
classical antiviral therapy for hepatitis infection results in clinical recovery from HCV-
associated MC (Saadoun et al. , 2006). Along the same lines, HCV -infected lymphoid 
cells have been detected in HCV patients with non-Hodgkin' s lymphoma (Ferri et al. , 
1997). Alterations in T cell characteristics and function in HCV -infected individuals 
have also been described. In peripheral blood and intrahepatic T lymphocytes in patients 
with CHC, T cells have been found to display markers of exhaustion, such as the 
expression of inhibitory receptor PD-1 (Golden-Mason et al., 2007) and negative immune 
regulator TIM-3 (Golden-Mason et al., 2009)(see Section 1.6.2). As well, T cells 
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exposed to HCV in vitro show impaired IFN-y signalling with suppressed levels ofStat-1 
mRNA expression (Kondo et al., 2007). In our HCV-T cell infection system, we 
evaluated the phenotype, proliferation and degree of apoptotic death of HCV -exposed 
lymphoid cells and found that exposure to HCV selectively inhibits CD4+ T cell, but not 
CD8+ T cell proliferative capacity without having an influence on T cell apoptosis in 
vitro. 
The data from our studies uncovered several previously unknown facts. It was 
discovered in the first study (Section 2) that T cell-enriched cultures derived from PBMC 
of healthy individuals are susceptible to infection with wild-type HCV following mitogen 
stimulation and support its replication when intermittently. This finding was supported 
by the detection ofHCV RNA negative (replicative), detection of non-structural protein 
expression in infected cells, identification and characterization of the biophysical 
properties of enveloped virion particles by sucrose gradient centrifugation and by 
immune electron microscopy with HCV -specific antibodies against virus envelope (E2) 
protein, and by determining the in vitro infectivity of the secreted virus to virus-na'lve 
lymphocytes. Subsequently, in the second study (Section 3), it was found that in vitro 
infection ofT cells with HCV can lead to an altered T cell phenotype characterized by an 
apparent enrichment of CD8+ T cells that occurs due to an inhibition of CD4+ cell 
proliferation. As is known, the quantities of HCV remaining in circulation after apparent 
resolution of hepatitis C and control ofviremia are quite low ( :SlOO vge/mL). However, 
it was important to determine if these small amounts of virus can transmit infection to 
na'lve human cells since it has been identified that even minute amounts (approximately 
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20 virus copies) ofHCV can be infectious in a chimpanzee model of hepatitis C 
(Katayama et al., 2004b). In the third study (Section 4), it was established, for the first 
time, that small amounts ofHCV RNA-containing virions which circulate or reside in 
peripheral lymphoid cells in patients after apparent complete resolution of CHC due to 
IFNIRBV therapy retains its infectivity and can propagate in mitogen pre-stimulated T 
cell cultures. 
Our findings have several important implications. They conclusively document, using 
different investigative techniques, that HCV productively replicates in immune cells, 
such as T lymphocytes, and that these cells can be reservoirs of biologically competent, 
infectious virus. This may have implications with regard to viral persistence since virus 
residing in these cells may not be susceptible to the effects of antiviral therapy, including 
treatment with IFN/RBV (Blackard et al., 2006). HCV reinfection has been well 
described as occurring almost invariably after liver transplantation in patients with HCV-
related end-stage liver disease (Testa et al., 2000). Furthermore, HCV recurrence has 
been reported in patients who had no detectable HCV RNA following antiviral therapy 
prior to liver transplantation (Thomas et al., 2003; Foms et al., 2003). Our findings 
suggest that lymphocytes harbouring replicating, virus may be a source of infectious 
virus capable to infect hepatocytes post-OLT. 
The observed inhibition ofCD4+ T cell proliferation in vitro after exposure to HCV 
may have significance in that the virus may be directly affecting CD4+ helper function 
which is required for resolution of hepatitis and clearance of viremia. Finally, the fact 
that minute amounts of HCV persisting in individuals after apparent resolution of 
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hepatitis C remains infectious to naive lymphocytes in vitro implies that the virus retains 
its pathogenic competence in these patients. 
The expected consequences of lymphotropism in terms of immune response to HCV 
remain unclear. The factors determining control of HCV are the balance between virus 
propagation and the strength of the immune response; in this regard, spontaneous 
resolution of hepatitis represents a predominance of the immune system over the virus. 
In patients with competent immune systems, virus persisting at low levels could provide 
protracted antigenic stimulation and priming of the immune system. This notion is 
supported in studies in which CDS+ T cell infiltrates were observed in the liver of patients 
who apparently resolved viremia and had normal liver functions (Hoare et al. , 200S) and 
HCV -specific T cells were found to be circulating in patients with no clinical signs of 
infection (Quiroga et al., 2006). Along the same line, HCV -specific CD4+ and CDS+ T 
cell responses have been described in patients who were exposed to HCV eighteen years 
earlier but had undetectable anti-HCV antibodies (Takaki et al. , 2000). Recently, work 
from our lab has shown that in individuals with low-level (occult) HCV infection, either 
in the presence or absence of occult HBV co-infection, histological examination of livers 
biopsies obtained up to 5 years after clinical SVR revealed low grade inflammation in 
most cases although in almost all patients improvement in the degree of liver lesions was 
evident (Pham et al., manuscript submitted). The consequences of these intrahepatic 
immune infiltrates are unclear but the possibility exists that these T cells might be 
involved in a control of progressing viral replication while, at the same time, they may 
worsen liver injury and over many years perhaps lead to cirrhosis and HCC in some 
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cases. On the other hand, considering that in patients with CHC T lymphocytes can 
exhibit an exhausted phenotype, infiltrating lymphoid cells may be rendered functionally 
defective or exhausted which would lead to poor control of viremia and promote viral 
persistence. 
In situations of immune compromise, the pool of virus persisting at low-levels could 
increase due to the absence of immune control and this may lead to reactivation of 
symptomatic infection. This has been observed in apparently HCV RNA-negative 
individuals receiving corticosteroid therapy (Lee et al. , 2005), those treated with 
immunosuppressive agents after having undergone renal transplantation (Melon et al., 
2005; Savas et al., 2007), and individuals receiving bone marrow transplants (Zekri et al., 
2004). 
Taking all of our findings into consideration, this work has furthered our 
understanding of the ability of cells of the immune system to act as a reservoir of HCV. 
Viral propagation in this compartment, occurring albeit at a low rate, is resulting in the 
production and assembly of infectious virions. We have, for the first time, shown clear 
evidence that these particles are able to de novo infect virus-naive lymphoid cells. 
We showed that ongoing replication in this cell compartment may contribute to viral 
spread to naive lymphocytes. 
While the clinical consequences of the lymphatic (immune) system HCV infection are 
presently unclear, we believe that in certain cases, i.e., such as during 
immunosuppression, co-infection with other pathogens or toxic (anti-cancer) therapy, this 
residual virus can be reactivated. Overall, the model of infection and propagation of 
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wild-type HCV in normal human cells that was established and utilized in this work is a 
tool that can be employed to examine cytopathic mechanisms ofHCV infection and can 
be used to uncover factors mediating susceptibility of host cells to this virus. Finally, at a 
time in which treatment modalities for HCV are shifting from IFN/RBV alone to 
incorporate HCV -specific drugs, such a system will be valuable to determine whether the 
virus can finally be eradicated not only from the liver but also from extrahepatic sites that 
can potentially serve as a source for reinfection of hepatocytes. 
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Chapter Six: Conclusions and Future Directions 
Throughout these experiments, we examined how HCV infection in lymphoid cells may 
contribute to viral persistence. We investigated whether cells of the lymphatic system 
can be infected in vitro with HCV and whether these cells have the ability to produce 
complete infectious virions. We explored whether the functions ofT cells could be 
altered following exposure to or infection with HCV. We further studied the infective 
potential of virus lingering at low levels after clinical resolution of hepatitis C using the 
in vitro HCV infection system established in the course of these works. The findings of 
these studies can be summarized and concluded as follows: 
Study 1: The multiparametric analysis revealed that mitogen-stimulated T cells are 
susceptible and supportive of the complete cycle of HCV replication including the 
production of infectious virions capable of de novo infecting virus-na'ive cells. The 
findings conclusively showed that T cells do not merely harbour adhered virus but can 
support propagation of biologically competent, infectious virus. The in vitro replication 
system created is also able to support replication of wild-type virus of different 
genotypes, although it is not as efficient, in terms of virus production, as recently 
established systems applying molecularly adapted HCV strains and Huh-7 hepatoma 
cells. This system represents a tool for investigations of factors that promote virus 
replication and determine susceptibility to infection, and can be employed to test the 
efficacy of novel antiviral treatment modalities. 
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Study 2: We found that in vitro infection ofT cells with HCV can lead to a change in the 
T cell subset distribution, with an apparent enrichment of CD8+ T cells. This phenotype 
shift appeared to be a result of an inhibition of CD4+ T cell proliferation in the presence 
of virus. Meanwhile CD8+ T cell proliferation and both CD4+ T cell and CD8+ T cell 
apoptosis were unaffected by virus exposure. As such, we conclude from this study that 
HCV infection or even exposure to virus may affect the function of CD4+ T cells. The 
mechanism mediating this effect is yet unclear. It is presumed that a comparable event 
can occur in vivo, promoting virus persistence. 
Study 3: For the first time, this study revealed that residual HCV, detectable at low 
quantities for years after apparent complete resolution of CHC due to standard antiviral 
IFNIRBV therapy, retains its infectious potential and is capable of producing infection in 
mitogen-induced T cells in vitro. This strongly suggests that HCV persisting at low-
levels in the seemingly asymptomatic individuals can be a source of infectious HCV 
under certain conditions. 
As far as the future directions of this work, the in vitro infectivity of lymphoid-derived 
HCV in primary human hepatocytes cultures has yet to be shown. This would further 
support the notion that viral replication in the immune cell compartment may have 
implications regarding HCV persistence and recurrence. Specific factors that mediate 
virus entry into T cells and facilitate replication of HCV in this compartment should be 
examined. As well, the infectivity of HCV in other lymphocyte populations, such as B 
cells or dendritic cells should be investigated. In T cell cultures, full sequencing of HCV 
RNA genomes propagated in vitro at different time points may reveal the appearance of 
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adaptive mutations which could be subsequently tested for in vitro infectivity in 
hepatocyte cultures. In terms of the second study, it remains to be determined why CD4+ 
T cells are proliferating to a lesser degree than CD8+ T cells and whether the same 
situation occurs in HCV -infected patients. To uncover whether the virus is acting directly 
on CD4+ T cells or indirectly by acting on other cells, we would like to expose cultures of 
affinity purified CD4+ T cells to HCV in parallel with total PBMC and measure T cell 
proliferation. As well, although our limited analysis of cytokine gene expression did not 
show a difference between cells exposed or not to HCV, it would be interesting to 
determine the levels of IL-2 secreted into culture supernatant by ELISA to determine the 
amount of IL-2 being secreted, and by ELI SPOT to determine whether the frequency of 
IL-2-secreting cells is diminished. In addition, the question rises of whether treatment of 
HCV -infected CD4+ T cells with IFN-a will rescue proliferation. Microarray analysis of 
RNA, confirmed by quantitative RT-PCR, may reveal gene expression changes in T cells 
after exposure to HCV. 
Regarding our study on in vitro infectivity of low levels ofHCV persisting in patients 
who resolved CHC, it would be highly valuable to investigate further this topic by 
employing an appropriate animal model. However, this in highly challenging due to the 
fact that chimpanzees are practically not available for HCV research and the Scid-
Alb!uP A mouse model of infection requires approximately 105 vge in no more than 500 
f..LL to infect a singular animal. To acquire this amount of virus would be very difficult, 
since individuals with OCI usually carry no more than 102 vge per mL of plasma. Thus, 
to infect one animal virus recovered from approximately 1 liter of plasma would be 
required. 
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